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I. Abstract 
Introduction 
At present there is a pandemic of low serum vitamin D (25[OH]D) concentration, partly due to a 
lack of sun exposure (the primary route for synthesis) and modern lifestyle choices. The bioactive 
form of vitamin D, 1,25-dihydroxyvitamin D (1,25[OH]2D3) exerts its biological activity by 
binding to the vitamin D receptor (VDR). These receptors play a central role in the biological 
actions of vitamin D and are expressed in nearly every tissue and cell type in the body (M. Holick, 
2007).  
Vitamin D deficiency is widespread within many general and athletic populations and associated 
with a number of detrimental health conditions, including a long-term impact on cardiovascular 
health (M. Holick, 2007; Larson-Meyer & Willis, 2010; Pittas, Lau, Hu, & Dawson-Hughes, 
2007), and the aetiology of osteomalacia and osteoporosis (M. F. Holick, 2009).  Given the 
prevalence and potential negative morbidity associated with deficiency (Larson-Meyer & Willis, 
2010), regular vitamin D testing has been recommended as part of routine athlete screening. 
Current literature shows inconsistent associations between vitamin D status and bone mineral 
density and cardiac health; (Bischoff-Ferrari, Kiel, et al., 2009; Marwaha et al., 2011) particularly 
in racial minorities and athletic populations. Whilst it is considered that athletes should have 
‘sufficient’ vitamin D concentrations, the exact value to ‘optimise’ health is equivocal.  
Finally, there appears to be a ‘paradoxical relationship’ between ethnicity and vitamin D 
concentration, that has largely been ignored, i.e. blacks generally present with the lowest vitamin 
D concentrations but the greatest bone mineral density (BMD) and reduced risk of fracture (Cauley 
et al., 2005). Vitamin D–binding protein (DBP) may account for observed racial differences in 
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manifestations of vitamin D (Powe et al., 2013). To date, research on vitamin D status in athletes 
has overlooked DBP. Whilst there are data that support the associations between vitamin D and 
markers of bone and cardiac health in the general population, definitive relationships in the athletic 
population are yet to be established. Therefore, the aim of this thesis was to examine the 
relationship between vitamin D and measures of bone mass and cardiac structure and function 
within a large, ethnically diverse cohort of healthy athletes, with a focus to the role of DBP in 
determining racial differences in bioavailable levels. 
Studies 
1. Oral vs. Intramuscular Vitamin D Supplementation for Treating Insufficient Athletes 
2. No Association between Vitamin D Deficiency and Markers of Bone Mass in Athletes 
3. No Association between Vitamin D Status and Markers of Bone Mass in Non-Weight 
Bearing Athletes 
4. Why don’t serum Vitamin D concentrations associate with BMD by DXA? A case of being 
‘bound’ to the wrong assay? Implications for Vitamin D screening 
5. Severely Vitamin D-Deficient Athletes Present Smaller Hearts than Sufficient Athletes 
Methodical overview 
Male athletes registered with the Qatar Olympic Committee (QOC) presented for pre-competition 
medical assessment at Aspetar Sports Medicine Hospital, Qatar. All athletes completed a vitamin 
D questionnaire that included questions specifically related to country of origin, sporting 
discipline, skin type, self-reported exposure to daily sunlight, use of sunscreen, dietary 
supplements and/or medication, and an assessment of skin colour.  
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All individuals undertook bone densitometry and body composition analysis by dual-energy x-ray 
absorptiometry (DXA; Osteocore III, Perols, France, version 5.22b).  Venous blood samples were 
collected from athletes following an overnight fast and was analysed for PTH, calcium, albumin 
and serum 25[OH]D. Athletes were split into four 25[OH]D categories; severely deficient (<10 
ng/mL), deficient (10–20 ng/mL), insufficient (20–30 ng/mL), or sufficient (>30 ng/mL). Serum 
vitamin D binding protein (DBP) concentrations (µg/mL) were determined using a commercially 
available kit (R&D Systems, UK). Free, bioavailable, and DBP-bound 25[OH]D were calculated 
using equations from supplementary material of (Powe et al., 2013).  Lastly, all individuals 
assessed for family history of cardiovascular disease and personal symptoms, with a physical 
examination, 12-lead electrocardiogram and an echocardiogram. 
Results 
The key findings from the thesis are 1) serum 25[OH]D concentrations are not associated with 
markers of bone mass 2) bioavailable vitamin D is a better preceptor of BMD that serum 25[OH]D 
concentration and 3) severely 25[OH]D deficient athletes present with smaller cardiac structure 
that sufficient athletes.  
Conclusion 
In a healthy, ethnically diverse athletic population, there is no relationship between serum 
25[OH]D concentration and makers of bone mass, regardless of sporting type and that bioavailable 
vitamin D is a better predictor of bone mineral density. Suggesting that our chosen method of 
assessment may not be appropriate to identify true deficiencies. 
Systematic screening to determine 25[OH]D concentrations is expensive, and demonstrates a poor 
relationship to bone mass in an ethnically diverse athletic population. It can be argued that vitamin 
D testing should be reserved for the symptomatic athlete (i.e. musculoskeletal injury, REDs). In 
6 
 
turn, prophylactic vitamin D supplementation (2000IU/d D3) to ‘correct’ insufficient athletes with 
normal bone health can be questioned, since supplementation recommendations are based on a 
measure that is not associated with bone health. Severely 25[OH]D deficient athletes present with 
smaller (<10 ng/ml) presented significantly smaller cardiac structures than insufficient (20–30 
ng/ml) and sufficient (>30 ng/ml) athletes. The precise mechanism(s) causing this cardiac 
hypertrophy (or in our case, lack of hypertrophy) in the 25[OH]D-deficient state remains unclear.  
Clinically low vitamin D concentrations are detrimental to aspects of health that influence athletic 
performance. Therefore, the widespread prevalence of low serum 25[OH]D concentrations should 
not be ignored. However, vitamin D metabolism is a rapidly evolving field, with the prospect of a 
more complete picture of this complex endocrine system becoming ever so closer. The challenge 
for future research is to determine ethnically specific concentration ranges and evidenced based 
guidelines for the diagnosis and treatment of ‘true’ vitamin D deficiency and its impact on athlete 
health and performance. 
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1.1 Introduction 
Vitamin D is a lipophilic pro-hormone created when adequate exposure to sunlight is available via 
synthesis in the skin. Produced in the earliest forms of life over 750 million years ago (M. F. 
Holick, 2003b), vitamin D synthesis became essential for land-dwelling vertebrates that required 
a mechanism to increase the efficiency of calcium absorption and maintain calcium and phosphate 
homeostasis. The natural selection hypothesis suggests that lighter skin colour evolved to optimise 
vitamin D synthesis for humans living at higher latitudes.  
Fossil samples suggests the genus Homo sapiens evolved in equatorial Africa some 160,000 years 
ago, where the ultraviolet-B (UVB) rich insolation produced a deeply melaninised integument. 
The dark skin protected the dermis including the sweat glands from UV-induced damage, hence 
preserving thermoregulation function (Jablonski & Chaplin, 2000). Approximately, 40,000 years 
ago, hominids migrating into non-tropical latitudes faced the challenge of gaining sufficient 
vitamin D to meet their physiological requirements. As man’s exposure to solar radiation lessened, 
so did the need for melanin; which absorbs ultraviolet radiation in the dermis, required for 
converting 7-dehydrocholesterol, a derivative of cholesterol, to pre-vitamin D under thermal 
isomerisation (Yuen & Jablonski, 2010). Depigmentation evolved to optimise vitamin D 
production at higher latitudes as the amount of UVB radiation is weaker and filtered by the more 
angled and longer path through the atmosphere (Loomis, 1967). Despite the evolutionary drive for 
skin depigmentation, vitamin D deficiency is pandemic in general and athletic populations, partly 
due to modern migration, a predominately indoor lifestyle alongside increased air pollution 
(Hosseinpanah et al., 2010) and increased use of sunscreen due to an increased awareness of skin 
melanomas (de Gruijl, 1999; Smedby et al., 2005). 
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In 1914, McCollum et al. successfully isolated and subsequently identified fat soluble vitamin D. 
This discovery together with a greater understanding of vitamin D led to treatment of the bone 
disease, rickets, with ultra-violet light (McCollum & Davis, 1914). In recent years the interest in 
vitamin D research has increased exponentially (Figure 1.1), partly due to the observation of an 
increased prevalence of deficiency in many populations (regardless of age, gender and ethnicity) 
and the association between vitamin D deficiency and a wide range of disease states (B. Hamilton, 
2010).  In athletes, vitamin D research currently goes beyond the exploration of bone health and 
disease, into athletic performance. Given the prevalence and potential negative morbidity 
associated with deficiency (Cannell & Hollis, 2008; Larson-Meyer & Willis, 2010), regular 
vitamin D testing has been recommended as part of routine athlete screening. 
 
Figure 1.1 Research interest in vitamin D based on number of publication published per annum (PubMed) 
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1.2 Pre-competition medical assessment at Aspetar  
The Aspetar Athlete Screening Programme is a multidisciplinary sports medicine initiative 
designed to optimise the health of athletes. Aspetar (Qatar Orthopaedic Sports Medicine Hospital) 
is a FIFA medical centre of excellence based in Doha, Qatar, built in 2007 to provide world class 
sports medicine services to athletes of the region.  Unencumbered by historical biases and 
bureaucracy, Aspetar recognises the critical role pre-participation screening plays in the 
comprehensive care of the athlete and has set about establishing a preeminent screening service. 
To date, 13,000 plus athletes have presented for an annual athlete Periodic Health Examination 
(PHE); consisting of a number of standard components including but not limited to: Detailed 
medical and injury questionnaire, full blood work up, vitamin D assessment, DXA scan, dental X-
ray, chest X-ray, musculoskeletal and cardiovascular examination, electrocardiogram, 
echocardiogram and resting lung function. Analysis of the data from PHE has enabled Aspetar to 
identify cardiac pathologies, dental disease, haemoglobinopathies and vitamin D and iron 
deficiencies that are particularly prevalent within the athletic population in Qatar. Ongoing 
analysis of PHE data via an established research programme is essential to enable the identification 
of any new injury or disease trends, and to assess the efficacy of any injury and illness prevention 
interventions with each sport.  
1.3 Vitamin D deficiency 
Current clinical ranges (Figure 1.2) (M. Holick, 2007) are based upon the association between 
25[OH]D deficiency with osteomalacia and rickets (Heaney, 2011), and the approximate 
concentration at which parathyroid hormone (PTH) rises abruptly (Holick, 2009; Hollis, 2005; 
Zittermann, 2003). The cut off for insufficiency is the approximate concentration in which calcium 
absorption is maximized (Holick, 2009). Aspetar laboratory uses the conventional units for 
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25(OH)D (nanogram per milliliter [ng/mL]) whereas other laboratories use international system 
(SI) units (nanomole per liter [nmol/L]). The conversion factor to SI units is: 1 ng/mL = 2.496 
nmol/L. 
 
 
Figure 1.2 Vitamin D concentration classification (M. Holick, 2007) 
 
1.4 Prevalence of vitamin D deficiency 
Vitamin D deficiency is widespread within many athletic populations, with many severely 
deficient (Constantini, Arieli, Chodick, & Dubnov-Raz, 2010; Hamilton, Grantham, Racinais, & 
Chalabi, 2010; Magee et al., 2013), independent of sporting type or geographic location (Binkley 
et al., 2007; Hamilton et al., 2010; Lovell, 2008).  This is reflected in the data from Aspetar pre-
competition medical assessment (Table 1.0). 
Table 1.0 Distribution of vitamin D status of athletes screened at Aspetar 
Vitamin D Status Frequency Percentage 
Severely deficient 1167 21.6 
Deficient 2249 41.6 
Inadequate 1357 25.1 
Adequate 627 11.6 
Total 5400 100 
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There is accumulating evidence suggesting the role of vitamin D in skeletal muscle and 
performance (Close, Leckey, et al., 2013; D. J. Owens et al., 2015; D. J. Owens et al., 2014). 
However, there are no studies examining the impact of vitamin D status on bone mass and cardiac 
structure in an ethnically diverse, dynamically loading population? Given the high prevalence of 
25[OH]D deficiency in this cohort the relationship between vitamin D status and two main health 
parameters were identified for further examination; 1,) Bone mass and 2,) Cardiac structure and 
function, resulting in the production of this thesis.  
 
1.5 Bone Health 
Stress fractures are frequently observed in athletes, accounting for 0.7% to 20% of all sports 
medicine clinic injuries (Fredericson, Jennings, Beaulieu, & Matheson, 2006). Adequate vitamin 
D and calcium are required for bone development, growth and integrity. In the presence of low 
vitamin D concentrations and hypocalcaemia, levels of parathyroid hormone (PTH) are elevated 
to increase activation of bone resorption resulting in skeletal pathologies such as rickets, 
osteomalacia, or osteoporosis (B. Hamilton, 2010). However, current literature shows inconsistent 
associations between bone mineral density (BMD) and vitamin D status (Bischoff-Ferrari, Kiel, et 
al., 2009; Marwaha et al., 2011), particularly in racial minorities and athletic populations 
(Gerdhem, Ringsberg, Obrant, & Akesson, 2005; Hannan et al., 2008; Kremer, Campbell, 
Reinhardt, & Gilsanz, 2009). Athletes are a unique population, in that many are severely vitamin 
D deficient (Constantini et al., 2010; Hamilton et al., 2010; Magee et al., 2013), yet have the added 
stimulus of loading the musculoskeletal system through high-intensity dynamic sporting activity 
(Weidauer et al., 2014). Whilst it is considered that athletes should have ‘sufficient’ vitamin D 
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concentrations to optimise bone-mineral density (BMD), the exact value to ‘optimise’ bone health 
is equivocal. 
1.6 Cardiac structure and function  
Vitamin D deficiency is well known to have an adverse, long-term impact on cardiovascular 
function (M. F. Holick, 2006a; J. M. Lappe, Travers-Gustafson, Davies, Recker, & Heaney, 2007; 
Pittas et al., 2007). However, these studies were not deliberately designed to assess vitamin D 
status and established associations between vitamin D and cardiac structure and function only as 
a secondary marker. Yet the majority of these studies have only examined pathological conditions 
such as chronic kidney disease (Thadhani et al., 2012), thalassaemia-major (Noetzli, Carson, 
Coates, & Wood, 2011), hypertension (Kong et al., 2010), peripheral arterial disease (Fahrleitner 
et al., 2002) and congestive heart failure (Pilz, Marz, et al., 2008). Vitamin D receptors (VDR) are 
present throughout the heart and vascular system, specifically located in cardiac myocytes and 
fibroblasts (Chen et al., 2008). Furthermore, vitamin D deficiency is known to adversely affect 
cardiac contractility, vascular tone, cardiac collagen content, and cardiac tissue maturation 
(Achinger & Ayus, 2005).  
Regular participation in intensive physical exercise is associated with several structural and 
electrophysiological adaptations of the heart. Such cardiac adaptations are collectively referred to 
as the “Athlete’s Heart” (Chandra, Bastiaenen, Papadakis, & Sharma, 2013). Numerous factors 
affect the adaptations of the athlete’s heart including; sporting modality, duration and intensity of 
training, age, ethnicity, gender, anthropometry and performance enhancing substance abuse. 
However, it is also well recognized that many professional athletes are Vitamin D deficient (Close, 
Russell, et al., 2013; Magee et al., 2013), and currently no studies have examined the association 
between vitamin D status and cardiac structure and function in healthy athletes.  
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1.7 Ethnicity  
There appears to be a ‘paradoxical relationship’ between ethnicity and vitamin D concentration, 
that has largely been ignored, i.e. blacks generally have the lowest vitamin D but the greatest BMD, 
bigger hearts and reduced risk of fracture than Caucasians (Cauley et al., 2005; Hannan et al., 
2008; Riding et al., 2012). Vitamin D–binding protein (DBP), may account for observed racial 
differences in manifestations of vitamin D (Powe et al., 2013). DBP is the primary vitamin D 
carrier, binding 85%–90% of total circulating vitamin D, thus altering the biologic activity of 
circulating vitamin D (Bikle et al., 1986). Polymorphisms in the DBP coding are known to differ 
between ethnic groups (Engelman et al., 2008). Furthermore, Black African athletes are known to 
present with larger cardiac dimensions than Caucasians. Given this, it is reasonable that ethnic 
variations in DBP and bioavailable vitamin D may be related to cardiac structure.  
To date, research on vitamin D status in athletes has overlooked DBP, given the ethnic diversity 
of the athlete population screened at Aspetar (Figure 1.1), advice on treating vitamin D deficiency 
may be inaccurate.  
 
Figure 1.3 Ethnic distribution of athletes screened at Aspetar 
Arab
73%
Asian
6%
Black
10%
Caucasian
6%
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5%
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1.8 Aims and Hypotheses 
This thesis aims to examine the relationship between vitamin D and measures of bone mass, and 
cardiac structure and function within a large, ethnically diverse cohort of healthy athletes, with a 
particular focus the role of DBP in determining racial differences in bioavailable levels. 
To achieve this, the following objectives were established: 
1. To examine which modality of 25[OH]D supplementation was more efficacious at improving 
serum 25[OH]D status in an ethnically diverse athlete population (Chapter 4). 
2. To investigate the relationship between serum 25[OH]D concentrations and measures of bone 
mass in weight-bearing athletes (Chapter 5). 
3. To examine the relationship between serum 25[OH]D concentrations and markers of bone mass in 
non-weight bearing, Arabic athletes (Chapter 6). 
4. To evaluate the role of bioavailable vitamin D as a predictor of bone mass within a large cohort of 
healthy athletes (Chapter 7).  
5. To identify the associations between 25[OH]D status and cardiac structure and function in a large 
cohort of healthy athletes (Chapter 8). 
 
It was hypothesised that 1,) serum bioavailable vitamin D would associate more accurately with 
markers of bone mass and 2,) cardiac structure than serum 25[OH]D concentration in an ethnically 
diverse athlete population. 
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2.1 Background 
The beneficial effects of vitamin D are thought to have been known as far back as ancient Greece, 
when Hippocrates believed that living in areas with increased exposure to sunlight were 
advantageous to health. Centuries later, British medical missionary and epidemiologist, Theodore 
Palm, noted geographic differences in the prevalence of rickets, a disease that affected the young 
in epidemic proportions across Europe, America and North Africa.  Observing that children living 
in equatorial countries did not develop the condition (Palm, 1890).  
In 1906 Hopkins (Hopkins, 1906) postulated  the existence of essential dietary factors necessary 
for the prevention of diseases such as scurvy or rickets. McCollum and his co-workers furthered 
this work. In 1914, they isolated a fat soluble, non-saponifiable factor from butterfat that was 
necessary for normal growth and prevention of the eye disease xerophthalmia in young rats. This 
was named vitamin A (McCollum & Davis, 1914). 
By 1918, Sir Edward Mellanby, had conducted over 100 canine experiments investigating a cure 
for rickets. The experiment consisted of sunlight depravation and a diet of oats; the combination 
in which induced rickets. Mellanby further observed that feeding rachitic dogs with cod liver oil 
cured rickets within a few of months (Mellanby, 1941). This led to additional experimentation on 
canine puppies, in which he was able induce rickets in the animals by feeding them milk and bread 
(Mellanby, 1989). It was noted that the dogs had a similar appearance to that of rachitic children. 
The addition of B vitamins (yeast) and Vitamin C (orange juice) failed to prevent the manifestation 
of rickets. However, it was prevented with the addition of butterfat or more effectively with cod-
liver oil. 
In 1920 Hopkins (Hopkins, 1920) discovered that ‘vitamin A’ was destroyed when subjected to 
heat or aeration and no longer prevented the development of xerophthalmia in rats. McCollum et 
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al. (McCollum, Simmonds, Kinney, Shipley, & Park, 1995) tested his hypothesis, that cod liver 
retained its properties with respect to night blindness and fractures post-heat treatment. They 
observed that cod liver oil still prevented fractures after heating and oxygenation, but it no longer 
prevented night blindness (McCollum et al., 1995);  suggesting two separate compounds; one 
destroyed by heat and therefore responsible for preventing night blindness (vitamin A) and a 
second heat-stable component. Since water soluble factors had been termed “vitamin B” and anti-
scurvy factor “vitamin C”, the new factor was named “vitamin D”. 
This discovery and greater understanding of vitamin D was a major medical breakthrough and led 
to treatment of rickets with ultra-violet light. Furthermore, rickets could be cured not only by 
exposure of the host to sunlight, but also the ingestion of ultraviolet (UV) irradiated foods 
containing cholesterol (Goldblatt, 1923; Goldblatt & Soames, 1923; Hess, 1924; Steenbock, 1924). 
Initially the structure was named vitamin D1. However, this structure was later proven to be an 
adduct of tachysterol and vitamin D2, and thus vitamin D1 was actually identified in error. Further 
work led to the isolation of different forms of vitamin D. Ergocalciferol (vitamin D2) was derived 
from irradiation of plant sterols. The structure was confirmed by Windaus and Bock, who 
proceeded to induce the formation of vitamin D3 by irradiating precursor 7-dehydrocholesterol (7-
DHC) with ultraviolet radiation in animal skin (Goldblatt & Soames, 1923). Thus the structure of 
nutritional forms of vitamin D where identified (Windaus, Schenck, & von Werder, 1936).  
Today, there has been a considerable increase in research attention towards vitamin D. This is in 
part due to the re-emergence of the preventable bone disorder rickets and a well-documented 
worldwide prevalence of vitamin D deficiency (discussed in section 2.3). 
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2.2 Vitamin D biochemistry and function 
2.2.1 Forms of Vitamin D 
The majority of vitamin D is obtained from exposure of skin to sunlight, which produces vitamin 
D3 (cholecalciferol). Vitamin D can be obtained to a lesser extent from dietary intake in the form 
of vitamin D2 (ergocalciferol) (Figure 2.1). Ergocalciferol is obtained from UV irradiation of the 
yeast sterol ergosterol found in plants such as mushrooms. Vitamin D3 is produced in the skin on 
invertebrates and is present in oily fish such as mackerel, salmon and herring. Both undergo the 
same hydroxylation process and are transported in the blood, bound to vitamin binding protein 
(VDR) (Shinkyo, Sakaki, Kamakura, Ohta, & Inouye, 2004).  
 
Figure 2.1 Nutritional forms of Vitamin D. Vitamin D2 (left) and vitamin D3 (right). The structural difference between 
vitamin D2 and vitamin D3 is in their side chains. The side chain of D2 contains a double bond between carbons 22 
and 23, and a methyl group on carbon 24. 
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2.2.2 Synthesis and Metabolism 
Vitamin D is recognised as the ‘sunshine vitamin’, due to the production of Vitamin D3 
(cholecalciferol) in the skin via the photolytic process acting on 7-DHC, a derivative of cholesterol 
to pre-vitamin D3 by 6-electron conrotatory electrocyclic reaction (DeLuca, 2004). During 
exposure of mammalian skin to sunlight, 7-DHC in the epidermis cells absorbs ultra-violet B 
(UVB) radiation, specifically wavelengths at 290-315nm. This absorbed radiation rearranges the 
5, 7-diene in the B ring of the 7-DHC, causing the B-ring to form 9, 10-secosterol, pre-vitamin D3. 
Spontaneous isomerisation rearranges the doubles bonds of the thermodynamically unstable pre-
vitamin D3 to produce cholecalciferol (M. F. Holick, 2004). The thermal isomerisation process 
converts ~50 % of pre-Vitamin D3 to Vitamin D3 within 8 hours of exposure to UVB. The lower 
layers of the epidermis, stratum basale and stratum spinosum (Figure 2.2), have a greater capacity 
to produce pre-vitamin D3 (due to higher concentrations of 7-dehydrocholesterol (Norman, 1998).  
 
Figure 2.2 Layers of the human skin 
Once vitamin D3 enters the extracellular fluid space, it is attached to the vitamin D binding 
protein (DBP) in circulation, and thus enters the dermal capillary bed. Cholecalciferol is 
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subsequently converted to 25-hydroxyvitamin D (25[OH]D) in the liver (hepatocytes) under the 
control of a microsomal P450, CYP2R1 (Cheng, Levine, Bell, Mangelsdorf, & Russell, 2004; 
Shinkyo et al., 2004).  Further hydroxylation of 25[OH]D to the active form of vitamin D 1,25 
dihydroxyvitamin D (1, 25[OH]2D) occurs in the kidney (Figure 2.3).  The bioactive metabolite 
is transported in the blood and interacts with the VDR in the target tissue. When a sufficient 
quantity of vitamin D has been synthesised in the skin (at approximately 7-10% of the original 7-
dehydrocholesterol content), pre-vitamin D3 is converted to the biologically inactive 
photoproducts tachysterol and lumisterol (M. F. Holick, MacLaughlin, & Doppelt, 1981), 
serving as an endogenous toxicity regulator.
35 
 
 
 
Vitamin D obtained from dietary sources or via ultraviolet B 
exposure undergoes hydroxylation at the liver to form 
25[OH]D, the main marker of vitamin D status, and a further 
hydroxylation step in the kidney to form the biologically active 
1,25[OH]2D3. The bioactive metabolite interacts with the VDR 
in the target tissue. When biological activity is no longer 
required, further hydroxylation at carbon 24 inactivates 
1,25[OH]2D3 by acting as a blocking molecule at the VDR 
decreasing 1,25[OH]2D3 and forming 1,24,25[OH]D(Curtis, 
Aenlle, Roos, & Howard, 2014). 
Figure 2.3 Schematic of the Vitamin D metabolic pathway. 
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2.2.3 Vitamin D Receptor  
Research during the past two decades has established that the diverse biological actions of 
1,25[OH]2D3 are initiated through cell proliferation and specific gene expression, mediated by 
intracellular proteins termed vitamin D receptors (VDR) (Haussler et al., 1998; McDonnell, 
Mangelsdorf, Pike, Haussler, & O'Malley, 1987). Direct interaction between 1,25[OH]2D3 and the 
VDR prompts the receptor’s rapid binding to regulatory regions of target genes, resulting with the 
formation of large protein complexes whose functional activities are essential for directed changes 
in transcription (Sutton & MacDonald, 2003). The expression of networks of target genes combine 
to orchestrate specific biological responses. These highly complex responses are tissue-specific 
and range from actions essential for homeostatic control of mineral metabolism to cell 
proliferation, differentiation and functional activity (Bouillon et al., 2008). Historically, it was 
assumed that VDR targeted gene expression were limited to the intestinal mucosa and bone. 
However, vitamin D affects the expression of as much as 3% of the transcribed genome in target 
cells including those of the immune system, skin, the pancreas and bone (M. Holick, 2007).  
Of relevance to this thesis are the functional characteristics of the receptor in bone and cardiac 
tissue. In bone tissue 1,25[OH]2D3 binds and activates the VDR preventing the release of stored 
calcium in bone to serum by stimulating intestinal calcium absorption and renal reabsorption. This 
has been verified in genetically engineered VDR knock out mice (VDR-KO). Rachitic 
abnormalities could be recapitulated by ablation of the VDR gene. However, 1,25[OH]2D3 
supplementation did not ameliorate these abnormalities (Bouillon et al., 2008). Reduced dietary 
phosphate intake and high mineral content increased bone growth in VDR-KO mice. Furthermore, 
bone resorption was reduced in osteoblast specific VDR-KO mice due to decreased expression of 
receptor activator of nuclear factor kappa-B ligand (RANKL), an essential molecule in 
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osteoclastogenesis. This demonstrates that the skeletal VDR play a role in bone regulation, 
specifically the VDR in osteoblasts are a negative regulator of bone mass (Yamamoto et al., 2013). 
Inactivation of intestine-specific VDR in mature osteoblast and the intestine decreases intestinal 
calcium absorption. An increase 1,25[OH]2D3 levels stimulates bone turnover and suppress bone 
matrix mineralisation. Indicating that normocalcaemia has priority over skeletal integrity (Lieben 
et al., 2012).  
The notion of vitamin D involvement in cardiac function began over 25 years ago, with the 
identification of VDR in rat cardiac myocytes; thus establishing a link between vitamin D 
deficiency and cardiovascular dysfunctions, such as pathological cardiac hypertrophy, fibrosis and 
hypertension (Simpson, Thomas, & Arnold, 1985). These early animal studies supported the direct 
action of 1,25[OH]2D3 on cardiomyocyte VDR and indirect actions of circulating hormones. 
Furthermore, vitamin D deficient rats presented with enhanced ventricular muscle mass and 
contractile function (Weishaar, Kim, Saunders, & Simpson, 1990; Weishaar & Simpson, 1987a). 
Subsequently  the VDR was identified in human heart cells (O'Connell & Simpson, 1996). A 
significant breakthrough came with research showing VDR-KO mice presented with hypertension, 
significantly increased heart weight/body weight ratios and markedly increased left ventricular 
myocytes (Li et al., 2002; Zhou et al., 2008).  
These data strongly supported VDR involvement in the regulation of cardiovascular functions and 
bone health. 
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2.3 Vitamin D Deficiency 
2.3.1 Measuring Vitamin D 
Clinically, measuring serum 25[OH]D concentration provides the best estimate of vitamin D status 
(M. F. Holick, 1990; Iqbal, 1994) as both cholecalciferol and 1,25[OH]2D have short half-lives, 
24hrs and 4-6 hrs, respectively. Therefore, circulating levels provide limited information about 
vitamin D status. Additionally, cholecalciferol serum levels are affected by recent sunlight 
exposure and vitamin D ingestion and the assay is difficult to use due to the lipophilic nature of 
the molecule (Zerwekh, 2004). Whereas, 25[OH]D has a long serum half-life (3 weeks) and the 
25-hydroxylation step is unregulated, thus reflecting substrate availability. During vitamin D 
deficiency, parathyroid hormone increases and drives the renal 1-alpha-hydroxylase, so that 
1,25[OH]2D levels increase. Only in severe deficiency when substrate is depleted, does the 
1,25[OH]2D become low. Partially treated vitamin D deficiency also results in marked elevations 
of 1,25[OH]2D levels. 
 
2.3.2 Prevalence of Vitamin D deficiency 
Vitamin D deficiency is now recognised as one of the most common medical conditions in the 
world.  Deficiency (<20ng/mL), is common in countries at Northern latitudes (>35⁰ N) such as the 
UK (Bates et al., 2003), Ireland (Cashman et al., 2013), Denmark (Thuesen et al., 2012), France 
(Chapuy et al., 1997) and Germany (Hintzpeter, Mensink, Thierfelder, Muller, & Scheidt-Nave, 
2008). However, a similar prevalence has also been observed even in areas with ample sunlight 
exposure, for example  Australia (Daly et al., 2012), USA (Forrest & Stuhldreher, 2011) and Saudi 
Arabia (Elsammak, Al-Wosaibi, Al-Howeish, & Alsaeed, 2010). Vitamin D deficiency is also 
widespread within the global athlete population (Table 2.1). 
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As conferred in Chapter 1, serum 25[OH]D levels are categorised as being either severally 
deficient (<10 ng/mL), deficient (10-20 ng/mL), insufficient (20-30 ng/mL) or sufficient (>30 
ng/mL) (M. F. Holick, 2009). However, the categorisation of what constitutes 25[OH]D deficiency 
is widely debated. Studies suggest that a 25[OH]D value >30ng/mL promotes bone health and 
reduces fracture risk in healthy young and older adults, whilst others suggest levels 
>40ng/mL(Bischoff-Ferrari, Giovannucci, Willett, Dietrich, & Dawson-Hughes, 2006) maybe 
required. More conservatively, the US Institute of Medicine (IOM) advises concentrations of  ≥20 
ng/ml (50 nmol/l) would meet the needs of 97.5% of the population (Ross et al., 2011).  
Numerous endogenous factors and environmental influences can alter vitamin D production and 
contribute to deficiency, including altered vitamin D metabolism, mal-absorption and insufficient 
dietary intake of vitamin D.  Due to the significant role sunlight plays in vitamin D synthesis any 
factor that promotes UV light insulation contributes to vitamin D deficiency, such as sunscreen 
use, skin melanin, concealing clothing, atmospheric dust particles, latitude or time of day (M. F. 
Holick, 2004). 
The production of pre-vitamin D3 is directly related to the number of UVB photons absorbed by 
7-DHC. This process of production via photosynthesis is governed by a unique solar regulation to 
prevent intoxication from excessive sun exposure. Yet, UV radiation is a prominent and ubiquitous 
physical carcinogen.  Epidemiological evidence demonstrates that over exposure to UVB radiation 
has been linked to skin cancer and malignant lymphomas (de Gruijl, 1999; Smedby et al., 2005), 
but is dependent on various factors, such as age, skin type ethnicity and duration of exposure 
(Armstrong & Kricker, 2001). This increased awareness of the link between sunlight and skin 
cancer has be attributed to the rise in vitamin D deficiency (Reichrath, 2006). Sunscreen used in 
the prevention of skin melanomas reduces vitamin D synthesis with factor 30 sunscreen reducing  
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the conversation of  7-DHC to pre-vitamin D3 by more than 95% (Matsuoka, Ide, Wortsman, 
MacLaughlin, & Holick, 1987). The stratospheric ozone layer is efficient in absorbing UVB 
radiation above 290nm, which is responsible for producing pre-vitamin D3 in the skin (M. F. 
Holick, 2004). Air pollution is one of the primary factors in determining the percentage of ground 
level UVB. The level of air pollution is inversely related to the extent of solar UVB that reaches 
earth surface, consequently, more polluted areas have less UVB passage and as a result, lowers 
vitamin D cutaneous synthesis (Hosseinpanah et al., 2010).  
Table 2.1 Summary of studies assessing Vitamin D status in athletic populations 
Study Sample 
size 
Country (latitude) Type of sport Vitamin D status 
Allison et al. (2015) 750 Qatar (25⁰N) Soccer, handball, volleyball, 
basketball, sailing, archery, 
shooting, bowling 
Deficient:n=398 
(53%)         
Insufficient: 207 
(n=28%) 
Bescos Garcia and 
Rodriguez Guisado  
2011 
21 Spain (41⁰N) Basketball Deficient: 12  
Insufficient: 0 
Close et al. (2013) 61 
athletes, 
30 
controls 
UK (50⁰N) Rugby, soccer, flat jockeys, 
jump jockeys 
Deficient: 2 
Insufficient: 18 
(Close, Russell, et 
al., 2013) 
30 UK (53⁰N) Various sports including 
soccer and rugby 
Deficient: 6 
Insufficient: 11 
Constantini et al. 
(2010) 
98 Israel (31⁰N) Dancing, basketball, 
swimming, Tae Kwon Do, 
judo, gymnastics, table tennis, 
tennis, soccer, running, 
triathlon, sailing 
Deficient: 6 
Insufficient: 66 
Ducher et al. (2010) 18 Australia (31⁰S) Ballet Deficient: 2 
Insufficient: 7 
Galan et al. (2012) 28 Spain (37°N) Soccer Inadequate: fall: 2, 
winter: 18 
Guillaume, 
Chappard and 
Audran (2012) 
29 France (46°N) Cycling Insufficient: 3 
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Halliday et al. 
(2011) 
41 USA (41°N) Soccer, football, cross-country, 
track and field, cheerleading, 
dance, wrestling, swimming, 
basketball 
Deficient: fall: 1, 
winter: 1, spring: 1 
Insufficient: fall: 4, 
winter: 20, spring: 4 
Hamilton et al. 
(2010) 
93 Middle East (29°N) Football, handball, shooting, 
squash, cycling, martial arts, 
body building 
Deficient: 85 
Insufficient: 8 
Hamilton et al. 
(2014) 
342 Qatar (25°N) Soccer Deficient: 190 
Insufficient: 98 
He et al. (2013) 267 UK (53°N) Running, cycling, swimming, 
triathlon, team games, racquet 
sports 
Deficient: 18 
Insufficient: 68 
Lewis, Redzic and 
Thomas (2013) 
45 USA (38°N) Swimmers and divers Deficient: 0 
Insufficient: 0 
Lovell (2008) 18 Australia (35°S) Gymnastics Deficient: 1 
Insufficient: 5 
Magee et al. (2013) 84 Ireland (53°N) Gaelic games, boxers, 
Paralympians 
Insufficient/deficient: 
46 
Peeling et al. (2013) 72 Australia (25°S) Gymnastics, diving, sailing, 
field hockey, rowing, water 
polo, sprint cycling 
Deficient: 3 
Insufficient: 11 
Pollock et al. 
(2012) 
63 UK (53°N) Track and field Summer: deficient: 8; 
insufficient: 7 Winter: 
deficient: 8; 
insufficient: 6 
Shanely et al. 
(2013) 
50 USA (40°N) Football, basketball, baseball, 
track, wrestling, lacrosse, 
tennis 
Deficient: 13 
Insufficient: 20 
Shindle et al. 
(2011) 
89 USA (40°N) Football Deficient: 27 
Insufficient: 45 
Storlie et al. (2011) 39 USA (47°N) Football, cross-country, rugby, 
track and field 
Deficient: 1 
Insufficient: 10 
Willis et al. (2012) 19 USA (30°N) Running Deficient: 2 
Insufficient: 8 
Wilson et al. (2013) 37 UK (53°N) Jump and flat jockeys Deficient: 17 
Insufficient: 11 
Wolman et al. 
(2013) 
19 UK (52°N) Ballet Summer: deficient: 2; 
insufficient: 14 
Winter: deficient: 5; 
insufficient: 14 
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2.3.3 Ethnicity  
Skin pigmentation plays an essential role in the production of vitamin D from sunlight exposure. 
Melanin is the primary determinant of skin pigmentation and protects the body against UV 
radiation; however dermal synthesis of vitamin D is dependent of UV light. Highly pigmented 
skin, such as those of African origin, abrogates the majority of UV induced vitamin D synthesis 
(Shoenfeld, Amital, & Shoenfeld, 2009). The evolution of a more darkly pigmented complexion 
occurred early in the evolution of the human genus. Melanocytes produce the pigment melanin, 
which is deposited in vesicles termed melanosomes that exist in cutaneous epidermal cells. 
Melanosomes cover the cell nucleus and protect its components; in particular, nuclear DNA, from 
the deleterious effects of ultraviolet radiation (280–400 nm), which can lead to gene mutations. 
Melanin can also scavenge for reactive free radicals and oxidants (Shoenfeld et al., 2009). 
Unsurprisingly, people with dark skin require longer sunlight exposure to produce the equivalent 
amount of vitamin D as light skin individuals (M. F. Holick, 2003a).  Therefore, dark skinned 
populations living at high latitudes typically have lower serum 25[OH]D concentrations than those 
living at lower latitudes (Kant & Graubard, 2008). Studies examining vitamin D in an ethnically 
diverse population, demonstrate strong evidence that certain ethnicities (Black, Hispanic and South 
Asian) living in the USA and UK present with vitamin D deficiency, but are at lower risk of 
osteoporosis, rapid bone loss and associated fractures compare to Caucasians (Giovannucci et al., 
2006; Mersch, Middendorp, Bouhuys, Berrsma, & van der Hoofdakker, 1995; Patel et al., 2013; 
Powe et al., 2013) 
The genetic factors that may be attributed to variations between vitamin D in ethnicity are 
discussed later in this chapter (2.4.3. Vitamin D binding protein and Bioavailable vitamin D). 
 
43 
 
2.4 Role of vitamin D in health and associated disease  
2.4.1 Vitamin D and Cardiovascular disease  
The heart and vascular system, like skeletal muscle, contain VDR (Bischoff-Ferrari et al., 2005) 
and the associated apparatus for 1,25[OH]2D3 production; with the VDR are specifically located 
in cardiac myocytes and fibroblasts (Chen et al., 2008). The association between serum 25[OH]D 
concentration and cardiovascular function was first observed 25 years ago in Sprague-Dawley rats. 
Subsequent research groups have established associations between serum 25[OH]D concentration 
and cardiac structure and function (in both human and animal models). Studies on rat models have 
shown that depletion of vitamin D3 results in an increase in the contractile function of isolated 
hearts (Weishaar & Simpson, 1987b) and that 25[OH]D deficient rats present with significantly 
smaller ventricular myofibrils and increases in extracellular matrix proteins compared to 25[OH]D 
sufficient rats (Weishaar et al., 1990).  
There is increasing body of evidence that vitamin D deficiency is associated with increased risk of 
cardiometabolic outcomes. Although, many of these studies are cross-sectional, thus limiting the 
strength of the conclusions, several longitudinal observational studies have examined vitamin D 
status and aspects of cardiovascular disease. The Framingham Offspring study found an 
association between lower serum 25[OH]D concentrations and increased risk of cardiovascular 
events. Still, the association was only among those participants that were hypertensive at baseline 
(Wang et al., 2008). Studies have also demonstrated a link between vitamin D status and fatal 
cardiovascular events. Two studies found similar associations between fatal stroke and vitamin D 
status (Kilkkinen et al., 2009; Pilz, Dobnig, et al., 2008).  
Analysis from the Health Professionals Follow-up Study (HPFS) found a significant association 
between lower 25[OH]D concentration and increased risk of myocardial infarction (MI). However, 
44 
 
MI cases in this study were generally unhealthier than the controls, e.g. higher BMI, family history 
of MI, diabetes, hypertension and hypercholesterolemia (Giovannucci, Liu, Hollis, & Rimm, 
2008). Scragg et al, also demonstrated an inverse relationship between 25[OH]D levels and the 
incidence of MI in the general population. The authors acknowledge that this association may have 
been intermediated by physical activity (Scragg, Jackson, Holdaway, Lim, & Beaglehole, 1990). 
Data from the Third National Health and Nutrition Examination Survey (NHANES III) 
demonstrated a strong association between vitamin D deficiency and cardiovascular disease 
(CVD) risk factors (BP, diabetes, overweight, hypertriglyceridemia) (Melamed, Michos, Post, & 
Astor, 2008). A number of studies have examined the association between vitamin D deficiency 
and pathological conditions such as chronic kidney disease, thalassaemia-major, hypertension 
peripheral arterial disease and congestive heart failure (Table 2.2) (Dobnig et al., 2008; Fahrleitner 
et al., 2002; Giovannucci et al., 2008; Noetzli et al., 2011; Pilz, Marz, et al., 2008; Wang et al., 
2008).  
Studies examining the relationship between vitamin D and cardiac structure and function provide 
mixed results. In both the Tromsø and Hoorn studies serum 25[OH]D was not associated with LV 
structure and function. (Kamycheva, Johnsen, Wilsgaard, Jorde, & Mathiesen, 2013; Pilz et al., 
2009). Whereas, a recent study showed serum levels of 25[OH]D were significantly associated 
with LV diastolic dysfunction (Akin et al., 2014). Moreover, 25[OH]D deficiency was shown to 
adversely affect cardiac contractility, vascular tone, cardiac collagen content, and cardiac tissue 
maturation (Achinger & Ayus, 2005). Lastly, supplementation with an active vitamin D 
compound, paricalcitol, over 48 weeks in patients with chronic kidney disease (CKD), had no 
impact on left ventricular mass (Thadhani et al., 2012) The heterogeneity of studies may be caused 
by different definitions of vitamin D status, age structures, definition and determination of 
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cardiovascular endpoints and other confounding factors. The relationship of vitamin D with 
cardiac function remains highly controversial and despite the growing body of evidence 
demonstrating a link between vitamin D deficiency and cardiovascular risk factors, to date, no 
studies have examined the association between 25[OH]D status and cardiac structure and function 
in healthy athletes; a population known to be vitamin D deficient. 
Table 2.2 Summary of epidemiologic studies that have shown an association between hypovitaminosis D and 
mortality/cardiovascular events in the general population 
Reference N Population Key Findings 
(Dobnig et al., 2008) 3258 
Single center, referred 
for coronary 
angiography 
Lower two quartiles of serum 25[OH]D with 
higher all cause and cardiovascular mortality 
(Noetzli et al., 2011) 54 
Patients with 
thalassemia major 
(TM) 
While cardiac iron loading was more common 
in patients with vitamin D deficiency and 
secondary PTH elevation, values did not reach 
statistical significance. 
(Fahrleitner et al., 
2002) 161 
Patients with 
peripheral arterial 
disease (PAD) 
Patients with PAD IV showed significantly 
lower vitamin D3   and significantly higher 
PTH levels as compared to patients with PAD 
II. 
(Giovannucci et al., 
2008) 18255 
Health professionals 
follow up study 
Adjusted hazards for myocardial infarction 
compared with 25[OH]D levels 
(Pilz, Marz, et al., 
2008) 3316 
Single center, referred 
for coronary 
angiography 
Low vitamin D levels associated with increased 
fatal/nonfatal strokes 
(Wang et al., 2008) 1739 Framingham Offspring Study 
Low vitamin D levels associated with increased 
cardiovascular events 
(Melamed et al., 2008) 13311 NHANES III Lowest quartile of serum 25[OH]D with higher all-cause mortality 
(Kilkkinen et al., 2009) 6219 
Fatal cardiac event 
(national mortality 
registry 
Low vitamin D levels associated with higher 
risk of a fatal CVD event 
PTH = parathyroid hormone, PAD = peripheral arterial disease, NHANES III = Third National Health and Nutrition 
Examination Survey 
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2.4.2 Vitamin D and Bone Mass 
Vitamin D status is indicative of calcium absorption and bone mineralisation (Berry, Davies, & 
Mee, 2002), but observations of deficiency fail to universally affirm a proportionate susceptibility 
to bone loss, osteoporotic fractures or rickets (Hamson, Goh, Sheldon, & Samanta, 2003; Lowe, 
Mitra, Foster, Bhojani, & McCann, 2010). 
Bone is a metabolically active tissue capable of adapting to mechanical stimuli and repairing 
structural damage (Frost, 1969). Bone remodeling is a dynamic physiological process in which the 
combined effect of bone formation and bone resorption occurs at a specific location of the bone 
architecture. This enables bone to adapt to mechanical stresses, to repair its microstructure and 
thus maintain the mechanical integrity of the skeleton, and to maintain mineral homeostasis. Bone 
remodeling consists of two main subprocesses, 1) creation and mineralisation of bone by 
osteoblasts and osteocytes, 2) reabsorption of bone by osteoclasts, followed by bone formation by 
osteoblasts without causing large changes in bone quantity, geometry, or size (Ashman et al., 1985; 
Cowin, 1993). An imbalance in the regulation of bone remodeling’s two subprocesses results in 
many metabolic bone diseases, such as osteoporosis (Hsieh & Turner, 2001). 
The regulation of osteoblast function is of greatest relevance in understanding the function of 
vitamin D in bone mineralisation. Bone tissue is broken down by osteoclasts and rebuilt by 
osteoblasts. Osteoclasts are nucleated cells that play a crucial role in bone homeostasis, through 
the liberation of minerals and other molecules stored in the bone matrix. Particularly, osteoclasts 
store phosphate and growth factors and regulate the release calcium from bone. Osteoblasts are 
responsible for building new tissue, by producing osteoid, the organic component of bone, 
composed of collagen. As osteoblasts form new bone tissue, many become embedded within the 
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matrix and differentiate into osteocytes. The strength of this new tissue and risk of fracture can be 
assessed using bone mineral density (BMD g/cm2) by DXA. 
The active form of vitamin D, 1,25[OH]2D3 affects osteoblast function via different mechanisms. 
It controls remodeling via induction of receptor activator of NF-κB ligand (RANKL) (Kim, 
Yamazaki, Zella, Shevde, & Pike, 2006), regulates phosphate homeostasis by increasing fibroblast 
growth factor 23 (FGF23) (Shimada et al., 2004) and may enhance the response of mechanical 
loads via stimulation of mitogen-activated protein kinase signaling (Robling, Castillo, & Turner, 
2006). Lastly, 1,25[OH]2D3 stimulates mesenchymal stem cell (MSC) differentiation to the 
osteoblast lineage and suppresses adipocyte formation. Although all cells in the osteoblast lineage 
express VDR, 1,25[OH]2D3 may target different cells for different regulatory actions. The effect 
1,25[OH]2D3 on osteoblasts has been clearly shown in vitro models, however, there is poor 
agreement between in vitro and in vivo studies. Net bone growth ceases with the onset of 
adulthood, however, bone is constantly renewed throughout maturity by the action of osteoclasts 
that resorb bone and osteoblasts that replace bone lost by resorption. Vitamin D impacts on this 
osteoblast/osteocyte regulation in the process of bone remodeling and osteoblasts respond to a 
variety of resorptive signals including 1,25[OH]2D3 and PTH. There is now evidence that bone 
cells are capable of producing 1,25[OH]2D3 from the 25-hydroxyvitamin D3 (25[OH]D3) 
precursor, and that this activity is likely to account for the skeletal effects of circulating 25[OH]D3. 
This recent evidence suggests that bone is an intracrine organ of vitamin D metabolism (Figure 
2.4)(Anderson & Atkins, 2008). 
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Figure 2.4 Bone cells are capable of producing 1,25[OH]2D3 from the 25-hydroxyvitamin D3 (25[OH]D3) precursor, 
and that this activity is likely to account for the skeletal effects of circulating 25[OH]D3. 
 
The active vitamin D metabolite, 1,25[OH]2D3, is known to have systematic effects on both 
calcium and phosphate homeostasis. Adequate concentrations of vitamin D and calcium are 
required for bone development, growth and integrity; with skeletal  pathologies such as rickets and 
osteomalacia presenting when 25[OH]D concentrations are low (B. Hamilton, 2010). The role of 
vitamin D as a regulator of calcium and bone homeostasis is well established. 1, 25[OH]2D3, 
regulates intestinal calcium absorption, bone calcium resorption, and renal calcium reabsorption 
to maintain normal calcium levels in the blood (Lieben & Carmeliet, 2013). During periods of low 
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vitamin D concentration and hypocalcaemia, PTH secretion increases, resulting in an increased 
production of 1, 25[OH]2D3, that enhances mobilization of calcium from bone, when unable to 
acquire sufficient calcium from dietary absorption. Studies examining vitamin D deficiency and 
gene ablation, have demonstrated that 1,25[OH]2D3 also has a subtle, but direct action on osteoblast 
function, mediated by its interaction with the VDR. 
Low 25[OH]D status is a worldwide issue and is particularly low in northern Europe during winter, 
with one study highlighting that one-third of adolescent girls have a value lower than 10ng/ml and 
nearly all below 20ng/ml (Andersen et al., 2005). Although, vitamin D and calcium are regarded 
as fundamental in bone health the vast majority of evidence supporting this relationship is derived 
from cohorts of elderly individuals or groups with existing skeletal disorders (Bischoff-Ferrari et 
al., 2005; Cauley et al., 2008; B. Dawson-Hughes, Harris, Krall, & Dallal, 1997; Vanderschueren 
et al., 2013). There is increasing evidence of low BMD as a result of 25[OH] D deficiency in 
today’s youth (Franchi et al., 2014; Gordon, DePeter, Feldman, Grace, & Emans, 2004). Genetic, 
environmental and cultural factors associated with 25[OH]D deficiency (Kanis, 2002) impact on 
increase the risk of osteoporosis (Allali et al., 2006) and fracture risk (Dhesi, 2004). Low vitamin 
D concentration contributes to decreased BMD by elevating PTH, leading to increased calcium 
malabsorption, secondary hyperparathyroidism which sequentially increases osteoclast production 
(Breen et al., 2010; Cashman et al., 2008; Collins, Jasani, Fogelman, & Swaminathan, 1998; M. 
F. Holick, 2006b; Wöfl et al., 2013), resulting in increased incidence of stress fractures (Ruohola 
et al., 2006) and osteomalacia (Allali et al., 2006).  
Studies examining supplementation and bone health suggest that a higher dose (>700IU/d D3) may 
reduce hip and non-vertebral fractures by up to 20% (Bischoff-Ferrari et al., 2005; Boonen et al., 
2007), while lower intakes (<400 IU/d) failed to offer benefit (Bischoff-Ferrari, Willett, et al., 
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2009). Additionally, a study examining a mega oral dose of 500,000IU per year resulted in an 
increased risk of falls and fractures (Sanders et al., 2010). Conversely, improvements have been 
demonstrated with smaller doses (200IU/d and 400IU/d) in femoral and vertebral BMD (El-Hajj 
Fuleihan et al., 2006; Viljakainen et al., 2006) . Vitamin D supplementation may increase calcium 
absorption, suppress intact PTH secretion, slow bone loss and reduce the number of skeletal 
fractures (Bischoff-Ferrari, Dietrich, Orav, & Dawson-Hughes, 2004; Bess Dawson-Hughes & 
Bischoff-Ferrari, 2007). A recent study demonstrated vitamin D supplementation reduces the 
incidence of fractures in older adults, partly mediated by the effect of vitamin D on neuromuscular 
function (Chapuy et al., 1997).  
Optimum concentrations of serum 25[OH]D for the best possible skeletal health are still debated. 
Many investigators define the threshold for vitamin D sufficiency as the lowest serum 25[OH]D 
concentration that maximally suppresses PTH secretion and/or optimises BMD (Bischoff-Ferrari 
et al., 2006; Chapuy et al., 1997; Malabanan, Veronikis, & Holick, 1998). Based upon these 
criteria, most experts suggest that 25[OH]D levels of 21 to 30 ng/ml are indicative of relative 
vitamin D insufficiency, while levels ≤20 ng/ml constitute vitamin D deficiency. The US Institute 
of Medicine (IOM) states a serum 25[OH]D concentration of 20ng/mL is sufficient to maintain 
normal bone health in 97.5% of the population (Ross et al., 2011). Observational studies show 
inconsistent associations between bone mineral density (BMD) and serum 25[OH]D status, 
(Bischoff-Ferrari, Kiel, et al., 2009; Marwaha et al., 2011) particularly in racial minorities and 
athletic populations (Gerdhem et al., 2005; Hannan et al., 2008; Kremer et al., 2009).  
2.4.3 Vitamin D binding protein and Bioavailable Vitamin D 
Darker skin pigmentation has a photo-protective effect (Matsuoka, Wortsman, Haddad, Kolm, & 
Hollis, 1991), reducing the capacity of the skin to synthesise vitamin D3 (Clemens, Adams, 
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Henderson, & Holick, 1982). When examining 25[OH]D deficiency in ethnically diverse 
populations, studies demonstrate that Black and Hispanic men are at elevated risk of 25[OH]D 
deficiency but at lower risk of osteoporosis, rapid bone loss and associated fractures compare to 
Caucasians (Engelman et al., 2008). In Caucasians, BMD significantly decreases as serum 
25[OH]D declines but this is not observed in Black adults (Gutierrez, Farwell, Kermah, & Taylor, 
2011).  
Vitamin D–binding protein (DBP) provides insight into why certain ethnic groups may have 
distinct 25[OH]D and BMD relationships (Powe et al., 2013). Originally identified in 1959 
(Hirschfeld, 1959), its function as a binding protein for all vitamin D metabolites in serum was 
discovered in 1975 (Daiger, Schanfield, & Cavalli-Sforza, 1975). DBP is the primary vitamin D 
carrier, binding 85–90 % of circulating 25[OH]D and 1,25-dihydroxyvitamin D3 [1,25[OH]2D3], 
the biologically active form of vitamin D, with the remaining unbound 25[OH]D is considered to 
be bioavailable.  Bioavailable vitamin D is defined as 25[OH]D that is either free or bound to 
albumin, (10-15% of total 25[OH]D is bound to albumin) in contrast to free 25[OH]D, which 
accounts for less than 1% of total circulating vitamin D (Bikle et al., 1986). Since the affinity of 
albumin to 25[OH]D or 1,25[OH]2D3 is weaker than that of DBP, the loosely bound fraction and 
the free fraction consist of bioavailable 25[OH]D (Brown & Coyne, 2012).  
DBP is a 51–58 kDa multifunctional and highly polymorphic glycoprotein, synthesised primarily 
by the hepatic parenchymal cells. Originally known as the Group-specific component (Gc-
globulin), DBP is a member of a multigene family that includes albumin (Alb) and is a monomeric 
peptide of 458 residues and three disulfide-bonded, structural domains (Haddad et al., 1992). 
Recently, two binding regions have been localized, 1) vitamin D binding domain located between 
residues 35–49 at the N-terminal, and 2) actin binding domain positioned between residues 350–
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403 at the C-terminal. These are necessary to mediate DBP cellular functions (Zhang, Habiel, 
Ramadass, & Kew, 2010) (Figure 2.5). 
DBP has many physiologically important functions including transporting vitamin D3 metabolites, 
binding/sequestering globular actin and binding fatty acids to possible roles in inflammation and 
the immune system. Genotyping has identified two common single-nucleotide polymorphisms 
(SNP) in the coding region of the DBP gene (rs4588 and rs7041). These variants change the amino 
acid sequence and alter the protein function and are common enough to generate population-wide 
constitutive differences in vitamin D status (Malik et al., 2013). Combinations of these two SNPs, 
produce three major polymorphic forms of DBP (Gc1F, Gc1S, and Gc2) which differ substantially 
in their binding affinity for 25[OH]D, circulating concentration, and variation between ethnic 
groups and are in turn linked to DBP function. The frequencies of which differ globally, with Gc-
1F alleles more common in populations of African descent. (Powe et al., 2013). Bioavailable 
vitamin D is calculated from the concentrations of total 25[OH]D, DBP, and albumin, with or 
without a factor accounting for DBP genotype-specific binding affinities (Equation shown 3.6). 
Variants of DBP have been associated with adverse health outcomes including diabetes (Cho et 
al., 2007), cancer (Bijian et al., 2009), epilepsy (Xiao et al., 2009) and Alzheimer’s and Parkinson 
disease (Zhang et al., 2008). However, these correlations have been difficult to interpret, as the 
biology of DBP that is currently not well understood.  
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Figure 2.5 (A) 3D structure of DBP with 3 domains. (B) Schematic representation of the DBP domain structure. The 
458 amino acid sequence of human DBP with the three structural domains and known functional regions indicated. 
Domain I: amino acids 1–191; domain II: 192–378; domain III: 379–458; vitamin D binding: 35–49; C5a chemotactic 
cofactor: 130–149; G-actin binding: 373–403. The domain and functional regions are drawn approximately to scale. 
The N-terminus refers to the start of a protein or polypeptide terminated by an amino acid with a free amine group (-
NH2). By convention, peptide sequences are written N-terminus to C-terminus (Malik et al., 2013).  
 
DBP is not included in the majority of studies examining vitamin D deficiency and measures of 
health, however, the racial differences in DBP have been explored.  A recent study demonstrated 
that community-dwelling blacks had lower levels of DBP and serum 25[OH]D compared to 
Caucasians. The authors hypothesised that blacks have similar levels of bioavailable 25[OH]D 
which may explain why blacks present with consistently low serum 25[OH]D compared with 
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whites but higher BMD (Powe et al., 2013). This questions the validity of the commonly used lab 
test for 25[OH]D levels in assessing vitamin D deficiency. DBP may provide insight into why 
currently no universally accepted consensus for vitamin D levels exist. Consistent with the ‘free 
hormone’ hypothesis, several recent studies have shown that some functions of vitamin D may be 
more closely related to the free or bioavailable fraction of vitamin D than to total serum 25[OH]D 
concentrations. For instance, the free or bioavailable fraction of circulating 25[OH]D was more 
strongly associated with bone mineral density than the total levels in healthy adults (Powe et al., 
2011). Therefore, serum bioavailable vitamin D may be more accurate for assessing bone mass in 
a healthy ethnicity diverse athletic population.  
 
2.5 Effect of vitamin D supplementation on health 
2.5.1 Treatment/Supplementation 
In the early part of the 20th Century, UVB radiation was used as an ergogenic aid (Cannell, 
Hollis, Sorenson, Taft, & Anderson, 2009) and research over that period suggested that both 
cardiovascular fitness and muscular endurance were enhanced with increased exposure to 
ultraviolet radiation (B. Hamilton, 2012). However, there remains little direct evidence for 
this and these findings are yet to be reproduced (Racinais, Hamilton, Li, & Grantham, 2010).  
 
2.5.2 Ergocalciferol vs. Cholecalciferol 
Two forms of vitamin D supplementation are commonly used, cholecalciferol (D3) and 
ergocalciferol (D2) (M. Holick, 2007). Both cholecalciferol, the most common form of Oral 
supplementation and ergocalciferol, its intramuscular (IM) counterpart, appear to improve 
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serum 25[OH]D levels in deficient individuals (Biancuzzo, Clarke, Reitz, Travison, & Holick, 
2013; M. F. Holick et al., 2008). In turn, there is evidence to suggest that D2 has poorer 
bioefficacy than D3, to increase serum 25[OH]D (Binkley et al., 2011) and thus may have 
limited use as a treatment supplement (Houghton & Vieth, 2006). 
 
2.5.3 Mode of Supplementation (Oral vs. Intramuscular) 
A single IM injection removes potential gut malabsorption and compliance issues, however a 6-
month wait is required to ascertain if the deficiency has been corrected. Previous studies have 
attempted to examine the efficacy of oral vs. IM modalities, but with variable dosages and 
durations in many of these investigations, the clinical effectiveness of both modalities at 
correcting 25[OH]D deficiency remains unclear (Billoo et al., 2009; Zabihiyeganeh, Jahed, & 
Nojomi, 2013). Furthermore, the majority of these studies have only examined individuals with 
known pathologies or health related issues, such as rickets, chronic kidney disease 
hyperparathyroidism, diabetes, cancer, osteoporosis and CVD, and not otherwise healthy 
athletes.  
Zabihiyeganeh et al, examined the efficacy of 300,000IU/D3 given orally or intramuscularly in 
92 adults with hypovitaminosis D. Both regimens were considered effective in treating 
hypovitaminosis D. Although the oral route produced significantly higher serum 25[OH]D levels 
at the 3 month point, although was not advantageous at 6 months (Zabihiyeganeh et al., 2013).  
Conversely, in a study involving paediatric patients with rickets, both oral and injectable forms 
of cholecalciferol were observed to be effective at increasing 25[OH]D levels, but the injectable 
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form was shown to be more efficacious. The authors suggest these findings are due to poor 
adherence to oral supplementation (Billoo et al., 2009). 
Despite worldwide deficiency and increased public awareness of 25[OH]D deficiency, there are 
unanswered questions around which pharmaceutical form of vitamin D supplementation (oral or 
injection) is the most effective at correcting deficiency (Hashemipour et al., 2004). 
The recommended maximum intake of vitamin D varying, dependent on age and vitamin D status. 
The US institute of medicine (IOM) recommends a daily intake from 400 to 4000IU, and state that 
toxicity is unlikely to be observed with intakes as high as 10,000IU/d. However, high dose, 
(50,000IU/d) vitamin D are readily available. These ‘mega dose’ capsules are seen to improve 
adherence, i.e. one 50,000IU capsule per month vs. 1000IU/d over a one-month period. However, 
research shows high dose vitamin D3 supplementation (70,000 IU/wk) may be detrimental for its 
intended purposes due to increasing 24,25[OH]2D production. Furthermore, withdrawal from high 
dose supplementation may inhibit the bioactivity of 1,25[OH]2D3 as a consequence of sustained 
increases in 24,25[OH]2D that persist as 25[OH]D and 1,25[OH]2D concentrations decrease. These 
data infer that smaller daily doses (1000-2000IU) may be most appropriate and gradual withdrawal 
from supplementation as opposed to rapid withdrawal may be favorable (D. Owens et al., 2016). 
 
2.6 Effect of vitamin D on Athletic Performance 
Athletic performance is determined by many genetic and environmental factors (MacArthur & 
North, 2005). Recently, vitamin D has been proposed as both performance limiting and enhancing 
when in deficiency and abundance (Cannell et al., 2009; B. Hamilton, 2012). The suggestion that 
vitamin D deficiency may act as a performance inhibitor has potentially widespread ramifications 
for athletes. Indeed, vitamin D deficiency may impact on athletic performance as a cause of 
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reduced training quality, increased injury/illness frequency and duration (Halliday et al., 2011). 
Despite variation in sun like exposure due to higher latitude and seasonal variation, athletes that 
train and compete indoors are at risk of vitamin deficiency all year round (M. Holick, 2007). 
Numerous studies have examined the association between serum 25[OH]D and factors that may 
impact athletic performance, such as maximal oxygen uptake (Ardestani et al., 2011), 
cardiovascular system (Allison, Close, et al., 2015), immune function (He et al., 2013) and 
neuromuscular coordination (Bischoff-Ferrari, Dietrich, Orav, Hu, et al., 2004), but currently 
evidence is inconclusive. 
 
2.6.1 Bone 
Whilst numerous studies have examined the relationship between 25[OH]D deficiency and bone 
health in the general population,  little is known about athletes, a population where stress fractures 
are frequently observed (Johnson, Weiss, & Wheeler, 1994).   
Mechanical loading from training or competition is associated with higher BMD even when 
adjusting for weight. Nikander et al., (Nikander, Sievanen, Heinonen, & Kannus, 2005) identified 
weight modality as a determinant of the structure and strength of femoral neck; observing that 
athletes competing in high-impact (basketball and volleyball) and odd-impact sports (football) 
demonstrated greater BMD scores than low impact sports such as swimming and cycling, whilst 
increased body mass contributes to the process of bone remodeling, and forms mechanically 
appropriate bone structure (Nikander et al., 2005). These findings are supported by studies 
examining different athlete groups such as, senior athletes (mean 65.9 years old; male and female) 
(Leigey, Irrgang, Francis, Cohen, & Wright, 2009), female adult athletes (Narra, Nikander, Viik, 
Hyttinen, & Sievanen, 2013), male combat sports (Andreoli et al., 2001), world-class skiers 
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(Nikander, Sievanen, Heinonen, Karstila, & Kannus, 2008) and in adolescent boys (Dias Quiterio, 
Carnero, Baptista, & Sardinha, 2011).  
However, non-weight bearing athletes forgo the same skeletal loads that produce greater BMD 
scores (Fredericson et al., 2007; Nikander et al., 2005) and are at higher risk for low BMD 
(Guillaume, Chappard, & Audran, 2012; Rector, Rogers, Ruebel, & Hinton, 2008; Smathers, 
Bemben, & Bemben, 2009). Exercise is associated with an increase in BMD (Nikander, Sievanen, 
Uusi-Rasi, Heinonen, & Kannus, 2006; Rantalainen, Nikander, Daly, Heinonen, & Sievanen, 
2011), whilst increased body mass contributes to the process of bone remodeling, and forms 
mechanically appropriate bone structure (Nikander et al., 2005).  
The stimulus of loading the musculoskeletal system through high-intensity dynamic sporting 
activity is believed to compensate for 25[OH]D deficiency with the absence of poor bone health 
in athletes (Nikander et al., 2006; Weidauer et al., 2014). However, Hamilton et al, demonstrated 
that BMD and 25[OH]D status were not statistically linked in a sample of Middle Eastern male 
athletes. Suggesting that genetic polymorphism in the 25[OH]D/1,25[OH]2D pathway may 
potentially account for some of these differences (Hamilton et al., 2010; Rabon-Stith et al., 2005).  
 
2.6.2 Athlete’s Heart  
Research examining the athlete’s heart started more than 100 years ago, when Henschen 
documented that Nordic skiers presented with larger hearts than sedentary individuals (Henschen, 
1899). Since then research has shown that regular and prolonged participation in intensive physical 
exercise is associated with several structural and electrophysiological cardiac adaptations that 
enhance diastolic filling and facilitate a sustained increase in the cardiac output that is fundamental 
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to athletic excellence. Such cardiac adaptations are collectively referred as the “Athlete’s Heart” 
and are frequently reflected on the 12-lead ECG and imaging studies (Papadakis et al., 2012). 
Pre-participation screening is becoming a global phenomenon, involving athletes of diverse ethnic 
groups. Main sporting bodies including FIFA, UEFA and the International Olympic Committee 
have endorsed pre-participation screening recommendations, despite limited understanding of the 
impact of ethnicity upon the 12-Lead ECG and cardiac structure. 
The vast majority of athletes exhibit relatively mild structural and electrical changes, which are 
considered to be within conventionally defined normal limits. A small proportion of athletes 
develop pronounced changes, which overlap with phenotypic expressions of cardiac diseases 
implicated in exercise-associated sudden cardiac death (SCD). In such circumstances, the 
differentiation between physiological adaptation and cardiac pathology is challenging but an 
erroneous diagnosis has the potential for grave consequences. 
Emerging studies suggest that ethnicity is an important determinant of cardiovascular adaptation 
to exercise, which should always be considered during assessment of an athlete. It is well 
established that ethnicity is one of the several factors that influence manifestations of athlete’s 
heart (Figure 2.6). The exponential increase in the number of elite athletes from varying ethnic 
backgrounds has driven the researchers to investigate the effect of exercise in those ethnicities. 
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Figure 2.6 Schematic representation of demographic and pathological factors, which may influence the cardiovascular 
adaptation to exercise (Papadakis et al., 2012). 
Studies demonstrate ethnic differences in cardiac structure and function. Papadakis et al., revealed 
that in elite male athletes African/Afro-Caribbean athletes exhibit an left ventricular (LV) cavity 
size of similar magnitude to white athletes (52.6±4.4 vs 52.6±4.3 mm, p>0.05) but demonstrate 
slightly larger left atria  (35.4±4.5 vs 34.7 ±4.7 mm, p=0.002) and aortic root (30.2±3.3 vs 29.5 
±3.3 mm, p<0.001) diameters (Papadakis et al., 2011). These findings are supported by the 
findings of Basavarajaiah et al, and Riding et al., who demonstrated that Black African athletes 
present significantly greater wall thicknesses and resultant LV masses than Arabic and Caucasian 
athletes (Basavarajaiah et al., 2008; Riding et al., 2012). Furthermore, a recent study examining 
athletes from Asia demonstrated that Japanese soccer players presented with a high end diastolic 
diameter compared to Black or Caucasian players (55.2±3.3 vs 52.2±3.8 vs 53.9±3.7 mm, 
respectively, p<0.01) (Kervio et al., 2013). 
Recent data has demonstrated a high prevalence of vitamin D deficiency across ethnicities, 
particularly within Arabic athletes (Hamilton et al., 2010). Whilst vitamin D deficiency is 
associated with hypertension, MI, and stroke, as well as other cardiovascular-related diseases 
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(Brøndum-Jacobsen, Benn, Jensen, & Nordestgaard, 2012; Hsia et al., 2007). To date no studies 
have investigated the association between vitamin D status, ethnicity and cardiovascular function 
in athletic populations.  
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3.1 Ethical approval 
Ethical approval for the research studies described in Chapter 4 and Chapter 8 were obtained 
from the Shafallah Medical Genetics Centre Ethics Committee, with all athletes completing 
informed consent in either Arabic or English. For subsequent studies (Chapters 5,6 & 7) ethical 
approval was obtained from Qatar Anti-Doping Laboratory IRB, with all athletes completing 
informed consent. All procedures conformed to the standards of the Declaration of Helsinki. 
 
3.2 General Screening & Inclusion Criteria 
Male athletes registered with the Qatar Olympic Committee presented for pre-competition medical 
assessment at Aspetar Sports Medicine Hospital, Qatar. All athletes completed a vitamin D 
questionnaire in collaboration with an Arabic, French or English-speaking nurse. This included 
questions specifically related to country of origin, sporting discipline, skin type, self-reported 
exposure to daily sunlight (nil or <30 min, 30–60 min, 60–120 min, >120 min), use of sunscreen, 
dietary supplements and/or medication, and an assessment of skin colour (dark, olive, fair). 
Inclusion criteria for all studies were: 
 Male athletes (No female athletes were included in the study because of low participation 
rates in Qatar)  
 Aged 18-30 yrs. 
 Free from any known comorbidities or family history of osteoporosis or bone disease 
 Serum parathyroid hormone, calcium within normal range. 
 Not taking supplemental Vitamin D2 or D3, fish oils or multi vitamins 
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3.3 Assessment of Bone Mineral Density 
Dual-energy x-ray absorptiometry (DXA; Osteocore III, Perols, France, version 5.22b) scanning 
was used to assess hip and spine bone mineral density (BMD). A certified technologist from the 
International Society of Clinical Densitometry performed all calibrations and measurements. 
Quality assurance was performed each morning before testing. The coefficient of variation for 
these records is <1.01% in Aspetar. BMD was calculated in g/cm2 for spine (L2–L4), hip-neck and 
hip-total. In addition, the clinical age-matched and gender-specific Z-score index was used to 
classify the BMD. T-scores were calculated for those athletes older than 20 years as per WHO 
recommendations ("Prevention and management of osteoporosis," 2003). Participants under 20 
years were not included in the sub-analysis for (T-score) osteoporosis and osteopenia. 
 
3.4 Laboratory analyses 
3.4.1 Blood sampling 
Venous blood samples were collected from athletes following an overnight fast. For the 
biochemical measures, samples (10 mL) were drawn from an antecubital vein using a tourniquet. 
The tourniquet has been applied for less than one minute (~20-30 seconds), in order to avoid local 
hemoconcentration that may result in erroneous laboratory findings (Nikolac et al. 2013). Serum 
was collected using blood collection tubes from BD vacutainer from the UK that were purple 
(spray-coated K2EDTA) and gold (acrylic based gel and a spray-dried clot activator coating). The 
blood sample was separated into two aliquots (5mL SST tubes), one aliquot for the immediate 
analysis of PTH, calcium and albumin and one aliquot for 25[OH]D analysis. Blood samples were 
centrifuged ~30 second after collection in a swinging bucket rotor of the Multifuge® 1S/1S-R for 
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10 minutes at 3000-rpm. The resulting serum was decanted and stored in Eppendorf tubes 
(Eppendorf, Hamburg, Germany).  
 
3.4.2 25[OH]D 
Serum samples for 25[OH]D were stored at -80°C to be analyzed later by Enzyme-linked 
immunosorbent assay (ELISA). Serum 25[OH]D was analysed utilizing chemiluminescent 
immunoassay technology (Liaison® 25-OH Vitamin D Total Assay; DiaSorin Inc., Saluggia, 
Italy). Serum is incubated with antivitamin-D coated microparticles and isoluminol derivative-
conjugated 25OHD before measurement of the chemiluminescent signal.28 The Liaison 25(OH)D 
assay is co-specific for 25(OH)D2 and 25(OH)D3, so it reports a total 25(OH)D concentration with 
sensitivity set at 7 ng/mL. The intra- and inter-assay coefficient of variation (CV) was 7.6–9.4% 
and 9.8–13.4%, respectively. The dynamic range was 4.0 – 150 ng/mL and functional sensitivity: 
<_ 4.0 ng/mL. An automatic ELISA microplate reader (Infinite® 200 PRO NanoQuant, 
Switzerland) and Magellan Standard software (version 7.1) were used. Based upon the serum 
25[OH]D results, athletes were split into four 25[OH]D categories; severely deficient (<10 
ng/mL), deficient (10–20 ng/mL), insufficient (20–30 ng/mL), or sufficient (>30 ng/mL). Serum 
25(OH)D levels have been demonstrated to be stable in spite of multiple freeze-thaw cycles 
 
3.4.3 PTH, calcium and albumin 
PTH: Levels of intact PTH were plasma samples were analysed (within ~15 minutes after 
collection) on Architect I1000 machine with chemiluminescence microparticle immunoassay 
(CMIA). The inter-assay CV was 2.5%. Calcium and albumin measures: serum samples were 
analyzed (within ~15 minutes after collection) on Dimension Vista® System with bi-chromatic 
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endpoint technique. Calcium reacts with o-cresolphthalein complexone to form a purple complex. 
The amount of complex thus formed is proportional to the calcium concentration and is measured 
using a bichromatic (577, 540 nm) endpoint technique. Analytical Measurement Range (AMR): 
5.0–15.0 mg/dL [1.25–3.75 mmol/L]. Albumin: In the presence of a solubilizing agent, 
bromocresol purple (BCP binds to albumin at pH 4.9. The amount of albumin-BCP complex is 
directly proportional to the albumin concentration. The complex absorbs at 600 nm and is 
measured using a polychromatic (600, 540, 700 nm) endpoint technique. Analytical Measurement 
Range (AMR): 0.0–8.0 g/dL [0–80 g/L]. 
All the biochemical measures and analyzes were completed at the Aspetar Hospital laboratory, 
which is accredited by the College of American Pathologists (CAP).  
 
3.4.4 Conversion Factor 
Aspetar laboratory uses the conventional units for 25(OH)D (nanogram per milliliter [ng/mL]) 
whereas other laboratories use international system (SI) units (nanomole per liter [nmol/L]). The 
conversion factor to SI units is: 1 ng/mL = 2.496 nmol/L. 
 
Concentration (ng/mL) = Concentration (pmol/mL) x Molar Mass 
                                                                      1000    
 
3.4.5 Vitamin D-Binding Protein 
Serum vitamin D binding protein (DBP) concentrations (µg/mL) were determined using a 
commercially available kit (R&D Systems, UK). The limit of sensitivity was ≤0.65 ng/mL and an 
inter-assay coefficient of variation was 7.2%. An automatic enzyme-linked immunosorbent assay 
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(ELISA) microplate reader (Infinite® 200 PRO NanoQuant, Switzerland) and computer software 
Magellan Standard (version 7.1) were used to analyse DBP. 
 
3.5 Estimation of Bioavailable Vitamin D 
Free, bioavailable, and DBP-bound 25[OH]D were calculated using equations from supplementary 
material (Powe et al., 2013) adapted from those described by Vermeulen and colleagues 
(Vermeulen, Verdonck, & Kaufman, 1999). These methods use the free hormone hypothesis to 
define bioavailable hormone as the fraction that is both free and albumin-bound, that is, the fraction 
not bound to circulating binding proteins such as DBP. 
Free levels of 25[OH]D were calculated using the following equation: 
[Dfree]  =
[DDBP]
KDBP
[𝑇𝑜𝑡𝑎𝑙 𝐷𝐵𝑃] − [DDBP]
 
 
After calculating free 25-hydroxyvitamin D, equation 2 was used to calculate the concentration of 
bioavailable (non-DBP bound vitamin):  
[Bio D] = [Dfree] + [DAlb] = (Kalb ∗ [𝐴𝑙𝑏] + 1) ∗ [DFree] ) 
Definitions 
 [DFree] = concentration of free (unbound) 25-hydroxyvitamin D 
 [DDBP] = concentration of D-binding protein-bound 25-hydroxyvitamin D 
 KDBP = genotype-nonspecific affinity constant between 25-hydroxyvitamin D and DBP = 0.7 x109 
M-1 
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 [Total DBP] = concentration of serum DBP g/L 
 [Bio D] = concentration of bioavailable D 
 [DAlb] = concentration of albumin-bound vitamin D 
 Kalb = affinity constant between vitamin D and albumin = 6 x105 M-1 
 Alb = albumin 
 
3.6 Pre-participation cardiovascular screening 
All individuals were screened using a precompetition medical assessment form, examining family 
history of cardiovascular disease and personal symptoms, with a physical examination undertaken 
by a sports medicine physician. A standard 12-Lead ECG was obtained using a GE Mac 5500 
(New York, USA) after a 5-min rest in the supine position. 
Echocardiographic examination was performed using a commercially available ultrasound system 
(Philips, USA) by an experienced sports cardiologist.  Images of the heart were obtained in the 
standard planes, using previously published criteria (Riding et al., 2013). The left ventricular (LV) 
wall thickness was measured from two-dimensional short-axis views in end-diastole, with the 
greatest measurement within the LV wall defined as the maximal LV wall thickness (mLVWT). 
M-mode echocardiograms derived from two-dimensional images in the parasternal long axis were 
used for the measurement of LV end-diastolic diameter (LVED), left atrial (LA) and aortic root 
(Ao) diameter according to American Society of Echocardiography standards (Sahn, DeMaria, 
Kisslo, & Weyman, 1978) with LV diastolic volume (LV volD) derived using Simpson’s biplane 
methodology. LV mass (LVM) was calculated using the formula of Devereux (Devereux & 
Reichek, 1977) but was also scaled for body surface area (BSA). LV diastolic function was 
assessed using pulsed-wave Doppler recordings from apical four-chamber orientations. All data 
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were analysed offline and a minimum of three cardiac cycles was averaged for all indices. For the 
tissue Doppler assessment of E’, the apical four-chamber orientation was utilized and a 2 mm 
sample volume was positioned at both the septal and lateral wall aspect of the mitral valve annulus 
ensuring the best alignment between wall motion and the ultrasound beam. The Nyquist limit was 
set between 10 and 35 cm/s. Peak early diastolic (E0) tissue myocardial velocity was recorded and 
E/E0 was calculated. 
 
3.7 Further exclusion 
Athletes reporting symptoms (i.e. Discomfort, pressure, heaviness, or pain in the chest or arm), a 
family history of sudden cardiac death (SCD), and echocardiographic and/or ECG abnormalities 
considered to represent potential pathology were investigated further with 24 h ECG, maximal 
exercise testing and cardiac MRI to evaluate the broader phenotype of common cardiomyopathic 
processes such as hypertrophic cardiomyopathy (HCM) and arrhythmogenic right ventricular 
cardiomyopathy (ARVC). 
 
3.8 Statistical analysis  
All data was coded and analysed using SPSS Predictive Analytics Software (v.20, IBM 
Corporation. New York, US). Descriptive statistics were presented as mean and standard deviation 
(SD) for continuous variables. For categorical variables, frequency and percentage were reported. 
For the comparison of two group means, a t-test was used and where comparison of multiple 
groups of means was required an analysis of variance (ANOVA) was used. Data sets were first 
checked for normal distribution and where data violated the assumption of normality, a natural 
log-transformation was applied prior to analysis. Post-hoc analyses with Bonferroni correction 
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were performed where appropriate for further comparisons in the event of significance. To 
determine the relationship of bone mass parameters with serum 25[OH]D, DBP and bioavailable 
25[OH]D, simple regression without covariates and multiple linear regression analysis including 
covariates such as age and ethnicity was performed with bone mass as a dependent variable, with 
age and ethnicity covariates. Parameter estimates along with standard error were reported. A p-
value<0.05 was used as a cut-off for statistical significance. 
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4.1 Abstract 
Purpose: To correct vitamin D (25[OH]D) insufficiency in athletes, the physician may decide to 
supplement. However, there is no consensus as to the most efficacious form of treatment to correct 
insufficiencies. The present study examined which modality of supplementation was more 
efficacious (Oral vs. single intramuscular injection IM) at improving serum 25[OH]D 
concentration in insufficient (<30 ng/mL) athletes. 
Methods: In a non-randomised patient-choice approach, 355 athletes presenting a serum 25[OH]D 
level ≤ 30 ng/mL were treated with either Oral Cholecalciferol D3 [2000IU/d for 60 days] (n =123) 
or a single IM Ergocalciferol D2 injection [300,000 IU] (n = 232), and reassessed at 2-months. 
Results: There were no significant differences in baseline serum 25[OH]D concentration between 
Oral vs. IM groups (13.2 ± 0.5 vs. 14.2 ± 0.4 ng/mL).  Following 2-months of treatment, both 
groups significantly improved serum 25[OH]D concentration (25.8 ± 0.9 vs. 24.7 ± 0.6 ng/mL); 
with no significant difference between treatments at 2-months. However, a significantly greater 
number of athletes became sufficient (>30 ng/mL) at 2-months following Oral vs. IM 
supplementation (37.4% vs. 21.6%, p <0.001). A greater percentage of athletes presenting with 
severe 25[OH]D deficiency (<10 ng/mL) at baseline moved to sufficiency (>30 ng/mL) after 2-
months with Oral vs. IM (27.5% vs. 10.0%). Oral supplementation also moved a greater number 
of insufficient athletes to sufficiency [(>30 ng/mL); 86.7% vs. 50%]. 
 
Conclusion: With appropriate education and adherence, 2000IU/d Oral 25[OH]D3 
supplementation may be more efficacious at improving 25[OH]D insufficiencies than IM 
injections of 25[OH]D2. 
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4.2  Introduction 
Vitamin D (25[OH]D) deficiency (<20 ng/mL) is associated with a number of detrimental health 
conditions including cardiovascular disease, diabetes mellitus, cancer, autoimmune disease, poor 
musculoskeletal health and depression (Brøndum-Jacobsen et al., 2012; Deeb, Trump, & Johnson, 
2007; Hyppönen, Läärä, Reunanen, Järvelin, & Virtanen, 2001; Kanis, 2002). Recent evidence has 
demonstrated that many athletes are 25[OH]D deficient (Constantini et al., 2010; Hamilton et al., 
2010; Magee et al., 2013), with some authors suggesting that correcting serum 25[OH]D 
concentrations in deficient individuals may in turn improve athletic performance (Close, Russell, 
et al., 2013; Wyon, Koutedakis, Wolman, Nevill, & Allen, 2013); however this is not universally 
supported (B. Hamilton, Whiteley, Farooq, & Chalabi, 2014). Nevertheless, given the high 
prevalence of deficiency across many athletic populations, the implication that deficiency may be 
detrimental to overall health, as well as being a possible athletic performance inhibitor has 
significant implications for the sports medicine physician.  
 
The categorisation of what constitutes vitamin D insufficiency is widely debated. Current ranges 
are based upon the association between 25[OH]D deficiency with osteomalacia and rickets (Robert 
P. Heaney, 2011). Currently, serum 25[OH]D concentrations are categorised as deficient (<10 
ng/mL), deficient (10-20 ng/mL), insufficient (20-30 ng/mL) or sufficient (>30 ng/mL) (M. 
Holick, 2007). Whilst it is considered that individuals should have ‘sufficient’ 25[OH]D 
concentrations, there is limited evidence to suggest that >30 ng/mL assists in the maintenance of 
‘good’ health or improves athletic performance. 
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Nevertheless, in order to improve 25[OH]D concentrations in deficient athletes, the sports 
medicine physician may decide to 1) provide sun exposure and dietary education, and/or 2) 
supplement. Even with the best nutrition advice, achieving an increase in serum 25[OH]D 
concentration can be problematic due to a lack of foods naturally containing vitamin D (M. Holick, 
2007). The method of supplementation may be achieved orally or via an intramuscular (IM) 
injection; both of which are available in a range of dosages and durations, and in two different 
forms (D2 or D3).  
 
Athlete’s where offered the choice between oral cholecalciferol or intramuscular (IM) 
ergocalciferol, as was current practice in Aspetar. Both cholecalciferol (D3 – the most common 
form of Oral supplementation) and ergocalciferol (D2 – its IM counterpart) appear to improve 
serum 25[OH]D concentrations in deficient individuals (Biancuzzo et al., 2013; M. F. Holick et 
al., 2008), yet there is limited evidence to demonstrate which modality is more efficacious in 
improving overall 25[OH]D status in athletes (Zabihiyeganeh et al., 2013). A single IM injection 
of ergocalciferol (D2) may remove the potential gut malabsorption and athlete compliance issues, 
however; it is unacceptable for the treating physician to wait 6-months to ascertain if the deficiency 
has been corrected when the athlete is competing weekly, as was current practice in Aspetar. In 
turn, there is evidence to suggest that D2 has poorer bioefficacy than D3, and thus may have limited 
use as a treatment supplement (Houghton & Vieth, 2006). 
 
Previous studies have attempted to examine the efficacy of oral vs. IM modalities, but with variable 
dosages and durations in many of these investigations, the clinical effectiveness of both modalities 
at correcting 25[OH]D deficiency remains unclear (Billoo et al., 2009; Zabihiyeganeh et al., 2013). 
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Furthermore, the majority of these studies have only examined individuals with known pathologies 
or health related issues, such as rickets, chronic kidney disease hyperparathyroidism, diabetes, 
cancer, osteoporosis and CVD, and not otherwise healthy athletes. 
 
4.3 Aims and Hypotheses 
The aim of the present investigation was to examine which modality of 25[OH]D supplementation 
(Oral Cholecalciferol D3 [2000IU/d] vs. a single IM Ergocalciferol D2 injection [300,000 IU]) was 
more efficacious at improving overall serum 25[OH]D status in severely deficient (<10 ng/mL), 
deficient (10-20 ng/mL) and insufficient (<30 ng/mL) athletes, following 2-months of treatment. 
It was hypothesised that oral vitamin D3 supplementation would be more efficacious at improving 
serum 25[OH]D concentrations than a single IM Ergocalciferol D2 injection. 
 
4.4 Methods 
Ethical approval was obtained from the Shafallah Medical Genetics Centre Ethics Committee, with 
all athletes completing informed consent in either Arabic or English 
 
4.4.1 Participants 
Three hundred and fifty-five athletes demonstrating serum 25[OH]D concentration of ≤30 ng/mL 
when presenting for pre-competition medical assessment in our facility, were invited to take part 
in the study. All 355 athletes completed a pre-assessment survey.  
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4.4.2 Vitamin D supplementation 
A non-randomised protocol was chosen, as our facility follows a patient choice approach to 
25[OH]D supplementation. After discussion with a sports medicine physician, athletes selected 
either an oral modality (2000IU/d) for 2-months [Oral Cholecalciferol D3, 2x 1000IU; Jarrow 
Formulas, Los Angeles, USA] or a single IM (300,000 IU) injection [IM Ergocalciferol D2, 
Biotika, Solvenska Lupca, Slovak Republic]. All athletes were given a 2-month follow-up 
appointment with a sports medicine physician to re-assess 25[OH]D status. One hundred and 
twenty three athletes eventually chose Oral supplementation vs. 232 who chose IM. Statistical 
analysis was carried out independently of the treating sports medicine physician(s), in order to rule 
out study bias. No athlete was supplemented with calcium, in order to independently ascertain the 
effects of the 25[OH]D treatment. 
 
4.4.3 Laboratory analyses 
As described in the general methodology chapter 
 
4.4.4 Statistical Analysis 
As described in the general methodology chapter  
 
4.5 Results 
4.5.1 Athlete Demographics 
The 355 athletes participating in the study came from 33 countries (Table 4.1). However, there 
were no significant differences in height, body mass, body surface area, body mass index, exposure 
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time to sunlight, use of sunscreen, athlete skin colour or the use of calcium supplements between 
Oral vs. IM groups at baseline.  
 
Table 4.1 Origin of screened athletes 
Region Number of nations from region (n) Total athletes (n) 
Gulf states 7 191 
Middle Eastern 5 86 
Africa 9 40 
Persia 1 13 
Western/European 6 15 
Asian 5 10 
Total 33 355 
 
4.5.2 25[OH]D and PTH 
No significant differences were observed at baseline in the distribution of serum 25[OH]D 
concentration in the severely deficient (<10 ng/mL) or deficient (10-20 ng/mL) groups between 
Oral vs. IM supplementation modalities (Table 4.2), whilst there were more insufficient (20-30 
ng/mL) athletes in the IM treatment group (p=0.05). However, there was no significant difference 
(p>0.05) in serum 25[OH]D or calcium values between Oral vs. IM groups at baseline, whilst PTH 
was significantly higher in the Oral vs. IM group at baseline (p=0.019;Table 4.3). 
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Table 4.2  Baseline characteristics of athletes, together with the distribution of serum 25[OH]D concentrations 
between Oral vs. IM supplementation modalities at baseline  
Variables Oral                        N=123 
IM                         
N=232 
Oral vs. IM             
P value 
Height (m) 1.75± 9.6 1.75 ± 8.5 0.691 
Body Mass (kg) 72.1 ± 15.6 76.7 ± 17.6 0.086 
Body surface area(m2) 1.87 ± 0.23 1.92 ± 0.22 0.136 
Body Mass Index (kg/m2) 23.3 ± 3.8 24.8 ± 5.0 0.052 
Ethnicities n (%)    
Caucasian 6 (4.9) 9 (3.9) 
0.028 
Asian 2 (1.6) 8 (3.4) 
African 5 (4.1) 35 (15.1) 
Middle-Eastern 34 (27.6) 52 (22.4) 
GCC 73 (59.3) 118 (50.9) 
Persian 3 (2.4) 10 (4.3) 
Exposure to sunlight n (%)    
No sunlight exposure 35 (28.5) 65 (28.0) 
0.846 
30-60 minutes 44 (35.8) 125 (35.2) 
60-120 minutes 23 (18.7) 61 (17.2) 
>120 minutes 21 (17.1) 69 (19.4) 
Use of sunscreen n (%)    
Yes 8 (6.5) 11 (4.7) 
0.483 
No 115 (93.5) 221 (95.3) 
Skin color n (%)    
Dark 25 (20.3) 63 (27.2) 
0.312 Olive 70 (56.9) 126 (54.3) 
Fair 28 (22.8) 43 (18.5) 
Calcium supplements n (%)    
Yes 5 (4.1) 18 (7.8) 
0.179 
No 118 (95.9) 214 ( 92.2) 
Serum 25[OH]D    
<10 (ng/mL) (%) 40 (32.5) 60 (25.9) 
0.101 10-20 (ng/mL) (%) 68 (55.3) 124 (53.4) 
20-30 (ng/mL) (%) 15 (12.2) 48 (20.7) 
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4.5.3 Post-supplementation serum 25[OH]D concentration 
Both Oral and IM modalities significantly increased serum 25[OH]D concentration following 2-
months of supplementation (Table 4.3) with no significant difference in mean 25[OH]D status 
between treatments at 2-months. However, a significantly greater number of athletes became 
sufficient (>30 ng/mL) at 2-months following Oral vs. IM supplementation (37.4% vs. 21.6%, p 
<0.001). This result remained significant after adjusting for athlete ethnicity. 
A greater percentage of athletes presenting with severe 25[OH]D deficiency (<10 ng/mL) at 
baseline moved to sufficiency (>30 ng/mL) after 2-months when undertaking Oral vs. IM 
supplementation (27.5% vs. 10.0%;Table 4.4). Oral supplementation also moved a greater number 
of insufficient (20-30 ng/mL) athletes to sufficiency [(>30 ng/mL); 86.7% vs. 50%].   However, a 
similar number of athletes had reductions in 25[OH]D concentrations, moving from insufficiency 
(20-30 ng/mL) to deficiency (10-20 ng/mL) in 6.7% (Oral) vs. 8.3% (IM) after 2-months, 
respectively. 
Table 4.3 Comparison of mean serum measures at baseline and following 2-months of vitamin D supplementation 
Variable Oral IM 
Oral vs. IM  
same time 
point 
Oral Baseline vs. 
2-month 
IM Baseline vs. 
2-month 
25[OH]D (ng/mL) 
   
<0.001 <0.001 Baseline 13.2 ± 0.5 14.2 ± 0.4 0.107 
2 Month 25.8 ± 0.9 24.7 ± 0.6 0.075 
PTH (pg/mL) 
   
0.009 0.821 Baseline 53.9 ± 2.7 49.6 ± 1.5 0.019 
2 Month 47.2 ± 2.2 50.0 ± 1.7 0.239 
Ca (mmol/L) 
   
0.179 0.084 Baseline 2.26 ± 0.01 2.26 ± 0.01 0.456 
2 Month 2.28 ± 0.01 2.25 ± 0.01 <0.001 
PTH, parathyroid hormone, Ca; calcium.  
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4.5.4 Post-supplementation serum parathyroid hormone concentration 
All athletes presented with clinically normal PTH values at baseline (range 14-72 pg/mL). Baseline 
PTH levels were significantly higher in the Oral group vs. IM group (53.9 ± 2.7 vs. 49.6 ± 1.5 
pg/mL, p<0.05), which was removed following 2-months of 25[OH]D supplementation (Table 
4.3). A significant decrease in PTH was observed after 2-months following Oral supplementation 
(p=0.009), whereas PTH remained unchanged in the IM treatment modality (p=0.821). 
Table 4.4 Inter-group improvements in serum 25[OH]D concentrationfrom baseline and following 2-months of 
vitamin D2/D3 supplementation  
Treatment 
Serum 25[OH]D after 2-months of 
supplementation (ng/mL) 
<10 10-20 20-30 >30 
Oral (D3) 
Baseline Group (ng/mL)     
<10 (%) 11(27.5) 8 (20.0) 10 (25) 11 (27.5) 
10-20 (%) 0 (0.0) 17(25.0) 29 (42.6) 22 (32.4) 
20-30 (%) 0 (0.0) 1 (6.7) 1 (6.7) 13 (86.7) 
IM (D2) 
Baseline Group (ng/mL)     
<10 (%) 5 (8.3) 18 (30.0) 31 (51.7) 6 (10.0) 
10-20 (%) 2 (1.6) 29 (23.4) 72 (58.1) 21 (16.9) 
20-30 (%) 0 (0.0) 4 (8.3) 20 (41.7) 24 (50.0) 
 
4.5.5 Post-supplementation serum calcium concentration  
Baseline serum Ca levels were within the normal range (2.12-2.52mmol/L), with no significant 
differences at baseline between Oral vs. IM groups. Following 2 months of 25[OH]D 
supplementation, Ca levels were significantly lower following IM supplementation vs. Oral (2.25 
± 0.01 vs. 2.28 ± 0.01, p<0.001).  
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4.6 Discussion 
The present study aimed to examine which modality of vitamin D supplementation (Oral 
Cholecalciferol D3 [2000IU/d] vs. a single IM Ergocalciferol D2 injection [300,000 IU]) was more 
efficacious at improving serum 25[OH]D status in severely deficient (<10 ng/mL), deficient (10-
20 ng/mL) and insufficient (<30 ng/mL) athletes, following 2-months of treatment. We were 
motivated by the fact that to date, there is no consensus amongst the sports medicine community 
when treating insufficient athletes, as to the optimum mode, dose or type of vitamin D 
supplementation. 
 
4.6.1 Vitamin D (25[OH]D) 
The main finding of this study is that, in athletes presenting at baseline as either severally deficient, 
deficient or insufficient, both Oral and IM supplementation significantly improved mean serum 
25[OH]D (p<0.001). Although there was no difference in the group mean serum 25[OH]D 
concentrations between treatment modalities following 2-months of vitamin D supplementation, a 
significantly greater percentage of athletes shifted to sufficiency (>30 ng/mL) with Oral vs. IM 
supplementation (45 37% vs. 50 21.6%, p <0.001). The precise mechanism(s) explaining this result 
remain unclear. One possible explanation is the type of vitamin D supplementation used in the 
present study. We used Oral cholecalciferol D3 [1000IU/d] vs. a single IM ergocalciferol D2 
injection [300,000 IU]. Recent studies have demonstrated no significant difference in serum 
25[OH]D concentrations after ingestion of 1,000 IU 25[OH]D2 or 25[OH]D3 (Biancuzzo et al., 
2013; M. F. Holick et al., 2008), implying that 25[OH]D-1-hydroxylase recognises both 
secosteroids equally. However, it is known that there is a small molecular structural difference 
between D3 and D2.  This minor variation in the side-chain chemistry between the two forms of 
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25[OH]D may result in differences at the site of hydroxylation, leading to differing biologically 
active metabolites (Houghton & Vieth, 2006). These differences do not appear to affect activation, 
but deactivation. It may be possible that the supplement given in a sustained manner (2000IU/day) 
provides a constant supply for conversion to 25[OH]D. In contrast, a singular IM (300,000IU) may 
cause an initial increase in 25[OH]D which ultimately cannot be sustained over time. 
 
Trang et al. (Trang et al., 1998) observed that both D2 and D3 increased serum 25[OH]D 
concentrations, yet the increase in 25[OH]D was found to be 1.70 times greater (70%) with D3 
than D2. This data is supported by Logan et al. (Logan, Gray, Peddie, Harper, & Houghton, 2013) 
who recently observed that daily supplementation with vitamin D3 was more effective than D2 at 
improving serum 25[OH]D concentrations. Even in individuals with pathology, Mastaglia et al. 
(Mastaglia, Mautalen, Parisi, & Oliveri, 2006) observed that in a 3-month supplementation study 
using osteoporotic women, a 2.5-times higher dose of D2 (250 µg D2/d) was required to match 
similar serum 25[OH]D values when compared to a similar study using D3 (100 µg D3/d). Whilst 
in patients with chronic kidney disease, Daroux et al. (Daroux et al., 2013) found that D3 was more 
effective than D2 in providing adequate 25[OH]D serum concentrations in hemodialysis patients.  
 
In summary, it may not necessarily be the modality of supplementation (Oral vs. IM) that causes 
the observed differences in the percentage of athletes that became 25[OH]D sufficient after 2-
months of supplementation, but the type of 25[OH]D (D2 vs. D3) provided to the athlete. Although, 
it is impossible to differentiate between mode entirely, this study demonstrates that Oral D3 
supplementation has a greater efficacy at increasing serum 25[OH]D compared to IM D2. 
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4.6.2 Parathyroid Hormone (PTH) 
In order to exert its effects on bone metabolism and Ca absorption, 25[OH]D must first be 
converted to 1,25[OH]2D3, which occurs through the action of PTH. This is a self-regulating 
process, for which evidence of 25[OH]D deficiency may also manifest itself through high levels 
of PTH, as observed in this study. PTH has also been shown to directly regulate 1 α-hydroxylase 
activity and mRNA in renal proximal tubular cells via changes in cyclic AMP through stimulation 
of 1 α -hydroxylase gene transcription (Khan et al., 2012). The mechanism(s) explaining why PTH 
was significantly reduced following 2-months of Oral supplementation remain unclear. It is 
possible that the variance in PTH was random; however, in keeping with previous studies from 
non-athletic populations, PTH levels tended to be inversely related to 25[OH]D (Bjorkman, Sorva, 
& Tilvis, 2008; Khan et al., 2012). Soliman et al. (Soliman, Adel, Wagdy, Alali, & Aziz Bedair, 
2011) also observed a significant inverse relationship between serum 25[OH]D and PTH 
concentrations, following a single IM dose of cholecalciferol in 100 vitamin D deficient Arabic 
adolescents. This may be explained because PTH increases CYP27B1 activity, the enzyme 
responsible for the hydroxylation 25[OH]D to 1,25[OH]2D. Therefore, when CYP27B1 becomes 
saturated and adequate 1,25[OH]D is synthesised, PTH is suppressed. Therefore, the stimulation 
of CYP27B1 reduced comparable to when serum 25[OH]D in deficiency. 
 
4.6.3 Treatment 
Our facility follows a patient choice approach to 25[OH]D supplementation. Prior to treatment, 
athletes consult with a sports medicine physician and make an informed choice between taking 
either an Oral (2000IU/d) supplement for 2-months or a single intramuscular injection 
(300,000IU), with reassessment at 2 months unless otherwise indicated. Our data demonstrates 
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that a greater proportion of severely deficient (<10 ng/mL) athletes became sufficient (>30ng/mL) 
with Oral supplementation vs. IM (11 (27.5%) vs. 6 (10.0%)). However, 27.5% of athletes 
participating in the Oral supplementation pathway remained severely deficient after 2-months, 
compared to 8.5% of the IM cohort (Table 4.4).  Adherence to any form of Oral 
treatment/supplementation is a concern for any sports medicine physician. Thus, from a clinical 
prospective, a strong argument can be made, that for those severely deficient athletes (regardless 
of adherence or compliancy), there is a 91.7% chance of moving out of the severe deficient 
category with a single IM injection (300,000IU) of 25[OH]D2. 
 
4.6.4 Alternative vitamin D dosages 
Whilst the ergocalciferol dosage of 300,000IU provided in this study is considered to be the 
standard dose, some clinicians consider the Oral dose of 2000IU/d of 25[OH]D3 for 2-months to 
be inadequate at correcting 25[OH]D deficiencies. (Biancuzzo et al., 2013; M. F. Holick et al., 
2008). Yet, 8.3% of the IM cohort had reductions in serum 25[OH]D values at 2-months post 
injection; moving from insufficiency (20-30 ng/mL) to deficiency (10-20 ng/mL), respectively. 
Thus, whether our findings of serum 25[OH]D reductions in these 19 athletes are a true reflection 
of 25[OH]D status reduction, or is a consequence of the athletes being supplemented with D2 and 
is thus, a metabolism and/or an assay error remains unclear. These findings have potential clinical 
implications for routine supplementation of vitamin D. Although both modes of supplementation 
significantly improved mean serum 25[OH]D after 2-months, 1.6% of deficient athletes became 
severely deficient and 8.3% of insufficient athletes became deficient at 2-months following IM. 
These reductions in concentration following IM injection cannot be attributed to poor adherence. 
Furthermore, Oral supplementation significantly increased a greater percentage of insufficient (20-
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30 ng/mL) athletes to sufficiency (>30 ng/mL) at 2-months [86.7% vs. 50%]. Therefore, our data 
strongly suggest Oral cholecalciferol should be the modality of choice in the compliant insufficient 
athletes. 
 
4.7 Limitations 
Whilst the prescribing sports medicine physician was unbiased in providing counsel to the athletes 
in the decision of which modality of supplementation to take (the physician was not privy to 
recruitment or statistical analysis), significantly more Africans chose IM supplementation over 
Oral. Additionally, the assay used for 25[OH]D analysis (Diasorin Liaison), is known to recognise 
25OHD2 more than 25OHD3, an anomaly that remains to be explained. Adherence to the Oral 
treatment was also not recorded, as our experience with athlete-led training/nutrition diaries are 
particularly unreliable. No measurement of UVB exposure during the 2-months after 
supplementation was undertaken. We accept that the treating physician provided dietary and sun 
exposure education before supplementation took place. Consequently, the interpretation of the 
dose–response for 25[OH]D supplementation, for both Oral and IM, may have been affected by 
the athlete exposing themselves to UVB radiation. There is a current lack of solid evidence 
concerning the validity of serum 25[OH]D measure as a biomarker of effect. In order to make 
definitive conclusions about the efficacy of mode of supplementation, future work should aim to 
examine the impact of oral cholecalciferol vs. IM cholecalciferol, controlling for adherence and 
the effect of supplementation on bioavailable vitamin D should also be addressed. Finally, recent 
evidence showing that rapid withdrawal from high dose vitamin D supplementation may be 
insufficient at correcting deficiencies. These data should be considered in future supplementation 
studies and supplementation protocols.   
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4.8 Conclusion 
Whilst the optimal dosages for either Oral or IM 25[OH]D supplementation have yet to be 
established, our data demonstrates that both Oral (Cholecalciferol D3 [2000IU/d]) and IM 
(Ergocalciferol D2 [300,000 IU]) injection significantly improve serum 25[OH]D concentrations 
following 2-months of supplementation. However, a significantly greater number of athletes 
became sufficient (>30 ng/mL) at 2-months following Oral vs. IM supplementation. Our data 
supports that with appropriate athlete education and compliance, Oral 25[OH]D3 supplementation 
may be more efficacious at improving 25[OH]D insufficiencies than IM injections of 25[OH]D2.  
Lastly, these data demonstrate a high prevalence of 25[OH]D insufficiency in professional 
athletes, yet the majority present with no symptoms of deficiency. Future studies should aim to 
examine associations between 25[OH]D status and markers of athlete health. 
 
4.8.1 Practical outcomes 
The findings from this study had direct clinical applications on the treatment of vitamin D 
deficiency at our institution, culminating with the implication of updated vitamin D 
supplementation pathway for use by the treating physician (Figure 4.1). Future work should assess 
the efficacy of this pathway at correcting vitamin D deficiencies. 
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Figure 4.1 Aspetar’s Vitamin D supplementation pathway based on 25[OH]D concentrations 
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M. G. Wilson. No Association between Vitamin D Deficiency and Markers of Bone Mass in 
Athletes. Med. Sci. Sports Exerc., Vol. 47, No. 4, pp. 782–788, 2015 
89 
 
5.1 Abstract 
Purpose: Adequate vitamin D (25[OH]D) is required to maintain good bone mass, yet many 
athletes are 25[OH]D deficient. This study sought to examine the relation between serum 25[OH]D 
and measures of bone mass in an ethnically diverse athletic population.  
Methods: Nine hundred and fifty male athletes presented for pre-competition medical assessment 
in our facility. An additional 436 individuals registered with a Qatari sporting federation (such as 
sailing, archery, shooting, bowling) but exercising <2h.wk-1 were used as control population. There 
were 30 Asian, 242 Black African, 235 Caucasian, 491 from Gulf Cooperation Countries, 336 
Middle Eastern, and 52 Persian participants. All individuals undertook bone densitometry and body 
composition analysis by dual-energy x-ray absorptiometry and serum 25[OH]D evaluation. 
Results: From 950 athletes, 17.5% demonstrated severe deficiency, 39.2% demonstrated 
deficiency, 24.5% demonstrated insufficiency, and 18.8% demonstrated sufficiency, compared with 
436 controls, 25.9% of whom demonstrated severe deficiency, 46.3% demonstrated deficiency, 
19.0% demonstrated insufficiency, and 8.7% demonstrated sufficiency. No athlete presented with 
a T-score suggestive of osteoporosis (-2.5 SD) or osteopenia (-1.0 SD) at hip total. After adjustment 
for age, anthropometry, ethnicity, and athletic participation, there was no association between 
25[OH]D and any BMD and T-score at any site within athletes. African and Caucasian athletes 
present with greater BMD and T-scores at the spine, neck, and hip total than those of Asian, Gulf 
Cooperation Countries, Middle Eastern, and Persian ethnicities. Athletes participating in high-
impact sports present with higher measures of bone mass than control participants regardless of 
25[OH]D status.  
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Conclusions: There is no association between 25[OH]D and BMD and T-score for any site within 
male athletes after adjusting for age, ethnicity, and sporting participation. 
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5.2 Introduction 
Adequate levels of both calcium and 25[OH]D are required to maintain good bone health. 
25[OH]D deficiency results in reduced absorption of dietary calcium by 85-90% in the small 
intestine. Current clinical ranges (M. Holick, 2007) of what constitutes 25[OH]D sufficiency 
[severally deficient (<10 ng/mL), deficient (10-20 ng/mL), insufficient (20-30 ng/mL) or sufficient 
(>30 ng/mL)] are based upon the association between 25[OH]D deficiency with osteomalacia and 
the approximate concentration at which parathyroid hormone (PTH) rises abruptly (M. F. Holick, 
2009; Hollis, 2005; Zittermann, 2003); whereas the cut off for insufficiency is the approximate 
concentration in which calcium absorption is maximized (M. F. Holick, 2009). Whilst sufficient 
levels of serum 25[OH]D are important in optimising bone-mineral density (BMD) in active (J. 
Lappe et al., 2008; Ruohola et al., 2006) and inactive individuals (Bischoff-Ferrari et al., 2006), 
the exact 25[OH]D value to ‘optimise’ bone health for the regulation of calcium homeostasis 
(calciotropic properties) is still debated (M. F. Holick, 1996).  Studies suggest that a 25[OH]D 
value >30ng/mL promotes good bone health and reduces fracture risk in both healthy young and 
older adults (Bischoff-Ferrari, Dietrich, Orav, & Dawson-Hughes, 2004; Bischoff-Ferrari et al., 
2006), while some authors suggest levels>40ng/mL maybe required (Bischoff-Ferrari et al., 2006).   
Although studies have demonstrated a significant association between serum 25[OH]D and bone 
health (Collins et al., 1998; Gutierrez et al., 2011; Sadat-Ali, Al Elq, Al-Turki, Al-Mulhim, & Al-
Ali, 2011), there are no studies examining the relationship between serum 25[OH]D concentration 
and measures of bone health in a large ethnically diverse athletic population. Athletes are a unique 
population, in that many are known to be severely 25[OH]D deficient (Constantini et al., 2010; 
Hamilton et al., 2010; Magee et al., 2013), but have the added stimulus of loading the 
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musculoskeletal system through high-intensity dynamic sporting activity  resulting in greater bone 
mass at loaded sites compared with non-athletes (Nikander et al., 2006; Weidauer et al., 2014).  
 
5.3 Aim and Hypothesis 
A high prevalence of 25[OH]D insufficiency is observed in many athletic populations 
(range, 67%–91%) (Constantini et al., 2010) including athletes screened at Aspetar (Chapter 
1,Figure 1.1). and negatively associated with bone mass. Chapter 4 highlights that vitamin D 
supplementation improves mean 25[OH]D status (13.7ng/mL to 25.3ng/mL) regardless of 
modality (IM or Oral). Correcting vitamin D insufficiencies is the duty of sports medicine 
physician, but what the impact of vitamin D status on and bone mass in an ethnically diverse 
population is unknown.  
This study sought to examine the relation between serum 25[OH]D levels against markers of bone 
mass (BMD and T-scores) in a large and ethnically diverse athletic population.  
 
5.4 Methods 
5.4.1 Participants 
Nine hundred and fifty male athletes registered with the Qatar Olympic Committee (QOC) Asian 
(n=18), Black African (n=218), Caucasian (n=206), GCC (n=222), Middle Eastern (n=251) and 
Persian (n=35) exercising ≥6 h/week presented for pre-competition medical assessment in our 
facility; with a further 436 individuals registered with the QOC but exercising <2 h/week (such as 
sailing, archery, shooting and bowling) were used as control participants, Asian (n=12), Black 
African (n=24), Caucasian (n=29), GCC (n=269), Middle Eastern (n=85) and Persian (n=17). 
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Participants were screened for inclusion as described in the General Methods chapter of this thesis. 
After meeting this initial inclusion criteria, participants provided a venous blood sample, 
completed vitamin D questionnaire and undertook bone mineral density analysis as described in 
of the General Methods chapter of this thesis. 
5.4.2 Laboratory analyses 
As described in the general methodology chapter  
 
5.4.3 Assessment of Bone Mineral Density 
As described in the general methodology chapter  
 
5.4.4 Statistics 
Statistical analyses were performed as described in Chapter 3 with the additional calculations. 
Anthropometric comparisons between athletes and controls were performed using a Student’s t-
test. A one-way ANOVA was performed to assess anthropometric differences between the four 
25[OH]D groups (<10 ng/mL, 10-20 ng/mL, 20-30 ng/mL and >30 ng/mL). A post-hoc analysis 
with bonferroni correction was used for further comparisons in the event of significance. To 
compare osteopenia and osteoporosis DXA scores between athletes and controls, non-parametric 
exact tests were performed since expected count in cells was <5. To determine the relationship of 
bone mass parameters with 25[OH]D, multiple linear regression analysis was performed with bone 
mass as a dependent variable with athletic participation as fixed factor of interest and age, body 
composition and ethnicity as covariates. Beta-coefficients (β ± SE) were reported. A P-value <0.05 
was used as a cut-off for statistical significance. 
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5.5 Results 
5.5.1 25[OH]D status and anthropometry 
From 950 athletes, 17.5% (n = 166) demonstrated severe deficiency, 39.2% (n = 372) demonstrated 
deficiency, 24.5% (n = 233) demonstrated insufficiency, and 18.8% (n = 179) demonstrated 
sufficiency, compared with 436 controls, 25.9% (n = 113) of whom demonstrated severe 
deficiency, 46.3% (n = 202) demonstrated deficiency, 19.0% (n = 83) demonstrated insufficiency, 
and 8.7% (n = 38) demonstrated sufficiency. Compared with control participants, athletes were 
significantly (P <0.003) younger (24.3 ± 4.6 vs 25.9 ± 7.3 yr), taller (183.2 ± 10.6 vs 173.5 ± 6.6 
cm), and heavier (81.2 ± 14.3 vs 74.1 ± 15.6 kg) and had reduced body mass index (24.0 ± 2.9 vs 
24.6 ± 4.7 kg/m2), larger body surface area (2.0 ± 0.2 vs 1.9 ± 0.2 m2), lower percentile body fat 
(16.3% ± 5.5% vs 22.2% ± 8.4%), increased lean mass (64.5 ± 10.3 vs 54.5 ± 8.9 kg), and reduced 
fat mass (13.0 ± 6.5 vs 16.5 ± 9.6 kg). The majority of these anthropometric parameters remained 
significant when athletes and controls were compared in their respective 25[OH]D group (Table 
5.1). In both athletes and controls, a significant association was observed between serum 25[OH]D 
and skin exposure (p >0.05), sun exposure (p <0.002) and ethnic origin (p <0.001). 
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Table 5.1 Physical characteristics of athletes and controls based upon 25[OH]D status 
Variables 
Vitamin D category (ng/mL) 
<10 10-20 20-30 >30 
(n=279) (n=574) (n=316) (n=217) 
Age (yr) 
A 
23.89±5.0 23.90±4.4* 24.65±4.6* 25.24±4.6ab 
[15.7-38.0] [18.0-36.0] [16.9-38.0] [16.9-39.0] 
C 24.19±5.8 25.84±7.6 28.17±8.1
a 25.82±6.0 
[13.7-46.0] [13.9-53.0] [18.0-57.0] 25.5[18.0-42.0] 
Height (m) 
A 1.80±1* 1.82±1* 1.84.±1*
a 1.86±1.*ab 
[1.43-2.10] [1.58-211] [1.62-2.16] [1.57.0-2.14] 
C 1.73±0.6 1.73.07±6.5 174.44±7.3 173.70±6.0 [158.8-197.0] [151.2-190.6] [161.2-208.0] [164.0-186.0] 
Weight (kg) 
A 
77.85±15.3 80.11±14.9* 82.81±14.1*a 84.56±11.4*ab 
[50.8-129.8] [46.0-158.0] [52.8-156.1] [56.0-113.3] 
C 75.51±20.0 74.09±14.9 74.15±12.1 69.56±9.2 [42.7-157.7] [31.5-141.0] [52.6-115.2] [51.1-88.5] 
Body mass 
index (kg/m2) 
A 23.82±3.2 * 23.86±3.2* 24.09±2.5 24.08±2.3 [17.0-37.6] [15.4-53.8] [17.7-33.1] [18.0-29.5] 
C 25.05±5.9 24.69±4.7 24.28±3.1 22.93±2.4 [15.8-47.0] [13.8-41.0] [17.8-33.0] [18.5-27.5] 
Body Surface 
Area (m2) 
A 1.96±0.2 * 2.01±0.2* 2.06±0.2*
ab 2.09±0.2*ab 
[1.2-2.7] [1.5-2.6] [1.6-3.0] [1.6-2.6] 
C 
1.88±0.2 1.87±0.2 1.89±0.2 1.83±0.1 
[1.4-2.7] [1.2-2.6] [1.6-2.5] [1.6-2.1] 
Tissue % Fat 
A 17.18±6.1* 16.40±5.9* 16.05±5.1* 15.64±4.7* [7.6-38.9] [6.9-52.5] [7.0-36.7] [6.9-33.8] 
C 24.45±9.0
cd 22.12±8.3 20.74±7.9 18.63±6.4 
[10.2-49.7] [9.0-46.2] [5.7-39.4] [9.2-38.1] 
Lean Mass (kg) 
A 
61.06±11.3* 63.49±10.3* 65.99±9.7*ab 67.81±8.4*ab 
[18.9-102.6] [38.9-92.9] [42.3-95.3] [41.7-91.0] 
C 53.70±10.5 54.59±8.6 55.81±7.7 53.93±7.1 [34.7-99.2] [23.7-90.8] [41.7-77.1] [41.3-71.4] 
Fat mass (kg) 
A 
13.28±7.1* 12.98±7.1* 13.04±6.1* 12.83±4.9 
[5.2-46.2] [4.3-81.3] [4.6-55.3] [4.5-35.9] 
C 
18.90±12.0cd 16.49±9.2 15.24±7.6 12.60±5.2 
[5.7-76.6] [4.8-58.4] [4.1-38.2] [5.2-28.2] 
A, athletes; C, controls. *significant difference between A vs. C, p<0.05. a: significantly greater than <10ng/mL, b: 
significantly greater than 10-20ng/mL, c: significantly greater than 20/30ng/mL and d: significantly greater than 
>30ng/mL 
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5.5.2 25[OH]D and markers of bone mass 
Caucasian athletes demonstrated significantly greater (p <0.001) serum 25[OH]D concentrations 
than all other ethnicities.  Athletes of GCC origin presented significantly lower serum 25[OH]D 
values than Middle Eastern, African and Caucasian athletes.  African and Caucasian athletes 
demonstrated significantly greater (p<0.05) BMD and T-scores across all sites (spine, neck and 
hip) compared to Asian, GCC, Middle East and Persian athletes (Table 5.2). 
 
 Table 5.2 Bone mass parameters and serum 25[OH]D by ethnicity 
  Asian         GCC            Middle East  Persian  Africa           Caucasian  
Spine BMD 1.30±0.2* 1.27±0.2* 1.37±0.2* 1.31±0.1* 1.46±0.2 1.48±0.1 [1.0-1.7] [0.7-1.7] [0.8-1.8] [1.0-1.5] [0.9-2.0] [1.1-1.9] 
Neck BMD 1.29±0.2* 1.24±0.2* 1.34±0.2* 1.35±0.2* 1.46±0.2 1.42±0.2 [0.9-1.6] [0.7-1.8] [0.7-1.9] [1.0-1.8] [0.9-2.0] [0.9-1.9] 
Hip Total 
BMD 
1.28±0.2* 1.25±0.2* 1.34±0.2* 1.35±0.1* 1.45±0.2 1.41±0.1 
[0.9-1.6] [0.4-1.8] [0.7-1.9] [1.1-1.6] [1.0-1.9] [1.0-1.8] 
Spine T-
score 
0.55±1.4* 0.51±1.4* 1.28±1.3* 0.69±1.2* 2.03±1.3 2.14±1.2 
[-1.8-3.3] [-2.9-4.2] [-3.7-5.0] [-1.9-2.6] [-2.7-6.3] [-1.0-5.7] 
Neck T-score 1.59±1.9* 1.32±1.5* 2.11±1.3* 2.02±1.1* 2.92±1.3 2.72±1.2 [-1.5-4.1] [-2.5-5.3] [-3.2-6.0] [-0.2-4.3] [-1.4-7.0] [-1.0-5.9] 
Hip T-score 1.11±1.5* 1.09±1.3* 1.66±1.1* 1.58±0.9* 2.38±1.1 2.14±1.0 [-1.4-3.3] [-2.4-4.9] [-3.1-5.2] [-0.3-3.4] [-0.7-5.5] [-0.5-4.9] 
Mean serum 
25[OH]D  
17.84±9.7 13.82±7.6‡ 20.44±10.1 17.19±11.0 19.85±10.7 28.16±12.3† 
[6.4-55.6] [4.0-53.0] [4.0-74.9] [4.0-54.2] [4.0-62.7] [5.7-87.4] 
*Significantly lower compared with values for Africans and Caucasians. 
†Significantly higher than Asians, GCC, Middle Easterns, Persians, and Africans. 
‡Significantly lower than Middle Easterns, Africans, and Caucasians 
 
Athletes had significantly greater (p <0.05) bone mineral density (BMD) and T-scores across all 
sites (spine, neck and hip) compared to control participants. Athletes presenting with either 
25[OH]D insufficiency (20-30 ng/mL) or sufficiency (>30 ng/mL) demonstrated significantly 
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greater (p<0.05) BMD scores for spine, neck and total hip than severely deficient (<10 ng/mL) 
athletes (Table 5.3). For control subjects, there were no significant differences in any BMD or T-
scores across the four 25[OH]D categories. 
Table 5.3 Bone mineral density and T-scores for athletes and controls based upon 25[OH]D status 
Variables 
Vitamin D category (ng/mL) 
<10 10-20 20-30 >30 
Spine BMD 
A 
1.38±0.2* 1.42±0.2* 1.44±0.1*a 1.46±0.1*ab 
[1.0-1.7] [0.8-1.8] [1.0-2.0] [1.2-1.9] 
C 1.20±0.2 1.23±0.2 1.25±0.2 1.27±0.2 [0.7-1.6] [0.7-1.7] [0.8-1.6] [0.9-1.5] 
Neck BMD 
A 
1.37±0.2* 1.40±0.2* 1.43±0.2*a 1.42±0.2*a 
[1.0-1.8] [0.8-2.0] [1.0-2.0] [1.1-1.9] 
C 1.17±0.2 1.20±0.2 1.19±0.2 1.23±0.2 [0.8-1.6] [0.8-1.8] [0.7-1.8] [0.9-1.7] 
Hip Total BMD 
A 1.36±0.2* 1.40±0.2*
a 1.41±0.2*a 1.41±0.1*a 
[0.4-1.8] [0.8-1.9] [1.1-1.8] [1.1-1.8] 
C 
1.17±0.2 1.21±0.2 1.20±0.2 1.24±0.2 
[0.8-1.5] [0.8-1.6] [0.7-1.6] [0.9-1.6] 
Spine T-score 
A 1.54±1.2* 1.78±1.2* 1.85±1.2* 1.93±1.1*
a 
[-1.5-4.2] [-1.3-5.2] [-1.5-6.3] [-0.6-5.1] 
C 0.02±1.3 0.17±1.3 0.14±1.4 0.45±1.4 [-2.8-3.1] [-2.9-3.8] [-3.7-3.2] [-2.9-2.5] 
Neck T-score 
A 2.44±1.2* 2.60±1.3* 2.75±1.2* 2.60±1.2* [-0.4-5.5] [-1.2-6.8] [-0.3-7.0] [0.1-5.7] 
C 0.82±1.4 0.94±1.4 0.90±1.4 1.31±1.5 [-2.3-3.7] [-2.1-4.6] [-3.2-5.2] [-1.4-4.5] 
Hip T-score 
A 
1.93±1.0* 2.14±1.1* 2.19±1.1* 2.09±0.9* 
[-0.5-4.7] [-0.8-5.5] [-0.3-5.0] [0.1-4.3] 
C 
0.61±1.3 0.72±1.1 0.67±1.2 1.12±1.4 
[-2.1-3.0] [-1.8-3.8] [-3.1-3.1] [-1.6-3.4] 
A, athletes; C, controls. *significant difference between A vs. C, p<0.05. a: significantly greater than <10ng/mL and 
b: significantly greater than 10-20ng/mL 
No athlete had a T-score consistent with osteoporosis (-2.5 SD) at one of the three sites (neck, 
spine and hip), Osteopenia (-1 to -2.5 SD) was noted in 1 (0.1%) athlete at the neck and in 6 (0.8%) 
98 
 
athletes at the spine (Table 5.4). No athlete presented with a T-score suggestive of osteopenia at 
the hip.  
Table 5.4 Prevalence of osteopenia and osteoporosis based upon T-scores for athletes and controls 
Variables Status Athletes Controls p-value Athletes Mean 25[OH]D 
Controls Mean 
25[OH]D 
Neck T-score Normal 750(99.9) 317(90.1) <0.001 21.0±11.7 16.6±9.1 
 Osteopenia 1(0.1) 33(9.4)  11.5±0.0 17.2±12.2 
 Osteoporosis 0(0.0) 2(0.6)  0.0±0.0 23.5±1.3 
Hip T-score Normal 751(100.0) 323(91.5) <0.001 21.0±11.7 16.7±9.1 
 Osteopenia 0(0.0) 29(8.2)  - 17.0±12.6 
 Osteoporosis 0(0.0) 1(0.3)  -  
Spine T-score Normal 745(99.2) 283(80.6) <0.001 21.0±11.7 17.0±9.6 
 Osteopenia 6(0.8) 59(16.8)  13.9±6.3 15.0±7.6 
  Osteoporosis 0(0.0) 9(2.6)  - 20.7±13.3 
 
Control participants, however, presented with significantly (p<0.001) lower ‘normal’ T-scores 
than athletes across all sites (neck, hip and spine). Furthermore, control participants presented a 
significantly (p <0.001) higher prevalence of osteopenia at all sites compared to athletes. Although 
the prevalence of control participants who presented with T-scores consistent with of osteoporosis 
was higher than the prevalence among athletes in all sites, the difference was not significant. 
5.5.3 Indoor versus outdoor sports 
Outdoor athletes presenting with severe 25[OH]D deficiency demonstrated significantly (p<0.05) 
lower spine, neck and total hip BMD than insufficient (20-30 ng/mL) and sufficient (>30 ng/mL) 
outdoor athletes; with outdoor athletes presenting with severe 25[OH]D deficiency also 
demonstrating significantly (p<0.05) lower neck and hip T-scores that sufficient (>30 ng/mL) 
outdoor athletes. For athletes who compete indoors, there was no significant difference in any 
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BMD or T-score at either the neck, spine of hip across all four 25[OH] D categories (Figure 5.1).
 
Figure 5.1 BMD and T-scores for indoor versus outdoor athletes based on 25[OH]D status 
 
5.5.4 Logarithmic transformation 
After logarithmic transformation adjusting 25[OH]D for age, anthropometry and ethnicity athletes 
had a significantly greater BMD and T-scores across all sites than control participants. However 
after further adjustment for athletic participation, there was no association between 25[OH]D and 
any BMD and T-score for any site within athletes. 
 
5.6 Discussion 
There is a high prevalence of 25[OH]D deficiency across many athletic populations, correcting 
these deficiencies may in turn improve athlete health  (Close, Russell, et al., 2013; Constantini et 
100 
 
al., 2010; B. Hamilton et al., 2014) and we found 57% of athletes presenting with either 25[OH]D 
deficiency or severe deficiency. We observed, however, that despite this inadequate concentration 
of 25[OH]D, after adjusting 25[OH]D for age, anthropometry, ethnicity and athletic participation, 
there was no association between 25[OH]D and BMD and any T-score (spine, neck or hip). Control 
participants exercising less than 2 h / wk presented with significantly (p<0.001) lower ‘normal’ T-
scores than athletes across all sites (neck, hip and spine). 
 
5.6.1 Effect of ethnicity on 25[OH]D and markers of bone mass 
Our data demonstrate that across three key skeletal sites (spine, neck and hip), African and 
Caucasian athletes present with significantly greater (p<0.05) bone mineral density (BMD) and T-
scores than those of Asian, GCC, Middle East and Persian ethnicity. However, for the vast majority 
of athletes regardless of ethnicity, BMD and T-scores were within the normal clinical range set 
out by the World Health Organisation (Kanis, 2002). Caucasians present significantly greater mean 
serum 25[OH]D values compared to all other ethnicities, with participants originating from the 
GCC by contrast presenting the lowest mean serum 25[OH]D score.  
Ethnicity is an important factor when considering serum 25[OH]D status and its potential impact 
upon BMD. Previous research has shown that among Caucasian adults, BMD significantly 
decreases (p<0.01) as serum 25[OH]D declines but this is not observed in Black adults (p=0.2) 
(Gutierrez et al., 2011). Darker skin pigmentation has a photo-protective effect (Matsuoka et al., 
1991), reducing the capacity of the skin to synthesise vitamin D3 (Clemens et al., 1982).  
Vitamin D-binding protein provides insight as to why certain ethnic groups may have distinct 
25[OH]D and BMD relationships (Powe et al., 2013) Vitamin D-binding protein is the primary 
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vitamin D carrier, binding 85-90% of total circulating 25[OH]D with the remaining non-binding 
25[OH]D considered to be bioavailable (Bikle et al., 1986). Vitamin D-binding protein is therefore 
believed to inhibit certain actions of vitamin D because the bound fraction is unavailable to act on 
target cells. Polymorphisms in the vitamin D-binding protein however, produce proteins that differ 
in affinity for 25[OH]D, and it is these polymorphisms that are known to differ between ethnic 
groups (Engelman et al., 2012). Consequently, genotyping of common single-nucleotide 
polymorphisms in the coding region of the vitamin D-binding protein gene (rs4588 and rs7041) 
demonstrate variation between race and are in turn linked to vitamin D-binding protein function 
(Powe et al., 2013).Whilst controversy exists surrounding the role of vitamin D-binding protein 
and its effects on bioavailable 25[OH]D (Weintraub, 2014),  our data demonstrates higher BMD 
and lower 25[OH]D scores in Black athletes compared to Caucasians, similar to result observed in 
the studies above (Powe, Karumanchi, & Thadhani, 2014). 
 
5.6.2 Lifestyle 
Numerous lifestyle factors contribute to 25[OH]D deficiency, including sunlight exposure, sun-
block use, insufficient dietary vitamin D consumption, refraction and/or non-absorption of UVB 
light due to atmospheric dust particles, and the wearing of concealing clothing, particularly 
relevant in the Middle East (Fonseca, Tongia, el-Hazmi, & Abu-Aisha, 1984; Hamilton et al., 
2010; Hatun et al., 2005). Our data oppose previous research by Hamilton et al. who observed no 
association between serum 25[OH]D concentrations in male athletes and use of sunscreen, sunlight 
exposure or skin exposure. Furthermore, there was no significant difference in mean serum 
25[OH]D concentration between athletes that competed and trained indoors (volleyball, basketball 
and handball) and athletes that competed outdoors (football). This may be explained by the fact 
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that the majority of football training and competition in Qatar is performed after sunset due to 
several cultural, social and environmental factors. 
 
5.6.3 Sports participation and bone loading 
Exercise is associated with an increase in BMD (Nikander et al., 2006; Rantalainen et al., 2011). 
Physical loading contributes to the process of bone remodeling, and forms mechanically 
appropriate bone structure (Nikander et al., 2005). Indeed, numerous studies in adolescent female 
(Narra et al., 2013; Weidauer et al., 2014) and male athletes (Dias Quiterio et al., 2011; Silva, 
Goldberg, Teixeira, & Dalmas, 2011), adult athletes (Nikander et al., 2005; Nikander et al., 2006; 
Rantalainen et al., 2011) and senior athletes (Leigey et al., 2009) have all demonstrated the 
beneficial effect of load bearing physical activity upon bone mass. Athletes engaged in high-
impact sports, present significantly greater total BMD scores than low-impact sports (Fredericson 
et al., 2007). 
 
5.6.4 Future research 
Sport type is an important contributing factor to high peak bone mass. Nikander et al., observed 
that following adjustment for anthropometry, the sport (or loading modality) was the determinant 
of the structure and strength of femoral neck; observing that in athletes competing in high-impact 
(basketball and volleyball) and odd-impact sports (football) demonstrated greater BMD scores 
than low impact sports such as swimming and cycling (Nikander et al., 2005). Although unlike the 
current study, these studies did not factor serum 25[OH]D status or other lifestyle factors such as 
UVB exposure into their analysis.  
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We found that 25[OH]D insufficient or sufficient athletes present significantly greater (p<0.05) 
BMD scores than severely deficient athletes. However, after adjusting 25[OH]D for age, 
anthropometry, ethnicity and athletic participation, there was no association between 25[OH]D 
and BMD, and any T-score (spine, neck or hip). The fact that no athlete presented a T-score 
suggestive of osteoporosis despite a prevalence rate of 57% for 25[OH]D deficiency and severe 
deficiency, suggests that in this cohort, the osteogenic effect of impactful weight-bearing exercise 
is sufficient to maintain markers of bone mass, irrespective of 25[OH]D status in adults. 
 
5.6.5 Indoor versus outdoor athletes 
All athletes recruited in the present study competed in weight bearing sports (football, basketball, 
volleyball and handball), yet an association between serum 25[OH]D and bone mass (BMD and 
T-scores) was only observed for the outdoor and not the indoor athlete. Sports such as basketball, 
volleyball and handball appear to produce more site specific osteogenic effects with greater BMD 
scores compared to ‘odd-impact’ sports such as football (Fredericson et al., 2007). The rapid 
accelerating and decelerating movements associated with football, are often in directions that the 
body and hip region are not accustomed to, therefore eliciting a different effect on bone remodeling 
(Nikander et al., 2005).  
 
5.6.6 Do athletes require 25[OH]D supplementation? 
This study demonstrates that adjusting 25[OH]D for age, anthropometry, ethnicity and athletic 
participation, there was no association between 25[OH]D and BMD and any T-score; and thus 
questions the notion that sports medicine physicians should be supplementing athletes insufficient 
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in 25[OH]D on the basis of bone mass. Recent studies have suggested that correcting serum 
25[OH]D in deficient individuals may in turn improve athletic performance (Close, Russell, et al., 
2013); however this is universally supported (B. Hamilton et al., 2014). Ethical rules dictate that 
the physician should ‘do no harm’, yet several ethical and methodological issues regarding 
25[OH]D supplementation remain unanswered. For athletes, these may include potential 
supplement contamination, the effects of toxicity such as hypercalcemia and what exactly is an 
‘optimal’ 25[OH]D status.  
 
5.7 Limitations 
Whilst we acknowledge that training volume and intensity were not recorded; athletes were only 
included in the study if they were registered with the Qatar Olympic Committee, competed at 
national or international level and trained for more than 6 h / week. We also acknowledge that 
serum 25[OH]D measurement only offered a snapshot of current status. Thus it is possible for 
severely deficient (<10 ng/mL) and deficient (10-20 ng/mL) athletes in the present study to have 
spent many years sufficient (>30 ng/mL) prior to recruitment. 
 
5.8 Conclusion 
In summary, our data questions 25[OH]D supplementation programs for 25[OH]D deficient 
athletes purely on the basis of bone mass. Despite 57% presenting with either 25[OH]D deficiency 
or severe deficiency, after adjusting 25[OH]D for age, anthropometry, ethnicity and athletic 
participation, there was no association between 25[OH]D and BMD and any T-score (spine, neck 
or hip). We conclude that no athlete presented a T-score indicative of osteoporosis (-2.5 SD) in the 
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neck, spine or hip, or a T-score indicative of osteopenia (-1 to -2.5 SD) in the hip. These data 
suggest that the osteogenic effect of impactful weight-bearing exercise is sufficient to maintain 
markers of bone mass, irrespective of 25[OH]D status in adults. Finally, African and Caucasian 
athletes present with significantly greater (p<0.05) bone mineral density (BMD) and T-scores 
across all sites (spine, neck and hip) than those of Asian, GCC, Middle East and Persian ethnicity. 
Sports medicine physicians working with athletes who are presented with a 25[OH]D deficient 
athlete must factor in ethnicity, as athletes of Black African origin are known to present with lower 
serum 25[OH]D concentrations, alongside other factors such as diet and UVB exposure, in the 
decision to supplement that athlete. 
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6.1 Abstract 
Objectives: To examine the relationship between serum 25[OH]D concentrations and markers of 
bone mass [bone mineral density (BMD) & T-score] in non-weight bearing, Arabic athletes. 
Design: One hundred and two male athletes registered with the Qatar Olympic Committee in a 
non-weight bearing sport and originating from the Gulf Cooperation Council (GCC) (n=93) and 
Middle East (n=9), presented for pre-competition medical assessment in Aspetar.  
Methods: All participants undertook bone densitometry (neck, hip, spine and total), body 
composition via Dual-energy X-ray absorptiometry and serum 25[OH]D evaluation. 
Results: From 102 athletes, 29.4% (n=30) demonstrated severe vitamin D deficiency (<10ng/mL), 
40.2% (n=41) deficiency [10-20ng/mL], 23.57% (n=24) insufficiency [20-30ng/ml] and 6.8% 
(n=7) sufficiency [>30ng/mL]. No difference in serum 25[OH]D concentrations were observed 
between athletes with clinically normal T-score (n=76) and those presenting with osteopenia (-1 
to -2.5 SD) (n=20) or osteoporosis (-2.5 SD) (n=6) in any location (neck, hip, spine or total). There 
were no associations observed between serum 25[OH]D concentrations and age, body mass index, 
body fat %, calcium, parathyroid hormone and skin exposure (surface area and time) to sunlight. 
Cyclists had higher serum 25[OH]D concentrations compared with indoor athletes (P<=0.006). 
Mean body mass was lower (p˂0.05) in athletes with a T-score suggestive of 
osteopenia/osteoporosis. 
Conclusions: No association was observed between serum 25[OH]D concentrations and markers 
of bone mass in non-weight bearing Arabic athletes. Lower body weight was associated with 
osteopenia and/or osteoporosis regardless of serum 25[OH]D status. This study suggests 25[OH]D 
concentration is inappropriate in predicting bone mass in non-weight bearing athletes. 
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6.2 Introduction 
Exercise (loading) is associated with an increase in BMD (Nikander et al., 2006), whilst increased 
body mass contributes to the process of bone remodeling, forming mechanically appropriate bone 
structure(s) (Nikander et al., 2005). Studies show that exercise and sporting type (or weight 
modality) effect BMD; with athletes engaging in high-impact sports (football, basketball, and 
handball) presenting with significantly greater total BMD scores than low-impact sports 
(swimming and cycling) (Fredericson et al., 2007). Although numerous studies have demonstrated 
the impact of weight bearing exercise in a variety of populations [adolescent females (Narra et al., 
2013), male athletes (Dias Quiterio et al., 2011) and senior athletes (Leigey et al., 2009)], no 
studies have examined the relationship between serum 25[OH]D and measures of bone mass in 
non-weight bearing athletes. Further, this concept has not been studied in Arabic athletes, a 
population known to have a high prevalence of severe deficiency (Hamilton et al., 2010; B. 
Hamilton et al., 2014). 
Vitamin D deficiency is endemic across the GCC and Middle-East, given that 90% of Arabic 
athletes are 25[OH]D insufficient (Hamilton et al., 2010). It appears that the stimulus of loading 
the musculoskeletal system through high-intensity dynamic sporting activity has an osteogenic 
effect, regardless of serum 25[OH]D status (Nikander et al., 2006). However, popular sports in the 
region include archery, billiards bowling, cycling, diving, equestrian, racing, rowing, sailing, 
shooting, snooker, swimming and water polo; all of which are non-dynamic, non-weight bearing 
sports. The findings from Chapter 5 demonstrate no association between serum 25[OH]D 
concentrations and BMD or T-score within athletes regardless of 25[OH]D statuses, even after 
adjusting for age, ethnicity and sporting participation (Allison, Farooq, Hamilton, Close, & 
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Wilson, 2015). We postulated that the osteogenic effect of weight bearing exercise may be 
sufficient to maintain markers of bone mass, irrespective of 25[OH]D status in adults. 
 
6.3 Aims and Hypotheses 
Accordingly, the study described in Chapter 6 aimed to examine the relationship between serum 
25[OH]D concentrations against markers of bone mass (BMD and T-score) and anthropometrical 
measures in an Arabic athletic population participating in non-weight bearing sports. We 
hypothesize that 25[OH]D concentrations were not associated with markers of bone mass (BMD) 
in non-weight bearing Arabic athletes. 
 
6.4 Methods 
6.4.1 Participants 
One hundred and two male athletes registered with the Qatar Olympic Committee (QOC) in a non-weight 
bearing sport (archery, billiards bowling, cycling, diving, equestrian, motor-racing, rowing, sailing, 
shooting, snooker, swimming and water polo) and originating from the Gulf Cooperation Council (n=93) 
and Middle East (n=9), presented for pre-competition medical assessment in Aspetar.  
Participants were screened for inclusion as described in the General Methods chapter of this thesis. 
After meeting this initial inclusion criteria, participants provided a venous blood sample, 
completed vitamin D questionnaire and undertook bone mineral density analysis as in of the 
General Methods chapter of this thesis. 
110 
 
6.4.2 Laboratory analyses 
Venous blood samples were collected from athletes following an overnight fast and analysed for 
serum 25-hydroxyvitamin D (25[OH]D) as described in section 3.4 of General Methods Chapter. 
 
6.4.3 Assessment of Bone Mineral Density  
Dual-energy x-ray absorptiometry (DXA; Osteocore III, Perols, France, version 5.22b) scanning 
was used to assess hip and spine BMD. T-scores were calculated for those athletes older than 20 
years. Twenty-three participants under 20 years were not included in the sub-analysis for (T-score) 
osteoporosis and osteopenia. 
 
6.4.4 Statistical analysis 
Statistical analyses were performed as described in Chapter 5.  
 
6.5 Results 
6.5.1 25[OH]D status and anthropometry 
From 102 athletes, 29.4% (n=30) demonstrated severe vitamin D deficiency, 40.2% (n=41) 
deficiency, 23.6% (n=24) insufficiency and 6.8% (n=7) sufficiency. No significant associations 
were observed between anthropometrical measures (BMI, body surface area, height and weight) 
and serum 25[OH]D, except for body mass index (p=0.046) and body fat (%) (p=0.022). Post-
hoc analysis however, revealed no significant differences in anthropometric measures between 
the four different 25(OHD) status categories (Table 6.1).  
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Table 6.1 Physical characteristics based on 25[OH]D status (Mean±SD) 
Variables 
Vitamin D category (ng/mL) 
p-value <10 10-20 20-30 >30 
n=30 n=41 n=24 n=7 
Age (Yr) 24.1±6.7 30.0±9.8 30.0±10.3 27.4±8.9 0.056 
Height (m) 1.72±6.6 1.72±5.8 1.76±6.4 1.72±4.2 0.079 
Weight (kg) 74.0±23.1 82.2±18.0 77.9±14.9 67.7±8.6 0.139 
Body mass 
index (kg/m2) 24.9±7.1 27.7±5.6 24.9±3.6 22.9±2.8 0.046 
Body Surface 
Area (m2) 1.9±0.2 1.9±0.2 1.9±0.2 1.8±0.1 0.124 
Body fat (%) 27.3±9.8 30.5±8.9 25.0±8.2 21.1±8.0 0.022 
Lean mass (kg) 50.1±8.6 54.0±7.8 55.5±8.8 51.1±5.8 0.073 
Fat mass (kg) 21.3±15.5 25.3±11.8 19.4±8.9 14.1±6.8 0.074 
*P-values based on One way ANOVA, † P-value based on Kruskal Wallis test. 
 
6.5.2 25[OH]D and markers of bone mass 
Cyclists and rowers had the greatest serum 25[OH]D concentrations, with sporting type 
significantly associated with serum 25[OH]D status. Cyclists had greater serum 25[OH]D 
compared to equestrian, and all other indoor sport athletes (p<=0.006; Figure 6.1). No significant 
associations were observed between serum 25[OH]D and skin exposure area (p=0.133), but 
increased sun exposure (minutes) was associated with higher serum 25[OH]D concentration 
(p<0.001). Post-hoc pairwise comparisons revealed significantly higher serum 25[OH]D 
concentration only in those athletes exposed to ≥ 120 minutes per day, compared to <30 sunlight 
or less <60 minutes per day (p<0.004).  
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Figure 6.1 Serum 25[OH]D by sport 
 
There were no significant differences in T-score or total BMD between any of the four 25[OH]D 
categories. However, athletes presenting with 25[OH]D insufficiency (20-30ng/mL) demonstrated 
greater spine BMD than sufficient athletes (>30 ng/mL; p=0.029; Table 6.2).  
Table 6.2 Bone mineral density and T-score‡ based upon 25(OH)D status 
Variables 
Vitamin D category (ng/mL) 
p-value <10 10-20 20-30 >30 
n=30 n=41 n=24 n=7 
Spine BMD 1.1±0.1 1.1±0.1 1.2±0.2* 1.0±0.1 0.017 
Neck BMD 1.1±0.1 1.0±0.2 1.1±0.2 1.0±0.1 0.725 
Hip Total BMD 1.1±0.2 1.1±0.1 1.1±0.2 1.0±0.1 0.386 
Total BMD 1.1±0.1 1.2±0.1 1.2±0.1 1.1±0.1 0.030 
Neck T-score -0.3±1.1 -0.3±1.1 -0.3±1.4 -0.8±0.8 0.805 
Hip T-score -0.2±1.2 -0.3±0.9 -0.4±1.4 -1.1±0.5 0.419 
Total T-score -0.7±0.8 -0.3±1.0 -0.5±1.4 -1.2±0.4 0.254 
Spine T-score -0.8±0.9 -0.6±1.0 -0.5±1.3 -1.8±1.0 0.121 
Total BMC 2659.0±359.7 2936.4±402.3† 2979.8±516.2† 2564.9±190.9 0.004 
‡ T-score was not available for 23 athletes less than age 20. * Significantly higher than >30 Serum 25(OH)D 
group; † Significantly higher than <10 and >30 Serum 25(OH)D group 
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Overall, there were no differences between the prevalence of osteoporosis and osteopenia at neck, 
hip or total in any of the four 25(OHD) categories (Table 6.3).   
Table 6.3 Prevalence of osteopenia and osteoporosis based upon 25[OH]D status (Mean±SD) 
Variables 
Vitamin D category (ng/mL) 
p-value <10 10-20 20-30 >30 
n=20 n=33 n=20 n=5 
Neck T-score 
Normal 14(70.0) 23(69.7) 14(70.0) 2(40.0) 
0.22 Osteopenia 6(30.0) 10(30.3) 4(20.0) 3(60.0) 
Osteoporosis 0(0.0) 0(0.0) 2(10.0) 0(0.0) 
Hip T-score 
Normal 15(75.0) 26(78.8) 14(70.0) 1(20.0) 
0.103 Osteopenia 5(25.0) 7(21.2) 5(25.0) 4(80.0) 
Osteoporosis 0(0.0) 0(0.0) 1(5.0) 0(0.0) 
Spine T-score 
Normal 12(60.0) 24(72.7) 14(70.0) 2(40.0) 
0.163 Osteopenia 7(35.0) 7(21.2) 5(25.0) 1(20.0) 
Osteoporosis 1(5.0) 2(6.1) 1(5.0) 2(40.0) 
Total T-score 
Normal 13(65.0) 24(72.7) 13(65.0) 1(20.0) 
0.294 Osteopenia 6(30.0) 9(27.3) 6(30.0) 4(80.0) 
Osteoporosis 1(5.0) 0(0.0) 1(5.0) 0(0.0) 
 
No difference in serum 25[OH]D was observed between athletes with normal T-score and those 
presenting with osteopenia or osteoporosis (overall T-score<1.0) in any location (neck, hip, total) 
(p=0.383). Furthermore, 66% of severely deficient (<10ng/mL) and deficient (20-10ng/mL) 
athletes presented with T-score indicative of normal bone density (+1 to −1 SD) at neck, hip, spine 
and total. Finally, mean body mass was significantly lower in athletes with a T-score indicating 
osteopenia/osteoporosis compared to those athletes with a normal T-score (70.9kg vs. 87.3kg, 
p<0.05; Table 6.4). 
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Table 6.4 Prevalence of osteopenia and osteoporosis based upon 25[OH]D, body weight and body fat 
percentage(Mean±SD) 
Variables 25 [OH]D Body weight (kg) Body fat (%) 
Neck T-score 
Normal 15.8±7.4 84.1±20.1* 30.4±8.2 
Osteopenia 18.3±13.3 68.8±12.4 26.2±7.2 
Osteoporosis 23.5±1.3 68.6±6.4 24.3±4.5 
Hip T-score 
Normal 15.4±7.2 84.3±19.6* 23.9±6.3 
Osteopenia 19.9±13.7 65.7±9.6 27.5±0.0 
Osteoporosis 22.6±0.0 73.1±0.0 29.6±8.9 
Spine T-score 
Normal 16.7±8.7 83.5±20.8* 27.3±5.8 
Osteopenia 14.8±9.0 70.1±12.2 28.7±7.3 
Osteoporosis 23.6±15.0 71.9±10.4 23.9±6.3 
 
6.6 Discussion 
6.6.1 Sports participation and serum 25[OH]D 
The present study hypothesised that 25[OH]D concentration was not associated with BMD in non-
weight bearing Arabic athletes. Indeed, we observed no association between serum 25[OH]D 
concertation and BMD, but did observe that a lower body mass was associated with T-score 
suggestive of osteopenia or osteoporosis.  
In the present study, 93% athletes presented with 25[OH]D insufficiency with 29.4% (n=30) 
demonstrating severe vitamin D deficiency. The majority of 25[OH]D is generated de novo by the 
basal layers of the epidermis via ultraviolet-B radiation. Athletes who train and compete outdoors 
would be expected to present with sufficient vitamin D concentrations. Our data supports this 
notion, with athletes competing in cycling and rowing (outdoor sports) presenting with higher 
25[OH]D concentration that those athletes competing indoors (p<=0.006). Our group previously 
reported no difference in mean serum 25[OH]D between athletes that competed and trained 
indoors (volleyball, basketball, and handball) and athletes that competed outdoors (football). This 
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may be explained by the fact that the majority of football training and competition in Qatar is 
performed after sunset, whereas rowing and cycling are performed during daylight hours due to 
safety reasons. Furthermore, irrespective of sporting type, athletes that reported greater daily 
sunlight exposure >120minutes per day presented greater serum 25[OH]D concentrations than 
athletes <60 minutes per day (p<=0.004). This contradicts research by Hamilton et al. 2010 who 
observed no association between serum 25[OH]D concentrations in male athletes and sunlight 
exposure, but conversely supports our previous research (Allison, Close, et al., 2015; Allison, 
Farooq, et al., 2015).  
 
6.6.2 25[OH]D and markers of bone mass 
Despite a combined 25[OH]D deficiency and severe deficiency prevalence rate of 69%, there were 
no significant differences in T-score at any site (neck, hip, spine or total) across all four 25[OH]D 
categories (p<0.05); suggesting that for this cohort, markers of bone mass are independent of 
serum 25[OH]D status. Indeed, athletes presenting with 25[OH]D insufficiency (20-30 ng/mL) 
demonstrated greater spine BMD than sufficient athletes (>30 ng/mL) (p=0.029; Table 6.2). 
 
6.6.3 Bone Loading 
Mechanical loading from athletic training or competition is associated with higher BMD even 
when adjusting for weight. Nikander et al., 2005 identified weight modality as a determinant of 
the structure and strength of femoral neck; observing that athletes competing in high-impact 
(basketball and volleyball) and odd-impact sports (football) demonstrated greater BMD scores 
than low impact sports such as swimming and cycling. However, non-weight bearing athletes forgo 
the same skeletal loads that produce greater BMD scores (Fredericson et al., 2007) and are at 
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higher risk for low BMD (Guillaume et al., 2012; Smathers et al., 2009). One third of athletes in 
our cohort presented with a T-score indicative of osteopenia (-1 to -2.5 SD) or osteoporosis (-2.5 
SD), in at least one site (neck, hip, spine and total). However, this observation was independent of 
serum 25[OH]D concentration, suggesting that the osteogenic effect of weight-bearing exercise is 
more essential for good bone mass in athletes than 25[OH]D sufficiency. Furthermore, athletes 
with normal T-score presented with significantly greater mean body masses than athletes with T-
score indicative of osteopenia and/or osteoporosis (87.3kg vs. 70.9kg, respectively). Our data 
demonstrate that even in non-weight bearing athletes, a greater body mass contributes to a healthier 
BMD.  
 
6.6.4 Calcium and PTH 
Vitamin D and calcium are regarded as fundamental in bone mass, however observational studies 
show inconsistent associations between BMD and 25[OH]D status (Bischoff-Ferrari, Kiel, et al., 
2009), with optimum concentrations of serum 25[OH]D for optimal skeletal health greatly 
debated. According to the US Institute of Medicine, a serum 25[OH]D concentration of 20ng/mL 
is sufficient to maintain normal bone mass in approximately 97% of the population(Ross et al., 
2011). Yet 66% of athletes in this study had serum 25[OH]D concentrations below this value, but 
presented had T-score indicative of normal bone density (+1 to −1 SD) across all sites. Our data 
confirm that poor bone mass is not mediated by serum 25[OH]D deficiency alone. Bone is a 
dynamic tissue that undergoes continual adaptations to different physiological mechanical stimuli, 
in order to attain and persevere skeletal size, shape and structural integrity (Raggatt & Partridge, 
2010). Although the positive link between weight bearing exercise (or loading) and bone mass 
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have been established, there are still multiple mechanisms that regulate mechanosensation in bone 
are inextricably interdependent.  
 
The known beneficial effects of 25[OH]D on bone health are potentiated by the presence of 
adequate dietary calcium intake (Tenforde, Sayres, Sainani, & Fredericson, 2010). It is difficult 
however, to distinguish between the effects of calcium versus those of vitamin D on skeletal 
integrity, because the main mechanism of action for vitamin D is promotion of calcium absorption 
in the gut and not direct incorporation of calcium in bone (Xue & Fleet, 2009). Calcium 
homeostasis maintains serum calcium levels within a narrow physiological range. Hypocalcaemia 
increases PTH secretion, that enhances the production of the active form of vitamin D, 
1,25[OH]2D3.. The role of vitamin D as a regulator of calcium and bone homeostasis is well 
established. 1,25[OH]2D3, regulates intestinal calcium absorption, bone calcium resorption and 
renal calcium reabsorption, to maintain normal calcium levels in the blood (Lieben & Carmeliet, 
2013). Essentially, 1,25[OH]2D3 will mobilise calcium from bone, when unable to acquire 
sufficient calcium from dietary absorption.  
In a study where specific VDR inactivation was induced in both the intestine and in mature 
osteoblasts in order to interfere with calcium and bone homeostasis, resulting in decreased 
intestinal calcium absorption. Increased 1,25[OH]2D levels not only stimulated bone turnover, 
leading to osteopenia, but also suppressed bone matrix mineralization. These findings indicate that 
maintaining normocalcaemia is a greater priority than skeletal integrity, and that to minimise 
skeletal calcium storage, 1,25[OH]2D not only increases calcium release from bone but also 
inhibits calcium incorporation within bone (Lieben et al., 2012). In the present study, all athletes 
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presented with normal serum calcium and PTH, confirming that role of 25[OH]D in bone 
adaptation in healthy, weight bearing active people is inconsequential. 
 
6.6.5 Energy availability 
The association between lower body mass and markers of poor bone mass may be attributed to the 
osteogenic effects on weight. Yet, sports such as cycling (Vogt et al., 2005) and rowing where 
athletes routinely restrict energy intake for competition needs, may have a negative impact upon 
bone mass.  Low energy availability is defined as dietary energy intake minus exercise energy 
expenditure, and is the amount of dietary energy remaining for other body functions (Loucks, 
2004).  Low energy availability affects bone mass due to decreased IgF-1 and bone formation 
markers. Historically, low energy availability and poor bone mass was considered to be a 
component of the female athlete triad. However, it has also been reported to occur in male athletes, 
hence guidelines have been recently undated (Mountjoy et al., 2014). Whilst nutritional history 
was not assessed in the current study (and therefore energy intake could not be calculated), dietary 
insufficiencies increase the risk of stress fractures in both sexes (McCabe, Smyth, & Richardson, 
2012).  
 
6.6.6 Lifestyle 
Numerous lifestyle factors contribute to 25[OH]D deficiency, including lack of sunlight exposure, 
sun-block use, insufficient dietary vitamin D consumption, refraction and/or non-absorption of 
UVB light due to atmospheric dust particles, and particularly relevant in the Middle East, the 
wearing of concealing clothing for cultural reasons (Hatun et al., 2005). Our data opposes previous 
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research by Hamilton et al.(Hamilton et al., 2010)  who demonstrated no association between 
serum 25[OH]D concentrations in male athletes and use of sunscreen, sunlight exposure or skin 
exposure.  
 
6.6.7 Do athletes require 25[OH]D supplementation? 
Should non-weight bearing athletes take 25[OH]D supplementation or load their bones? We have 
previously demonstrated no association between 25[OH]D and measures of bone mass (BMD and 
T-score) in weight bearing athletes (Allison, Farooq, et al., 2015). This study further supports that 
serum 25[OH]D levels are not associated with BMD and T-score in male Arabic non-weight 
bearing athletes.  In the current study, none of the athletes were taking vitamin D supplementation 
at the time of screening. The impact of vitamin supplementation on athletic performance is still 
debated, with recent evidence reporting that vitamin D deficiencies may actually impair muscle 
regeneration (D. J. Owens et al., 2015), whilst others have shown that correction of serum 
25[OH]D in deficient individuals may improve athletic performance. Emerging work form Close 
et al.(Close, Hamilton, Philp, Burke, & Morton, 2016) suggests that in non-deficient individuals, 
high dose supplementation may have negative consequences related to the function of the vitamin 
D endocrine system, and that oral doses should not exceed 4000IU/d. In conclusion, blanket 
vitamin D supplementation for athletes without specific risk factors should be considered 
questionable. Male athletes in non-weight bearing sports such as cycling are at high risk for low 
BMD (Guillaume et al., 2012; Smathers et al., 2009). Steps to improve overall bone health in these 
cohorts should include, 1) avoiding unnecessary periods of low energy availability and 2) where 
possible, incorporate loading of the musculoskeletal system via strength training (Nikander et al., 
2006). Programs of high-impact loading and resistance training should be implemented at least 2–
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3 days/week for athletes in non-weight bearing sports and/or those with decreased BMD (Nattiv 
et al., 2007). Finally, reassess BMD via DXA every 12 months to ensure that long term bone mass 
is not being compromised by the athletes chosen sporting career.  
6.7 Limitations 
Whilst we acknowledge that training volume and intensity were not recorded; athletes were only 
included in the study if they were registered with the QOC, competed at national or international 
level and trained or competed for more than 6 h / week in their chosen sport. We also acknowledge 
that serum 25[OH]D measurement only offered a snapshot of current status. Thus, it is possible 
for severely deficient (<10 ng/mL) and deficient (10-20 ng/mL) athletes in the present study to 
have spent many years sufficient (>30 ng/mL) prior to recruitment. Finally, as previously 
mentioned, is the absence of robust diet history it is impossible to assess the athlete’s overall 
energy and dietary calcium intake. 
 
6.8 Conclusion 
This study demonstrated that in non-weight bearing Arabic athletes, there was no association 
between serum 25[OH]D concentrations and markers of bone mass (BMD and T-score), but that 
lower body mass was associated with osteopenia or osteoporosis regardless of serum 25[OH]D 
concentration. One third of athletes presented with a T-score indicative of osteopenia (-1 to -2.5 
SD) or osteoporosis (-2.5 SD), in at least one site (neck, hip, spine and total). This was independent 
of serum 25[OH]D concentration, suggesting that the osteogenic effect of weight-bearing exercise 
is more essential for good bone mass in athletes than 25[OH]D sufficiency.  
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6.9 Practical implications 
 
 Avoid unnecessary periods of low energy availability, rate of bone mineralisation declines 
as energy availability declines 
 Incorporate loading of the musculoskeletal system via strength training at least 2–3 
days/week for athletes in non-weight bearing sports and/or those with decreased BMD. 
 Reassess BMD via DXA every 12 months to ensure that long term bone mass 
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Why don’t serum Vitamin D 
concentrations associate with BMD by 
DXA? A case of being ‘bound’ to the 
wrong assay? Implications for Vitamin D 
screening 
 
 
 
 
 
 
 
 
Publications resulted from this chapter; Allison, R. J., A. Farooq, Cherif, A., B. Hamilton, G. 
L. Close, and M. G. Wilson. Why don’t serum vitamin D concentrations associate with BMD by 
DXA? A case of being ‘bound’ to the wrong assay? Implications for vitamin D screening. Br J 
Sports Med Published Online First: 10 August 2017. doi: 10.1136/bjsports-2016-097130 
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7.1 Abstract 
Background: The association between bone mineral density (BMD) and serum 25[OH]D 
concentration is weak, particularly in certain races (e.g. Black African vs. Caucasian) and in 
athletic populations. We aimed to examine if bioavailable vitamin D rather than serum 25[OH]D 
was related to markers of bone mass within a racially diverse athletic population. 
Methods: In 604 male athletes [Arab (n=327), Asian (n=48), Black (n=108), Caucasian (n=53) & 
Hispanic (n=68)], we measured total 25-hydroxyvitamin D (25[OH]D), vitamin D–binding 
protein, and bone mineral density (BMD) by (DXA). Bioavailable vitamin D was calculated using 
the free hormone hypothesis. 
Results: From 604 athletes, 21.5% (n=130) demonstrated severe 25[OH]D deficiency, 37.1% 
(n=224) deficiency, 26% (n=157) insufficiency and 15.4% (n=93) sufficiency. Serum 25[OH]D 
concentrations were not associated with BMD at any site.  After adjusting for age and race, 
bioavailable vitamin D was associated with BMD (spine, neck and hip). Mean serum vitamin D 
binding protein concentration was not associated with 25[OH]D concentrations (p=0.392). 
Conclusion: Regardless of age or race, bioavailable vitamin D and not serum 25[OH]D was 
associated with BMD in a racially diverse athletic population. If vitamin D screening is warranted, 
clinicians should use appropriate assays to calculate vitamin D binding protein and bioavailable 
vitamin D concentration rather than serum 25[OH]D. In turn, prophylactic vitamin D 
supplementation to ‘correct’ insufficient athletes should not be based upon serum 25[OH]D 
measures.  
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7.2 Introduction 
Vitamin D3 (cholecalciferol) is a lipophilic pro-hormone produced in the skin from exposure to 
sunlight. Cholecalciferol is transported bound to vitamin D-binding protein (DBP), and is 
hydroxylated in the liver to form 25-hydroxyvitamin D (25[OH]D). 25[OH]D undergoes further 
hydroxylation in the kidney, to form the active hormone 1, 25-dihydroxyvitamin D [1,25(OH)2D]. 
This bioactive metabolite, regulates intestinal calcium absorption, bone calcium resorption and 
renal calcium reabsorption in order to maintain calcium homeostasis, and promote skeletal 
mineralisation (M. F. Holick, 1996; Lieben & Carmeliet, 2013). Accordingly, skeletal pathologies 
such as rickets and osteomalacia often present when 25[OH]D levels are consistently deficient (B. 
Hamilton, 2010).  
Clinically to date, measuring serum 25[OH]D concentration provides the best estimate of vitamin 
D status as both circulating levels of cholecalciferol and 1,25(OH)2D have short half-lives, 
approximately 24hrs and 4-6hrs, respectively (M. F. Holick, 1990; Iqbal, 1994). Serum 
cholecalciferol levels can also be affected by recent sunlight exposure, and is difficult to measure 
due to the lipophilic nature of the molecule. Optimum concentrations of serum 25[OH]D for 
skeletal health are still debated (7). Many clinicians define vitamin D sufficiency as the lowest 
serum 25[OH]D concentration that maximally suppresses parathyroid hormone (PTH) secretion 
and/or optimises bone mineral density (BMD) (Bischoff-Ferrari et al., 2006; Chapuy et al., 1997; 
Malabanan et al., 1998). The generally accepted serum 25[OH]D concentration ranges are: 
severely deficient (<10 ng/mL), deficient (10–20 ng/mL), insufficient (20–30 ng/mL), or sufficient 
(>30 ng/mL); although the vast majority of evidence supporting these categories are derived from 
elderly cohorts or groups with existing skeletal disorders (Bischoff-Ferrari et al., 2005; Cauley et 
al., 2008; B. Dawson-Hughes et al., 1997; Vanderschueren et al., 2013).  
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Yet, the association between bone mineral density (BMD) and serum 25[OH]D concentration is 
weak  (Bischoff-Ferrari, Kiel, et al., 2009; Gerdhem et al., 2005; Hannan et al., 2008; Kremer et 
al., 2009; Marwaha et al., 2011). Our group previously demonstrated no association between serum 
25[OH]D and markers of bone mass in weight bearing athletes of different racial background, 
suggesting that markers of bone mass are independent of serum 25[OH]D concentrations (Allison, 
Close, et al., 2015). It appears there is a ‘paradoxical relationship’ between race and vitamin D 
concentration, that has largely been ignored, i.e. black individuals generally have the lowest serum 
25[OH]D concentrations but the greatest BMD and reduced risk of fracture (Cauley et al., 2005; 
Hannan et al., 2008). DBP may provide an insight as to why certain racial groups have distinct 
25[OH]D and BMD relationships (Powe et al., 2013). DBP is the primary vitamin D carrier, 
binding 85%–90% of total circulating 25[OH]D, with the remaining unbound 25[OH]D considered 
to be bioavailable (Bikle et al., 1986). Polymorphisms in the DBP coding genes (specifically 
rs4588 and rs7041) produce proteins that differ in affinity for 25[OH]D, and it is these 
polymorphisms that are known to differ between racial groups (Engelman et al., 2008). 
Differentiating between total vitamin D (measured as 25[OH]D) and bioavailable vitamin D is 
crucial, given that the latest evidence suggests that DBP inhibits certain actions of vitamin D, since 
the bound fraction is unavailable to act on target cells. (Bikle et al., 1986; Powe et al., 2013; Safadi 
et al., 1999). Consequently, serum bioavailable vitamin D may represent a better reflection of bone 
mass than serum 25[OH]D concentration (Powe et al., 2013). To date, research on vitamin D status 
in athletes has focused solely upon serum 25[OH]D and as a consequence, the current advice and 
guidelines given to athletes and clinicians treating vitamin D deficiency may be inaccurate.  
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7.3 Aims and Hypotheses 
Therefore, the present study set out to examine if bioavailable vitamin D is related to markers of 
bone mass within a racially diverse athletic population. It was hypothesised that bioavailable 
vitamin D and not serum vitamin D would be associated with markers of bone mass in a racially 
diverse athlete population. 
 
7.4 Methods 
7.4.1 Participants 
Six hundred and four male athletes registered with the Qatar Olympic Committee [Arab (n=328), 
Asian (n=48), Black (n=108), Caucasian (n=53) and Hispanic (n=35)], exercising ≥6 h/week 
presented for pre-competition medical assessment at Aspetar Sports Medicine Hospital, Qatar. 
Participants were screened for inclusion as described in the General Methods chapter of this thesis. 
After meeting this initial inclusion criteria, participants provided a venous blood sample, 
completed vitamin D questionnaire and undertook bone mineral density analysis as described in 
of the General Methods chapter of this thesis. 
 
7.4.2 Laboratory Analyses 
Venous blood samples were collected from athletes following an overnight fast and analysed for 
serum 25-hydroxyvitamin D (25[OH]D) as described in section 3.4.2, of General Methods 
Chapter. 
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7.4.3 Vitamin D-Binding Protein 
Serum vitamin D binding protein (DBP) concentrations (µg/mL) were determined using a 
commercially available kit (R&D Systems, UK). The limit of sensitivity was ≤0.65 ng/mL-1 and 
an inter-assay coefficient of variation was 7.2%. An automatic enzyme-linked immunosorbent 
assay (ELISA) microplate reader (Infinite® 200 PRO NanoQuant, Switzerland) and computer 
software Magellan Standard (version 7.1) were used to analyse DBP. 
 
7.4.4 Assessment of Bone Mineral Density  
As described in the general methodology chapter  
 
7.4.5 Calculation of Bioavailable 25-hydroxyvitamin 
Bioavailable and DBP-bound 25[OH]D were calculated using equations described in Chapter 3.  
 
7.4.6 Statistical analysis 
Statistical analyses were performed as described in Chapter 4 with the additional calculations to 
determine the relationship of bone mass parameters with serum 25[OH]D, DBP and bioavailable 
25[OH]D, simple regression without covariates and multiple linear regression analysis including 
covariates such as age and ethnicity was performed with bone mass as a dependent variable, with 
age and ethnicity covariates. Parameter estimates along with standard error were reported. A p-
value<0.05 was used as a cut-off for statistical significance. Furthermore, the statistical methods 
underwent external assessment by BJSM 
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7.5 Results 
7.5.1 Participants  
From 604 athletes, 21.5% (n=130) demonstrated severe 25[OH]D deficiency, 37.1% (n=224) 
deficiency, 26% (n=157) insufficiency and 15.4% (n=93) sufficiency. There was no difference in 
athlete age or body mass index across the four vitamin D status categories. However, 25[OH]D 
sufficient (>30ng/mL) athletes presented with significantly lower body fat % compared to 
insufficient (P=0.024), deficient (P=0.002) and severely deficient (P=0.001) athletes. Markers of 
bone mass were normal for all athletes across all sites. 
7.5.2 Vitamin D–Binding Protein, Bioavailable Vitamin D and Markers of Vitamin D Status  
Whilst there was a positive linear association between 25[OH]D status and bioavailable vitamin 
D (r=0.702; p<0.001), DBP concentration was not associated with 25[OH]D concentrations (r=-
0.035, p=0.392).  PTH was significantly greater in severely 25[OH]D deficient athletes compared 
to insufficient (P=0.010), deficient (P=0.005) and sufficient (P<0.001) athletes. Albumin was 
significantly greater in sufficient athletes compared to 25[OH]D deficient athletes (P=0.029) 
(Table 7.1). Bioavailable vitamin D showed a strong negative association with DBP (r =-0.733; 
P<0.001) and PTH (r =-0.310; P<0.001) but not with 1,25[OH]2D (r=-0.023, P=0.738). 
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Table 7.1 Measures of vitamin D, albumin and parathyroid hormone against 25[OH]D status categories 
 
Vitamin D category (ng/mL) 
<10 
(n=130) 
10-20 
(n=224) 
20-30 
(n=157) 
>30 
(n=93) 
Age Mean (SD) 23.7 (5.4) 24.6 (5.6) 25.4 (5.6) 25.0 (4.5) 
Body mass index Mean (SD) 23.6 (3.9) 24.7 (3.4) 24.2 (3.5) 24.0(3.6) 
Race n (%)     
Arab (n=327) 96 (29.4) 146 (44.6) 65 (19.9) 20 (6.1) 
Asian (n=48) 10 (20.8) 17 (35.4) 14 (29.2) 7 (14.6) 
Black (n=108) 17 (15.7) 43 (39.8) 32 (29.6) 16 (14.8) 
Caucasian (n=53) 4 (7.5) 13 (24.5) 20 (37.7) 16 (30.2) 
Hispanic (n=68) 3 (4.4) 5 (7.4) 26 (38.2) 34 (50.0) 
Blood markers (mean±SD)     
1,25(OH)2D 39.3 (14.3) 39.4 (14.9) 39.9(14.0) 34.9(9.9) 
ALB (g/L) 42.1(2.4) 41.8 (2.4) 41.9(2.5) 42.6(2.8) b 
PTH (pg/ml) 67.2 (50.8) bcd 52.9(16.2) 50.1(14.0) 41.3(8.3) 
DBP (μg/ml) 478.5 (410.4) 385.1(304.0) 416.6(298.4) 370.5(327.1) 
Bioavailable 25[OH]D 
(ng/mL) 0.7 (0.5) 1.5(0.9)
 a 2.6(1.7) ab 4.7(3.0) abc 
ALB; albumin, PTH; parathyroid hormone, DBP; vitamin D binding protein. a: significantly greater than <10ng/mL, 
b: significantly greater than 10-20ng/mL, c: significantly greater than 20-30ng/mL and d: significantly greater than 
>30ng/mL.  
 
7.5.3 Impact of Race upon Serum 25[OH]D, Bioavailable Vitamin D and BMD 
Mean serum 25[OH]D concentrations significantly differed between race, with Caucasians and 
Hispanics presenting greater serum 25[OH]D levels than Arabs, Asians and Blacks (Table 7.2). 
Whilst 1,25(OH)2D and PTH were not significantly different between racial groups, DBP was 
significantly lower in Black athletes compared to in Arabs (P<0.001), Caucasian (P<0.001) and 
Hispanic (P<0.001) athletes.  Arab athletes presented with significantly lower bioavailable 
25[OH]D concentrations compared to Black (P<0.001), Caucasian (P<0.001) and Hispanic 
(P<0.001) athletes. Arab athletes demonstrated significantly lower BMD scores across all sites 
(spine (P<0.001), neck (P<0.001) and total hip (P<0.001) compared to Caucasians, Blacks and 
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Hispanic athletes. There was no difference in BMD across all sites between Black, Caucasian and 
Hispanic athletes. Finally, 25[OH]D sufficient Arab athletes presented with higher spine BMD 
than severely deficient Arabs athletes (p=0.036; 1.39 vs. 1.24 g/cm3 respectively); this was not 
observed in any other race. 
 
Table 7.2 Measures of vitamin D, BMD, albumin and parathyroid hormone by athlete race (Mean±SD) 
 Athlete Race 
 Arab [A] (n=328) 
Asian [B]  
(n=48) 
Black [C] 
(n=108) 
Caucasian [D] 
(n=53) 
Hispanic [E] 
(n=35) 
25[OH]D 15.9(8.8) 19.3 (11.8) 19.9 (10.4)a 26.2 (12.9)abc 32.1 (13.5)abcd 
1,25(OH)2D 39.6(14.7) 39.8 (14.4) 39.3 (14.6) 38.8 (10.4) 33.0 (11.7) 
ALB (g/L) 41.8(2.32) 42.2 (2.1) 41.2 (2.5) 43.3 (2.6)ac 43.1 (2.7)ac 
PTH (pg/ml) 60.7(39.5) 47.7 (11.1) 52.1 (15.4) 47.2 (14.9) 41.2 (8.2) 
DBP (μg/ml) 449.8(314.6)c 376 (176.0) 288.2 (336.1) 422.2 (372.8)c 434.2 (416.4)c 
Bioavailable 
25[OH]D (ng/mL) 1.5(1.3) 1.7 (1.2) 3.3(2.7)
ab 2.5 (1.7)a 3.3 (2.8)ab 
Spine BMD 1.29 (0.21) 1.32 (0.16) 1.48(0.16)ab 1.50 (0.13)ab 1.45 (0.14)ab 
Neck BMD 1.25 (0.21) 1.31 (0.19) 1.48 (0.17)ab 1.43 (0.14)ab 1.41 (0.17)ab 
Hip BMD 1.26 (0.20) 1.31 (0.18) 1.47 (0.17)ab 1.40 (0.13)ab 1.40 (0.15)ab 
Total BMD 1.26 (0.16) 1.28 (0.10) 1.43 (0.13)ab 1.42 (0.10)ab 1.38 (0.10)ab 
Spine T-score 0.61 (1.20) 0.64 (1.19) 1.85 (1.43)ab 1.98 (1.33)ab 1.74 (1.16)ab 
Neck T-score 1.22 (1.42) 1.53 (1.49) 2.72 (1.65)ab 2.25 (1.37)a 2.44 (1.42)ab 
Hip T-score 1.02 (1.20) 1.20 (1.23) 2.18 (1.41)ab 1.68 (1.07)a 2.00 (1.12)ab 
Total T-score 0.63 (1.21) 0.67 (0.96) 2.06 (1.39)ab 1.78 (1.24)ab 1.72 (1.07)ab 
ALB; albumin, PTH; parathyroid hormone, DBP; vitamin D binding protein, BMD; bone mineral density. a: 
significantly greater than Arabs, b: significantly greater than Asian, c: significantly greater than Blacks and d: 
significantly greater than Caucasians.  
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7.5.4 Relationship between Markers of Bone Mass, Serum 25[OH]D, PTH and Bioavailable 
Vitamin D 
Serum 25[OH]D, DBP and bioavailable vitamin D showed skewed distributions and were 
logarithmic transformed in order to meet the assumptions of the parametric statistical techniques. 
P-values and parameter estimates presented are based on log-transformed data. The age and 
ethnicity adjusted spine BMD increased [B=0.032 95% CI (0.012 to 0.051); P=0.001] with each 
one log unit change in bioavailable vitamin D.  
Similarly, bioavailable vitamin D was also associated with spine [B=0.032 95% CI (0.012 to 
0.051), P=0.001], neck [B=0.037 95% CI (0.016 to 0.057), P<0.001] and hip [B=0.035 95% CI 
(0.016 to 0.055), P<0.001] BMD (Table 7.3). DBP was negatively associated with spine [B=-0.035 
95% CI (-0.059 to -0.012), P=0.004], neck [B=-0.040 95% CI (-0.065 to -0.016), P=0.001] and hip 
[B=-0.037 95% CI (-0.061 to -0.014), P=0.002] BMD. Serum 25[OH]D concentrations were not 
associated with BMD at any site.  DBP was positively associated with neck (P=0.034) and hip T-
score (P=0.040) but not spine (P=0.067). Serum 25[OH]D and bioavailable 25[OH]D were not 
associated with T-score at any site .  PTH was not associated with BMD across all sites and T-
scores of Spine (r=-0.029, P=0.641), Hip (r=-0.093, P=0.134) and Neck (R=-0.117, P=0.061). 
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Table 7.3 Parameter estimates (β 95% CI) of association of log transformed vitamin D parametersagainst independent 
bone mass variables (spine, neck and hip BMD and T-scores) after adjusting for age and race 
Dependent 
variables 
Vitamin D parameters* 
Serum 25[OH]D 
B (95% CI) 
P value DBP 
B (95% CI) 
P value Bioavailable 25[OH]D 
B (95% CI) 
P value 
Spine BMD 0.022 (-0.007 to 0.052) 0.141 -0.035 (-0.059 to -0.012) 0.004 0.032 (0.012 to 0.051) 0.001 
Neck BMD 0.028 (-0.002 to 0.059) 0.071 -0.040 (-0.065 to -0.016) 0.001 0.037 (0.016 to 0.057) <0.001 
Hip BMD 0.029 (0.000 to 0.059) 0.051 -0.037 (-0.061 to -0.014) 0.002 0.035 (0.016 to 0.055) <0.001 
Spine T-score -0.030 (-0.229 to 0.170) 0.770 -0.151 (-0.313 to 0.011) 0.067 0.078 (-0.055 to 0.211) 0.250 
Neck T–score -0.006 (-0.244 to 0.231) 0.957 -0.209 (-0.401 to -0.016) 0.034 0.119 (-0.038 to 0.277) 0.138 
Hip T-score 0.000 (-0.198 to 0.198) 1.000 -0.169 (-0.329 to -0.008) 0.040 0.098 (-0.034 to 0.230) 0.144 
* log transformed covariates and adjusted for age and ethnicity B: Unstandardised coefficient and (95 % confidence 
intervals.) 
 
 
7.6 Discussion 
The aim of the present study was to examine if bioavailable vitamin D was related to markers of 
bone mass within a racially diverse athlete population. It was observed that after adjusting for age 
and race, bioavailable vitamin D was closely associated with BMD (spine, neck and hip), whilst 
there was no association between serum 25[OH]D concentration and BMD at any site .  DBP was 
positively associated with neck and hip T-score but not at spine. Serum 25[OH]D and bioavailable 
25[OH]D were not associated with T-score at any site. Furthermore, mean serum DBP 
concentrations were not associated with 25[OH]D concentrations.  For clinicians treating vitamin 
D insufficiency, our data suggests that the current choice of assay is not fit for practice when 
examining the relationship between bone mass and vitamin D concentrations.  
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7.6.1 The role of bioavailable vitamin D upon Markers of Bone Mass  
Vitamin D is just one of many factors including energy availability and weight bearing exercise 
that can impact upon bone mass. The role of vitamin D and calcium in bone development, growth 
and integrity have been well documented (M. F. Holick, 1996). Previous studies however, 
demonstrate inconsistent associations between serum 25[OH]D concentrations and BMD in 
general (Bischoff-Ferrari, Kiel, et al., 2009; Marwaha et al., 2011) and athletic populations 
(Allison, Farooq, et al., 2015). It has be postulated that the osteogenic effect of weight-bearing 
exercise (i.e. loading the bones) may be sufficient to maintain markers of bone health, irrespective 
of 25[OH]D status in healthy adults . Though the present data also suggests that the clinical 
utilisation of serum 25[OH]D could be an additional factor for this inconsistency, given that 
bioavailable vitamin D and not serum 25[OH]D was associated with BMD at all sites in an racially 
diverse athletic population. Using the free hormone hypothesis, the unbound fraction (or 
bioavailable vitamin D) may exert a stronger biological effect on BMD than total 25[OH]D (Bikle 
et al., 1986; Safadi et al., 1999). Since serum 25[OH]D is generally used in previous observational 
and interventional studies, it may explain such inconsistencies in the poor association between 
serum 25[OH]D and BMD (Johnsen et al., 2014; Powe et al., 2011). Accordingly, our data supports 
the notion that current 25[OH]D reference ranges provide an inaccurate representation of true 
vitamin D status in athletes. In contrast to previous findings, DBP concentration was not associated 
with 25[OH]D concentrations (p=0.392) (Powe et al., 2011). Whilst there was a positive linear 
association between 25[OH]D status and bioavailable vitamin D, PTH levels were not associated 
with 25[OH]D levels, BMD or T-scores, suggesting that the association between bioavailable 
25[OH]D levels and BMD is not mediated via PTH. 
134 
 
7.6.2 Impact of Race 
Studies support that racial differences or a ‘paradox’ exists in the relationship between serum 
25[OH]D concentrations and markers of bone mass  (Gutierrez et al., 2011; Hannan et al., 2008; 
Powe et al., 2014). Specifically, recent studies in the general population have demonstrated that 
polymorphisms in the DBP gene were associated with corresponding changes in total 25[OH]D 
levels and the risk of osteoporosis (Engelman et al., 2008; Fang et al., 2009). Aggarwal et al. 
demonstrated that bioavailable 25[OH]D was a better measure of vitamin D status with respect of 
BMD in patients with nephrotic syndrome (Aggarwal et al., 2016). To our knowledge, this is the 
first study to examine DBP and bioavailable vitamin D alongside bone mass as assessed by DXA 
in athletes. Our data supports these previous observations, with Hispanic athletes presenting with 
greater mean serum 25[OH]D levels (32.1 ng/mL) compared to Caucasian (26.2ng/mL) and Black 
(19.9ng/mL) athletes, despite no difference in bioavailable vitamin D or BMD at any site. 
Bioavailable vitamin D is determined by vitamin D-binding protein concentration, which is 
encoded by the group-specific component (GC) gene (Malik et al., 2013). Polymorphisms in the 
GC gene, produce proteins that differ in affinity for 25[OH]D, and it is these polymorphisms that 
are known to differ between racial groups. Racial differences in the prevalence of common genetic 
polymorphisms provide a likely explanation for this observation. Consequently, our data have 
implications for the wider general population, with further research warranted on adolescent and 
female athletes. 
 
7.6.3 Financial considerations for treating clinicians 
Screening athlete for vitamin D insufficiency is expensive. In our facility, 25[OH]D assessment 
costs $255USD per athlete. Since Aspetar screens approximately 1500 elite athletes per year, 
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systematic 25[OH]D screening costs our facility $382,500USD per year.  Since our data clinically 
questions the value of routine 25[OH]D screening, the financial burden of vitamin D testing only 
adds weight to the debate of whether clinicians should be testing for vitamin D insufficiency, since 
all athletes in the present study demonstrated normal bone mass. Our data also questions the value 
of prophylactic vitamin D supplementation (typically 2000IU/d oral cholecalciferol) in insufficient 
athletes to ‘correct’ 25[OH]D status, but who show no symptoms of relative energy deficiency 
syndrome, poor bone mass or musculoskeletal injury. Perhaps targeted vitamin D screening and 
supplementation should be reserved for those athletes presenting with stress fracture related 
injuries, or those competing in non-weight bearing sports such as cycling and swimming where 
the osteogenic effect of bone loading is sub-optimal. If testing is warranted however, clinicians 
should use the appropriate assays to calculate DBP and bioavailable vitamin D status rather than 
serum 25[OH]D.  
 
7.7 Limitations 
The primary limitation of work is that the equation adopted to calculate bioavailable D used of the 
generic affinity constant of the Gc1F allele due to lack of genetic analysis.  The equations used to 
estimate free and bioavailable 25[OH]D in this study used the affinity constants of the Gc1F allele, 
as did the equations in Powe et al. (Powe et al., 2011). Genotyping has identified two common 
SNPs in the coding region of the DBP gene (rs4588 and rs7041). Combinations of these SNPs, 
produce three major polymorphic forms of DBP (Gc1F, Gc1S, and Gc2 phenotypes) which differ 
substantially in their binding affinity for 25[OH]D and proportionally vary between ethnicities, 
e.g. Blacks homozygotes present with a greater percentage of Gc1F and Caucasian homozygotes 
present with a greater percentage of Gc1S phenotype (92.7% vs 76.0% respectively). Furthermore, 
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a recent study has highlighted the potential discrepancies between monoclonal versus polyclonal 
ELISA (Jemielita et al., 2016). The monoclonal antibody (R&D ELISA) used in this study binds 
to a single peptide fragment of DBP and may bind differently to Gc1F and Gc1S variants, yielding 
underestimated concentrations in black individuals (Bouillon, Jones, & Schoenmakers, 2014; 
Hollis & Bikle, 2014). Prior studies have shown no racial differences in circulating DBP using 
polyclonal assays (Bouillon et al., 2014; Winters, Chennubhatla, Wang, & Miller, 2009). While 
there may be cross-reactivity of polyclonal antibodies with other proteins (Christiansen et al., 
2007; Powe et al., 2014) which likely explains the systematically higher DBP results with the 
polyclonal assay, this is non-differential by race.  Although, not significant in this study, Black 
athletes presented with higher mean bioavailable vitamin D, and lower DBP than Caucasian 
athletes, so the variation within the testing techniques cannot be ignored. Finally, the impact of 
training load, dietary intake data to assess total energy and calcium intake and the assessment of 
steroid hormones were not accounted for in this study. Future, longitudinal trials including 
genotype-specific binding affinity constants in the calculation for bioavailable vitamin D, training, 
dietary and hormone analysis on ethnically diverse populations are warranted. We also 
acknowledge that serum 25[OH]D measurement only offered a snapshot of current status. Thus, it 
is entirely possible for severely deficient (<10 ng/mL) and deficient (10-20 ng/mL) athletes in the 
present study to have spent many years sufficient (>30 ng/mL) prior to recruitment. Deuterium 
enrichment protocol, bone biopsy  
7.8 Conclusion 
In conclusion, regardless of age or race, bioavailable vitamin D and not serum 25[OH]D was 
associated with BMD in a racially diverse athletic population. Our data questions the value of 
routine 25[OH]D screening in athletes, since all athletes in the present study demonstrated 
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clinically normal bone mass, despite 85% of athletes presenting with either serum 25[OH]D 
insufficiency, deficiency or severe deficiency respectively. Our data suggest that bioavailable 
vitamin D, rather than the current standard of 25[OH]D is a better measure of vitamin D status 
with respect to BMD.  
What are the findings? 
 This study demonstrated that in a racially diverse athletic population, bioavailable vitamin D was 
closely associated with bone mineral density (BMD; spine, neck and hip; p<0.002).  
 No association was observed between serum 25[OH]D concentration and BMD at any site 
(p>0.05).   
 Mean serum DBP concentration were not correlated with 25[OH]D concentrations (p=0.392).   
 
How might it impact on clinical practice in the near future? 
 Determining bone mass is multifactorial. Systematic screening to determine 25[OH]D 
concentrations in isolation is expensive, and demonstrates a poor relationship to bone mass in a 
racially diverse athletic population.  
 If testing is warranted, clinicians should use the appropriate assays to calculate DBP and 
bioavailable vitamin D concentration rather than total serum 25[OH]D.  
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Severely Vitamin D-Deficient Athletes 
Present Smaller Hearts than Sufficient 
Athletes 
 
 
 
 
 
 
 
 
 
 
Publications resulted from this chapter; Allison, R. J., G. L. Close, A. Farooq, N. Riding, O. 
Salah, B. Hamilton, and M. G. Wilson. Severely vitamin D-deficient athletes present smaller 
hearts than sufficient athletes. Eur J Prev Cardiol., Vol. 22, No. 4, pp. 535-542, 2015 
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8.1 Abstract 
Background: Vitamin D (25[OH]D) deficiency has associations with bowl/colon cancer, arthritis, 
diabetes, and cardiovascular disease. Many athletes are vitamin D deficient, yet no studies have 
examined the association between 25[OH]D status and cardiac structure and function in healthy 
athletes. 
Methods: A total of 506 national-level athletes [football (50%), handball (23%), volleyball (16%), 
and basketball (11%)] and 244 control participants presented for precompetition medical 
assessment. Controls were healthy individuals registered with a sporting federation undertaking 
<2 h of exercise per week. All individuals undertook a physical examination, 12-lead 
electrocardiogram, echocardiogram, and serum 25[OH]D evaluation. 
Results: From 506 athletes and 244 controls, 23 and 12.3% demonstrated 25[OH]D sufficiency 
(>30 ng/ml), 30 and 23.4% insufficiency (20–30 ng/ml), 37.2 and 48.8% deficiency (10–20 ng/ml), 
and 11 and 15.6% severe deficiency (<10 ng/ml). Severely 25[OH]D-deficient athletes present 
significantly (p<0.05) smaller aortic root and left atria diameters, intraventricular septum diameter 
(IVSd), left ventricular diameter during diastole (LVIDd), left ventricular mass (LVM), left 
ventricular volume during diastole (LVvolD), and right atrial (RA) area than insufficient and 
sufficient athletes. Furthermore, following logarithmic transformation adjusting 25[OH]D for age, 
body surface area, ethnicity, and athletic participation, positive associations were observed 
between 25[OH]D and IVSd, LVIDd, posterior wall thickness during diastole, LVM, and LVvolD 
in athletes but not in the control participants. 
Conclusions: Severely 25[OH]D-deficient athletes present significantly smaller cardiac structural 
parameters than insufficient and sufficient athletes. Future research should investigate the precise 
mechanism(s) causing cardiac hypertrophy with increases in serum 25[OH]D in healthy athletes. 
26 
8.2 Introduction 
Ever since Weishaar et al. observed an association between 25[OH]D and cardiovascular function 
using 25[OH]D deficient rats 25 years ago, several research groups have established associations 
between 25[OH]D and cardiac structure and function (in both human and animal models) 
(Weishaar & Simpson, 1987b). Yet the majority of these studies have only examined pathological 
conditions such as chronic kidney disease (Thadhani et al., 2012), thalassaemia-major (Noetzli et 
al., 2011), hypertension (Kong et al., 2010), peripheral arterial disease (Fahrleitner et al., 2002) 
and congestive heart failure (CHF) (Pilz, Marz, et al., 2008).  
It is known that the vitamin D receptor and the associated apparatus for 1,25-dihydroxyvitamin D 
production are present throughout the heart and vascular system, with the vitamin D receptor 
specifically located in cardiac myocytes and fibroblasts (Chen et al., 2008). Further, 25[OH]D 
deficiency is known to adversely affect cardiac contractility, vascular tone, cardiac collagen 
content, and cardiac tissue maturation (Achinger & Ayus, 2005). Histological analysis of 25[OH]D 
deficient rats demonstrate significantly smaller ventricular myofibrils and increases in 
extracellular matrix proteins compared to 25[OH]D sufficient rats (Weishaar et al., 1990).  
Regular participation in intensive physical exercise is associated with several structural and 
electrophysiological cardiac adaptations that enhance diastolic filling and facilitate a sustained 
increase in cardiac output that is fundamental to athletic excellence. Such cardiac adaptations are 
collectively referred as the “Athlete’s Heart” and are frequently reflected on the 12-lead 
electrocardiogram (ECG) and imaging studies (Chandra et al., 2013). Numerous factors affect the 
adaptations of the athletes heart including; sporting modality, duration and intensity, age, ethnicity, 
sex, anthropometry and performance enhancing substance abuse. However, it is also well 
recognised that many professional athletes are vitamin D deficient (Close, Russell, et al., 2013), 
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and no studies have examined the association between 25[OH]D status and cardiac structure and 
function in healthy athletes. 
8.3 Aims and Hypotheses 
The present study aimed to examine the relationship between serum 25[OH]D and bioavailable 
vitamin D with cardiac structure and function within a large, ethnicity diverse cohort of healthy 
athletes for pre-competition medical assessment at our institution. 
8.4 Methods 
8.4.1 Participants 
Between November 2010 and June 2012, 521 male athletes (exercising ≥6 h/week) presented at 
our institution for pre-competition medical assessment [football (n=269, 51%), handball (n= 115, 
22%), volleyball (n = 82, 16%), basketball (n=55, 11%)]. A further 244 individuals registered with 
a Qatari sporting federation (such as sailing, archery, shooting, bowling) but exercising ≤2 h/week 
were used as a control population. Arabs (n=427) came from seven Gulf States and 
Five Middle-Eastern countries; Black Africans (n=207) came from nine African countries; 
Caucasians (n=116) came from six European/North American countries. 
8.4.2 Pre-participation cardiovascular screening 
All individuals were screened using a precompetition medical assessment form, examining family 
history of cardiovascular disease and personal symptoms, with a physical examination undertaken 
by a sports medicine physician. A standard 12-Lead ECG was obtained using a GE Mac 5500 
(New York, USA) after a 5-min rest in the supine position. 
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Echocardiographic examination was performed using a commercially available ultrasound system 
(Philips, USA) by an experienced sports cardiologist.  Images of the heart were obtained in the 
standard planes, using previously published criteria (Riding et al., 2013).  
8.4.3 Athlete exclusion and further evaluation 
Fifteen athletes demonstrated ECG and/or echocardiographic abnormalities suspicious of a disease 
associated with sudden cardiac death, and were excluded from further analysis.  
 
8.4.4 Vitamin D assessment 
The remaining 506 athletes and 244 controls undertook serum 25[OH]D evaluation via 
chemiluminescent immunoassay technology (Liaison® 25-OH Vitamin D Total Assay; DiaSorin 
Inc., Saluggia (Vercelli), Italy). Sensitivity for 25[OH]D was 7 ng/ml, below which levels were 
recorded as <7 ng/ml. The intra- and interassay CV was 7.6–9.4% and 9.8–13.4%, respectively. In 
addition, athletes completed a vitamin D questionnaire that addressed specific areas relevant to 
vitamin D status as described in Chapter 3.  
 
8.4.5 Statistical analysis 
Statistical analyses were performed as described in Chapter 3 with the additional calculations. 
Two-way ANOVA was used to compare athlete physical and lifestyle habits and cardiac structure 
and function parameters between four levels of serum 25[OH]D groups within and between the 
subject groups (athletes vs. controls). Post-hoc Bonferroni adjustments were performed where 
appropriate. Mean, standard deviation, and ranges were reported for the continuous variables. The 
Chi-squared test was used to test the association between lifestyle habits and serum 25[OH]D 
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groups. Multiple linear regression was used to determine the association of ECG and 
echocardiographic parameters against serum 25[OH]D. Natural log transformations were applied 
to serum 25[OH]D concentrations to remove positive skewness, adjusting for age, ethnicity, body 
surface area, and athletic participation (athlete vs. controls). To determine the relationship of 
cardiac structure parameters with bioavailable vitamin D, multiple liner regression analysis 
including covariates such as age and BSA with manual backwards-stepwise deletion was 
performed. Parameter estimates along with standard error were reported. A p-value<0.05 was for 
statistical significance. 
8.5 Results 
Of the 506 athletes, 23% demonstrated 25[OH]D sufficiency, 30% insufficiency, 37.2% 
deficiency, and 11% severe deficiency. Of the controls, 12.3% demonstrated 25[OH]D sufficiency, 
23.4% insufficiency, 48.8% deficiency, and 15.6% severe deficiency (Table 8.1). Athletes were 
significantly (p<0.05) taller, heavier, and had a larger body surface area than controls in their 
respective 25[OH]D groups. 25[OH]D severely deficient athletes were significantly (p<0.05) 
shorter and lighter compared to insufficient and sufficient athletes. The incidence of severe 
25[OH]D deficiency or deficiency in Caucasian athletes was significantly lower compared to 
Arabic and Black African athletes, while significantly more Caucasian athletes were 25[OH]D 
sufficient compared to Arabic and Black African athletes. Of both athletes and controls, 48% did 
not expose themselves to sunlight, and 17 and 18%, respectively, exposed themselves to >2 h of 
sunlight per week (Table 8.2). Of those individuals that received no UVB radiation, 16.9 and 9.4%, 
respectively, were sufficient in 25[OH]D, and of those that received >2 h of sunlight per week, 5.8 
and 6.8%, respectively, were severely deficient in 25[OH]D. For those individuals that exposed 
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themselves to sunlight, 86 and 69.3%, respectively, uncovered more than their hands and face. 
Finally, 8.2 and 5.3%, respectively, used sunscreen. 
Table 8.1 Physical characteristics of individuals severely deficient, deficient, insufficient and sufficient vitamin D 
Variables 
Vitamin D (ng/mL) 
 
<10 10 - 20 20-30 >30 p-value 
Numbers and percentage 
     
Athletes 55 (11) 186 (37.2) 150 (30) 115 (23) - 
Controls 38 (15.6) 119 (48.8) 57 (23.4) 30 (12.3) - 
Age (years) 
     
Athletes 21.7±4.8 22.3±5.2 24.0±5.5*a,b 23.3±5.3 0.008 
Controls 21.7±6.5 23.7±7.3 26.5±10.1a 27.0±9.0 0.013 
Height (m) 
     
Athletes 1.77±13.7* 1.81±11.8* 1.84±11.6*,a 1.84±11.1*,a <0.001 
Controls 1.72±6.5 1.73±6.6 1.72±9.1 1.72±6.4 0.88 
Body mass (kg) 
     
Athletes 75.3±20.8* 80.7±17.2* 84.2±14.5*,a 81.9±13.5*,a 0.005 
Controls 68.2±15.6 71.6±14.7 73.3±16.0 68.9±11.7 0.312 
Body surface area (m2) 
     
Athletes 1.9±0.3* 2.0±0.3* 2.1±0.2*,a 2.0±0.2* <0.001 
Controls 1.8±0.2 1.8±0.2 1.9±0.2 1.8±0.2 0.403 
Resting systolic BP (mmHg) 
    
Athletes 122.7±10.6 125.7±9.9* 125.2±11.7* 126.8±8.8 0.255 
Controls 118.0±9.6 122.4±13.0 120.0±11.1 122.3±9.1 0.403 
Ethnicity (%) 
     
Athletes 
     
Arabic 13.4 44.6 28.1 13.8 <0.001 
Black African 12.3 36.9 29.6 21.2 
 
Caucasian 2.9 19.4 33 44.7 
 
Controls 
     
Arabic 14.8 52.7 22.7 9.9 <0.001 
Black African 28.6 39.3 28.6 3.6 
 
Caucasian 0 7.7 23.1 69.2   
Values are Mean±SD or %.; *Significant difference between athletes vs. controls in their respective 25[OH]D groups.; 
a Significant difference compared to the <10 ng/ml cohort.; b Significant difference compared to the 10–20 ng/ml 
cohort. 
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Table 8.2 Lifestyle characteristics of individuals severely deficient, deficient, insufficient and sufficient vitamin D 
Variables 
Vitamin D (ng/mL)   
<10 10 - 20 20-30 >30 Total p-value 
Exposure time to sunlight 
(min)       
Athletes       
No sunlight exposure 27 (11.2) 99 (40.9) 75 (31.0) 41 (16.9) 242 
0.004 30-60 minutes 
10 (10.5) 43 (45.3) 22 (23.2) 20 (21.1) 95 
60-120 minutes 13 (15.7) 21 (25.3) 23 (27.7) 26 (31.3) 83 
>120 minutes 5 (5.8) 23 (26.7) 30 (34.9) 28 (32.6) 86 
Controls 
      
No sunlight exposure 21 (17.9) 57 (48.7) 28 (23.9) 11 (9.4) 117 
0.568 
30-60 minutes 11 (20.8) 22 (41.5) 12 (22.6) 8 (15.1) 53 
60-120 minutes 3 (10.0) 17 (56.7) 7 (23.3) 3 (10.0) 30 
>120 minutes 3 (6.8) 23 (52.3) 10 (22.7) 8 (18.2) 44 
Skin exposure to the sun 
      
Athletes 
      
None 1 (25.0) 1 (25.0) 2 (50.0) 0 (0.0) 4 
0.012 Hands and feet only 14 (19.4) 34 (47.2) 13 (18.1) 11 (15.3) 72 
More than hands and feet 40 (9.3) 151 (35.1) 135 (31.4) 104 (24.2) 430 
Controls 
      
None 0 (0.0) 2 (40.0) 3 (60.0) 0 (0.0) 5 
0.091 Hands and feet only 12 (17.1) 37 (52.9) 18 (25.7) 3( 4.3) 70 
More than hands and feet 26 (15.4) 80 (47.3) 36 (21.3) 27 (16.0) 169 
Use of sunscreen 
      
Athletes 
      
Yes 0 (0.0) 8 (19.5) 10 (24.4) 23 (56.1) 41 <0.001 
No 55 (11.8) 178 (38.3) 140 (30.1) 92 (19.8) 465 
Controls 
      
Yes 0 (0.0) 4 (30.8) 5 (38.5) 4 (30.8) 13 0.038 
 No 38 (16.5) 115 (49.8) 52 (22.5) 26 (11.3) 231 
Values are n (%) or n. 
8.5.1 Cardiac structure 
All athletes and control participants presented with cardiac morphological parameters within 
clinically accepted limits. Deficient, insufficient, and sufficient athletes had significantly (p<0.05) 
greater absolute aortic root (Ao) diameter, left atrium (LA) diameter, intraventricular septum 
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during diastole (IVSd), left ventricular diameter during diastole (LVIDd), left ventricular mass 
(LVM), left ventricular volume during diastole (LVvolD), and right atrial (RA) area than their 
respective 25[OH]D control participants (Table 8.3). However, severely deficient athletes had 
significantly (p<0.05) smaller Ao diameter, IVSd, LVIDd, LVM, LVvolD, and RA area than 
insufficient and sufficient athletes. Furthermore, LVvolD and LVM were significantly 
(p<0.05) smaller in deficient athletes compared to insufficient and sufficient athletes. LVIDd and 
LVM were significantly (p<0.05) smaller in severely deficient controls compared to insufficient 
and sufficient control participants, with no further cardiac structural parameter different between 
the respective 25[OH]D control participants. 
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Table 8.3 Cardiac structure of individuals severely deficient, deficient, insufficient, and sufficient in vitamin D 
Variables 
Vitamin D (ng/mL) P value
<10 10 - 20 20-30 >30 
Ao (mm) 
     
Athlete 26.3±3.1 (20–33)* 27.3±3.0 (19–35)* 28.0±2. 6 (21–34)*,a 27.7±2.4 (22–34)*,a 0.001 
Control 24.9±2.6 (21–30) 26.4±2.5 (21–33) 26.3±3.2 (21–34) 26.2±2.0 (22–29) 0.145 
LA (mm) 
     
Athlete 32.9±5.1 (22–47)* 33.9±3.9 (22–43)* 34.8±3.6 (26–48)*,a 33.8±3.6 (24–45)* 0.013 
Control 30.6±4.0 (24–39) 32.3±4.1 (21–43) 32.7±4.8 (18–43) 32.0±3.4 (24–39) 0.109 
IVSd (mm) 
     
Athlete 8.6±1.4 (6–11) 8.9±1.2 (6–14)* 9.1±1.0 (6–13)*,a 9.1±1.1 (6–13)*,a 0.014 
Control 8.1±1.1 (6–10) 8.5±1.1 (6–12) 8.3±1.1 (6–11) 8.5±1.0 (6–11) 0.172 
LVIDd (mm) 
     
Athlete 51.2±5.5 (39–61)* 53.5±4.7 (40–62)* 54.5±5.7 (45–64)*,a 54.6±4.2 (42–65)*,a <0.001 
Control 48.6±3.7 (41–57) 49.8±4.0 (42–59) 51.3±5.1a (41–60) 51.5±4.4a (42–58) 0.006 
PWTd (mm) 
     
Athlete 8.0±1.2 (6–10) 8.3±1.1 (6–13) 8.7±2.9 (6–13) 8.6±2.2 (6–10) 0.072 
Control 7.7±0.9 (6–9) 8.4±4.4 (6–14) 8.1±0.8 (6–10) 8.2±0.9 (6–10) 0.607 
LVM (g) 
     
Athlete 157.7±52.7 (63–285)* 173.9±42.6 (65–291)* 184.8±36.3 (80–271)*,a,b 184.0±36.2 (82–266)*,a,b <0.001 
Control 131.9±27.8 (81–205) 147.2±34.9 (75–286) 152.7±38.0a (68–237) 157.3±34.1a (79–218) 0.011 
LV vol D (ml) 
     
Athlete 117.1±34.1 (54–195) 131.8±29.9 (55–212)*,a 142.7±27.3 (70–245)*,a,b 140.3±30.9 (58–271)*,a,b <0.001 
Control 106.2±26.8 (64–159) 108.0±21.3 (53–176) 112.5±25.0 (63–175) 110.2±23.2 (66–161) 0.54 
LA area (mm2) 
     
Athlete 17.3±4.5 (9–27) 17.7±3.8 (8–29) 18.5±3.5 (11–31) 18.1±3.6 (8–33) 0.113 
Control 15.6±3.3 (10–24) 15.4±3.1 (9–23) 19.1±22.3 (10–183) 16.4±3.3 (11–25) 0.223 
RA area (mm2) 
     
Athlete 15.0±4.6 (7–28) 16.5±3.6 (8–28)* 17.3±3.1 (11–29)*,a 16.7±3.1 (7–24)*,a 0.001 
Control 13.6±2.8 (9–19) 14.9±7.0 (8–21) 14.7±3.1 (9–22) 14.9±3.5 (8–23) 0.643 
Values are Mean±SD (range).; *Significant difference between athletes vs. controls in their respective 25[OH]D 
groups.; a Significant difference compared to the <10 ng/ml cohort.; b Significant difference compared to the 10–20 
ng/ml cohort.; Ao, aortic root diameter; IVSd, intraventricular septum during diastole; LA area, left atrial area; LA, 
left atrial diameter; LVIDd, left ventricular internal diameter during diastole; LVM, left ventricular mass; LVvolD, 
left ventricular volume in diastole; PWTd, posterior wall thickness in diastole; RA area, right atrial area. 
 
 
 
148 
 
However, when adjusted for body surface area deficient, insufficient, and sufficient controls had 
significantly (p<0.05) greater (LA/BSA) diameter than athletes of the same 25[OH]D status (Table 
8.4). Deficient and sufficient controls had greater (IVSd/BSA) than athletes of the same 25[OH]D 
status. Insufficient and sufficient controls had greater (LVIDd) than athletes of the same 25[OH]D 
status, was greater in sufficient controls than insufficient controls. Deficient controls had greater 
PWTd/BSA but smaller LA/BSA than deficient athletes. Athletes have larger (LVM/BSA) than 
controls across all vitamin D groups, whereas both severely deficient athletes and controls had 
significantly smaller LVM/BSA than deficient, insufficient and sufficient counterparts.  
Deficient, insufficient and sufficient athletes had significantly (p<0.05) greater (LVvolD/BSA), 
than their respective 25[OH]D control participants and severely deficient athletes.  
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Table 8.4 Cardiac structures of individuals adjusted for BSA compared to vitamin D status 
 
Values are Mean±SD (range).; *Significant difference between athletes vs. controls in their respective 25[OH]D 
groups.; a Significant difference compared to the <10 ng/ml cohort.; b Significant difference compared to the 10–20 
ng/ml cohort.; Ao, aortic root diameter; IVSd, intraventricular septum during diastole; LA area, left atrial area; LA, 
left atrial diameter; LVIDd, left ventricular internal diameter during diastole; LVM, left ventricular mass; LVvolD, 
left ventricular volume in diastole; PWTd, posterior wall thickness in diastole; RA area, right atrial area. 
 
Variables 
Vitamin D (ng/mL) 
<10 10-20 20-30 >30 
Ao (mm)/BSA 
    
Athlete 13.43±3.06 12.5±4.09 12.26±4.32 12.45±4.1 
Control 12.61±4.62 13.09±4.38 12.05±5.37 11.5±6.0 
LA (mm)/BSA 
    
Athlete 17.35±2.00 17.0±2.03 16.88±1.93 16.62±1.8 
Control 17.08±1.75 17.54±1.89* 17.66±2.28* 17.7±1.4* 
IVSd (mm)/BSA 
    
Athlete 4.51±0.53 4.44±0.58 4.40±0.54 4.47±0.58 
Control 4.53±0.51 4.64±0.59* 4.48±0.54 4.74±0.50* 
LVIDd (mm)/BSA 
    
Athlete 27.15±3.03 26.8±2.55 26.46±3.26 26.82±2.30 
Control 27.24±2.83 27.17±2.52 27.75±2.69* 28.6±2.4*b 
PWTd (mm)/BSA 
    
Athlete 4.22±0.50 4.15±0.48 4.25±1.42 4.24±1.30 
Control 4.29±0.46 4.60±2.40* 4.38±0.49 4.55±0.56 
LVM (g)/BSA 
    
Athlete 80.95±19.4* 85.5±16.8*a 88.36±16.4*a 88.61±16.0a 
Control 73.29±13.53 78.99±18.1 81.48±15.9 86.8±17.0a 
LVvolD (ml)/BSA 
    
Athlete 60.32±10.9 65.2±11.0*a 67.22±13.7*a 68.09±11.0*a 
Control 58.92±12.86 58.23±11.6 60.40±10.4 60.8±11.0 
LAarea(mm2)/BSA 
    
Athlete 8.97±1.55 8.81±.158* 8.85±1.92 8.87±1.60 
Control 8.71±1.73 8.34±1.72 10.22±11.2 9.05±1.5 
RAarea (mm2)/BSA 
    
Athlete 7.77±1.69 8.17±1.45 8.26±1.79 8.17±1.4 
Control 7.58±1.36 8.08±4.54 7.92±1.51 8.23±1.7 
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8.5.2 Logarithmic transformation  
Following logarithmic transformation adjusting 25[OH]D for age, body surface area, and ethnicity 
(Table 8.5), athletes had significantly larger LA, IVSd, LVIDd, LVM, and LVvolD compared to 
control participants. When athletes and controls were grouped together, there were positive 
associations between 25[OH]D and LVIDd, PWTd, LVM, and LVvolD. However, after further 
adjustment for athletic participation, positive associations between 25[OH]D and IVSd, LVIDd, 
PWTd, LVM, and LVvolD were observed in athletes, that was not maintained in the control 
participants. 
 
Table 8.5 Logarithmic transformation adjusting 25[OH]D against cardiac morphology for age, body surface area, 
ethnicity and athletic participation in athletes and/or controls 
Variables Athletes vs. controls 
Athletes plus 
controls Athletes only Controls only 
Ao (mm) 0.3±0.2 (0.148)  0.2±0.2 (0.315)  0.2±0.2 (0.336)  0.0±0.3 (0.976) 
LA (mm) 0.8±0.3 (0.010)  0.1±0.2 (0.787)  0.1±0.3 (0.834)  0.1±0.4 (0.790) 
IVSd (mm) 0.2±0.1 (0.013)  0.1±0.1 (0.063)  0.1±0.1 (0.011)  –0.1±0.1 (0.536) 
LVIDd (mm) 1.6±0.4 (<0.001)  0.9±0.3 (0.002)  0.9±0.4 (0.016)  0.8±0.5 (0.120) 
PWTd (mm) –0.2±0.2 (0.479)  0.4±0.2 (0.037)  0.4±0.2 (0.016)  0.3±0.4 (0.466) 
LVM (g) 11.1±2.6 (<0.001)  6.7±2.1 (0.002)  5.9±2.6 (0.024)  4.8±3.6 (0.185) 
LV vol D (ml) 10.6±1.9 (<0.001)  3.8±1.5 (0.013)  5.6±1.9 (0.003)  –0.5±2.7 (0.860)   
LA area (mm2) 0.4±0.6 (0.471)  0.3±0.5 (0.558)  0.2±0.3 (0.464)  0.0±1.6 (0.986)  
RA area (mm2) 0.5±0.3 (0.198)  0.2±0.3 (0.388)  0.3±0.3 (0.239)  0.0±0.7 (0.976)  
Values are β±SE (p-value).; Ao, aortic root diameter; IVSd, intraventricular septum during diastole; LA area, left atrial 
area; LA, left atrial diameter; LVIDd, left ventricular internal diameter during diastole; LVM, left ventricular mass; 
LVvolD, left ventricular volume in diastole; PWTd, posterior wall thickness in diastole; RA area, right atrial area. 
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8.5.3 Cardiac function 
Regardless of serum 25[OH]D status, all athletes and control participants displayed normal cardiac 
functional parameters. There was no significant difference in any cardiac functional parameter 
between athletes and control participants, or within athletes or control 25[OH]D participants.  
 
8.6 Discussion 
It is well recognized that 25[OH]D is necessary for optimal bone mass. 25[OH]D-deficient athletes 
may be at an increased risk for potential problems such as stress fractures, respiratory infections, 
frequent illness, and muscle injuries. Yet, to our knowledge, this is the first study to investigate 
the association between 25[OH]D status and cardiac structure and function in young healthy 
athletes. 
The main finding of the study is that severely 25[OH]D-deficient athletes (<10 ng/ml) presented 
significantly smaller (p<0.05) Ao and LA diameter, IVSd, LVIDd, LVM, LVvolD, and RA area 
than insufficient (20–30 ng/ml) and sufficient (>30 ng/ml) athletes. Adjust for BSA severely 
deficient athletes had smaller LVM/BSA and LVvolD only. Whereas, deficient, insufficient, and 
sufficient controls had significantly (p<0.05) greater (LA/BSA) diameter than athletes of the same 
25[OH]D status. Athletes had greater developed cardiac structure than controls, but also greater 
BSA. 
Furthermore, following logarithmic transformation adjusting 25[OH]D for age, body surface area, 
ethnicity, and athletic participation, positive associations were between 25[OH]D and IVSd, 
LVIDd, PWTd, LVM, and LVvolD in athletes but not in the control participants. 
In the present study, 23% of athletes demonstrated 25[OH]D sufficiency, with near half 
demonstrating either 25[OH]D deficiency (37.2%) or severe deficiency (11%). This high 
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prevalence of deficiency has been noted previously (B. Hamilton et al., 2014). It is likely that this 
high deficiency prevalence reflects the cultural tendency to train and compete after sunset in Qatar, 
due to the high daily temperatures. However, it should be noted 16.9% of athletes and 9.4% of 
controls who did not expose themselves to sunlight were sufficient in 25[OH]D. The majority of 
25[OH]D is generated de novo by the basal layers of the epidermis via ultraviolet-B radiation 
and/or, to a lesser extent, consumed within the diet. While we did not measure nutritional intake 
prior to assessment, it is possible for individuals to become 25[OH]D sufficient with appropriate 
alimentation with foodstuffs as fish, milk, and cereals. Secondly, significantly more Caucasian 
athletes were 25[OH]D sufficient compared to Arabic and Black African athletes. Consideration 
for ethnicity and its impact upon 25[OH]D status is important, as a recent study by Powe et al. 
reported that Black individuals (n=1191) present significantly (p<0.001) lower serum 25[OH]D 
levels than Caucasians (n=904), despite being comparable in age, sex, body mass index, and 
menopausal status (15.6±0.2 vs. 25.8±0.4 ng/ml, respectively). A unique feature of this 
investigation was the examination of vitamin D-binding protein (the primary vitamin D carrier 
protein). The authors observed a higher prevalence among Black individuals of a polymorphism 
in the vitamin D-binding protein gene that was associated with low levels of vitamin D binding 
protein, resulting in bioavailable 25[OH]D levels similar to Caucasian individuals despite lower 
levels of total 25[OH]D. The authors suggest that low levels of vitamin D-binding protein in Black 
individuals may offer protection against the consequences of 25[OH]D deficiency, such as for 
example, a higher bone mineral density scores in Black individuals compared to Caucasians (Powe 
et al., 2013). 
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8.6.1 25[OH]D and cardiac structure and function; healthy vs. chronic disease states 
Few studies have examined 25[OH]D status in association with cardiac structure and function in 
the general population without significant comorbidities. In an older female population (mean±SD 
age 73.9±4.9 years, 69.7% female), Van Ballegooijen et al. measured serum 25[OH]D together 
with ECG and echocardiographic parameters in 2312 individuals free of cardiovascular disease at 
baseline(van Ballegooijen et al., 2013). While mean serum 25[OH]D demonstrated populational 
insufficiency (25.2±10.2 ng/ml), serum 25[OH]D was not associated with any ECG or 
echocardiographic parameter. However, the vast majority of evidence examining 25[OH]D 
deficiency against cardiac morphology is in individuals with established chronic disease, and 
suggests that those individuals who are 25[OH]D deficient display significant increases in LV 
hypertrophy. Ky et al. observed a significant negative interaction between serum 25[OH]D and 
LV mass, end-diastolic and end-systolic volumes in 1431 individuals with chronic renal 
insufficiency (Ky et al., 2013). This association between 25[OH]D deficiency and increased LV 
mass is also observed in paediatric patients with chronic kidney disease (Patange, Valentini, Gothe, 
Du, & Pettersen, 2013) and in individuals with essential hypertension, (Kulah et al., 2007) CHF 
(Bozic et al., 2011) and dilated cardiomyopathy (Al Azkawi & Al Mutair, 2012). 
The precise mechanism(s) causing this cardiac hypertrophy (or in our case, lack of hypertrophy) 
in the 25[OH]D-deficient state remains unclear. What is understood, however, is that the 
remodeling mechanisms associated with cardiac disease and chronic overloading (such as long-
standing mitral insufficiency, essential hypertension, CHF, kidney disease and dilated 
cardiomyopathy) differ considerably from the physiological adaptations seen in athletes induced 
though prolonged and intensive exercise. Furthermore, the observation that 25[OH]D deficiency 
is associated with, for example LVH in diseased individuals, may be a simple reflection of lack 
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UVB exposure due to severe limitations in their functional capacity to exercise; meaning that they 
do not walk outside and are thus 25[OH]D deficient. 
 
8.6.2 25[OH]D, cardiac structure and function in Murine models 
Unlike models using humans with chronic disease, murine models offer information regarding 
25[OH]D deficiency and cardiac structure at the cellular and myofibril level in apparently healthy 
hearts at baseline. However, unlike the present study which observed LV hypertrophy (wall 
thickness, mass and volumes) in 25[OH]D-sufficient athletes compared to severely deficient 
athletes, Assalin et al. recently reported that male weaning Wistar rats fed a 25[OH]D-deficient 
diet for 4 months compared to rats fed a diet with 1,000 IU of vitamin D/kg, demonstrated LV 
hypertrophy together with lower fractional shortening and ejection fraction (Assalin et al., 2013). 
Furthermore, biochemical analyses showed lower beta-hydroxyacyl coenzyme-A dehydrogenase 
activity and higher lactate dehydrogenase activity in 25[OH]D-deficient rats; with 25[OH]D 
deficiency significantly related to increased cytokines release, oxidative stress, apoptosis and 
fibrosis. These observations are supported by Weishaar et al. who found a significant increase in 
cardiac hypertrophy (an increase in heart to body mass ratio) in rats feed a 25[OH]D deficient diet 
after both 9 and 18 weeks (Weishaar et al., 1990).  
Yet the precise mechanism(s) causing cardiac hypertrophy in the 25[OH]D-deficient rat is unclear, 
with murine models demonstrating conflicting results. Histological analysis of Weishaar et al. rats 
observed significantly smaller ventricular myofibrils and increased extracellular matrix proteins 
compared to 25[OH]D-sufficient rats. However, Gezmish et al. examined the effects of a 
25[OH]D-deficient diet upon the hearts of 4-week-old Sprague Dawley rats whose mothers were 
feed a 25[OH]D-depleted diet from 6 weeks prior to pregnancy until 4 weeks of lactation. The 
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authors demonstrated that maternal 25[OH]D deficiency leads to an increase in LV volume, 
accompanied by an increase in both cardiomyocyte hypertrophy and number (proliferation), in the 
hearts of 4-week-old rats (Gezmish et al., 2010). 
 
8.6.3 To supplement with 25[OH]D or not 
No studies have examined the effect of supplementation upon cardiac structure and function in 
healthy hearts, but a few have examined those with known cardiac comorbidities. Shedeed 
evaluated the effect of 25[OH]D3 supplementation in infants with CHF. In this double-blind 
placebo-controlled intervention study of 80 infants with CHF, the intervention consisted of either 
giving vitamin D3 or placebo. After 12 weeks of 25[OH]D3 supplementation, significant 
improvements in LV end-diastolic and systolic diameters, ejection fraction, and myocardial 
performance index together with significant improvements in serum 25[OH]D status were 
observed compared to the placebo group (Shedeed, 2012). In the current study, none of the athletes 
were taking vitamin D supplementation at the time of screening. While the aim of this investigation 
was not to examine whether athletes should supplement with 25[OH]D to augment cardiac 
structure, future double-blind placebo-controlled studies should look to examine if 25[OH]D 
supplementation increases cardiac size in healthy athletes, especially in severely deficient and 
deficient cohorts. 
 
8.7 Limitations 
While we acknowledge that cardiorespiratory fitness, training volume, and intensity were not 
recorded, athletes were only included in the study if they competed at national level and trained 
for more than 6 h/week. It is felt that the logarithmic transformation adjustments of 25[OH]D for 
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age, body surface area, ethnicity, and, importantly, athletic participation were satisfactory to 
distinguish cardiac morphological differences between and within athletes and controls. 
 
8.8 Conclusion 
Severely 25[OH]D-deficient athletes (<10 ng/ml) present significantly (p<0.05) smaller Ao 
diameter, LAd, IVSd, LVIDd, LVM, LVvolD, and RA area than insufficient (20–30 ng/ml) and 
sufficient (>30 ng/ml) athletes. Furthermore, following logarithmic transformation adjusting 
25[OH]D for age, body surface area, ethnicity, and athletic participation, positive associations 
between 25[OH]D and IVSd, LVIDd, PWTd, LVM, LVvolD were observed in athletes but not in 
control participants. Future research should look to identify the precise mechanism(s) causing 
cardiac hypertrophy with increases in serum 25[OH]D in healthy athletes. 
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General Discussion 
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9.1 Realisation of Aims 
9.1.1 Aim 1 - Examine which modality of 25[OH]D supplementation was more efficacious at 
improving serum 25[OH]D status in an ethnically diverse athlete population. 
This aim was addressed in Chapter 4. Athletes presenting with total serum 25[OH]D ≤ 30 ng/mL 
were supplemented with either oral Cholecalciferol D3 [2000IU/d] or a single intramuscular 
Ergocalciferol D2 injection [300,000 IU] and reassessed at 2-months. Both modes of 
supplementation increased serum 25[OH]D concentrations (Oral; 25.8 ± 0.9 vs. IM; 24.7 ± 0.6 
ng/mL); from baseline with no significant difference in mean 25[OH]D status between treatments 
at 2-months. However, a significantly greater number of athletes became sufficient (>30 ng/mL) 
at 2-months following Oral vs. IM supplementation. Suggestive that supplementation with oral 
Cholecalciferol D3 may be more efficacious at improving 25[OH]D insufficiencies than IM 
injections of 25[OH]D2. The findings from this study had clinical implications that resulted in the 
production and implementation of a new vitamin D supplementation pathway (Chapter 4, Figure 
4.1). 
 
9.1.2 Aim 2 - Investigate the relationship between serum 25[OH]D concentrations and 
measures of bone mass weight-bearing athletes 
Aim 2 was addressed in Chapter 5. Nine hundred and fifty weight bearing athletes and 436 controls 
undertook bone densitometry and body composition analysis by dual-energy x-ray absorptiometry 
and serum 25[OH]D evaluation. After adjustment for age, anthropometry, ethnicity, and athletic 
participation, there was no association between 25[OH]D and BMD and T-score at any site (spine, 
neck, or hip total). African and Caucasian athletes presented with greater (p <0.05) BMD and T-
scores at the spine, neck, and hip total than those of Asian, GCC, Middle Eastern, and Persian 
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ethnicities. Although 57% were considered to be vitamin D deficient or severely deficient 
(<20ng/mL), no athletes presented with a T-score suggestive of osteoporosis (-2.5 SD) at any site 
or osteopenia (-1.0 SD) at hip total. These findings suggest that the osteogenic effect of impactful 
weight-bearing exercise is sufficient to maintain markers of bone mass, irrespective of 25[OH]D 
status. Therefore, it was necessary to explore these associations in non-weight bearing athletes. 
 
9.1.3 Aim 3 - Examine the relationship between serum 25[OH]D concentrations and markers of 
bone mass in non-weight bearing, Arabic athletes. 
This aim was addressed in Chapter 6. Findings from the previous study demonstrated no 
association between markers of bone mass and serum 25[OH]D concentration. We postulated that 
the osteogenic effect of weight bearing exercise may be sufficient to maintain markers of bone 
mass, irrespective of serum 25[OH]D concentration in adults. Exercise (loading) is associated with 
increased BMD, whilst increased body mass contributes to the process of bone remodeling, 
forming mechanically appropriate bone structure(s). Therefore Aim 3 sought to examine the 
relationship between serum 25[OH]D concentrations against markers of bone mass (BMD and T-
score) in an non-weight bearing Arabic athletic population.  
Despite a combined 25[OH]D deficiency and severe deficiency prevalence rate of 69%, no 
association was observed in serum 25[OH]D concentrations between athletes with clinically 
normal T-score (n=76) and those presenting with osteopenia (-1 to -2.5 SD) (n=20) or osteoporosis 
(-2.5 SD) (n=6) at any location (neck, hip, spine or total). However, mean body mass was lower 
(p˂0.05) in athletes with a T-score suggestive of osteopenia/osteoporosis. Thus supporting the 
hypothesis that 25[OH]D concentrations were not associated with markers of bone mass (BMD) 
in non-weight bearing Arabic athletes. Together with the findings from Chapter 5, there is strong 
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evidence to support the notion that multiple mechanisms regulate mechanosensation in bone that 
are inextricably interdependent of serum 25[OH]D concentration. 
 
9.1.4 Aim 4 - Evaluate the role of bioavailable vitamin D as a predictor of bone mass within a 
large cohort of healthy athletes 
This aim was addressed in Chapter 7. Six hundred and four male athletes [Arab (n=328), Asian 
(n=48), Black (n=108), Caucasian (n=53) & Hispanic (n=35)] undertook measures of total 25-
hydroxyvitamin D, vitamin D–binding protein, and bone mineral density (BMD) by (DXA). 
Bioavailable vitamin D was calculated using free hormone hypothesis. After adjusting for age and 
ethnicity, bioavailable vitamin D was associated with spine (P=0.001), neck (p<0.001) and hip 
BMD (p<0.001), with no association observed between serum 25[OH]D concentration and BMD 
at any site (p>0.05).  These findings allow acceptance of the hypothesis that bioavailable vitamin 
D is a better predictor of bone mass than serum 25[OH]D. 
 
9.1.5 Aim 5- Identify the associations between 25[OH]D status and cardiac structure and 
function within a large cohort of healthy athletes. 
This aim was addressed in Chapter 8. Five hundred and six athletes and 224 controls undertook 
cardiac structure and function assessment via physical examination, 12-lead electrocardiogram and 
echocardiogram in addition to serum 25[OH]D concentration. Severely 25[OH]D-deficient 
athletes present significantly (p<0.05) smaller cardiac structure (aortic root, left atria diameters, 
intraventricular septum diameter (IVSd), left ventricular diameter during diastole (LVIDd), left 
ventricular mass (LVM), left ventricular volume during diastole (LVvolD), and right atrial (RA) 
area) than insufficient and sufficient athletes. Following logarithmic transformation adjustment for 
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25[OH]D, age, body surface area, ethnicity, and athletic participation, positive associations were 
observed between 25[OH]D and IVSd, LVIDd, posterior wall thickness during diastole, LVM, 
and LVvolD in athletes but not in the control participants.  However, there was no significant 
difference in any cardiac function was observed between athletes and control participants, or 
within athletes or control 25[OH]D participants. Although Aim 5 was addressed the precise 
mechanism for lack of hypertrophy in the 25[OH]D deficient remains unclear. 
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9.2 Overview of the experimental studies in this thesis 
Pre-Competition Medical Assessment 
Annual medical assessment, consisting of several components; including cardiac screening, 
DXA, and vitamin D evaluation. 
Chapter 1.2.1: A high prevalence of vitamin D (25[OH]D) deficiency was identified 
 
 
Chapter 4: Oral Vs. Intramuscular Vitamin D Supplementation for Treating Insufficient 
Athletes 
Vitamin D supplementation improves mean 25[OH]D status (13.7ng/mL to 25.3ng/mL) 
regardless of modality (IM or Oral). The subsequent studies sought to examine the 
relationship between serum 25[OH]D concentrations and markers of bone mass in a large and 
ethnically diverse athletic population. 
 
 
Chapter 5: No Association between Vitamin D Deficiency and Markers of Bone Mass in 
Athletes 
25[OH]D status was not associated with markers of bone mass (BMD and T-score) at any 
site. The osteogenic effect of weight bearing exercise may be sufficient to maintain markers 
of bone mass, irrespective of 25[OH]D status in adults. Chapter 5 aimed to examine the 
relationship between serum 25[OH]D and measures of bone mass in non-weight bearing 
athletes. 
 
Chapter 6: No Association between Vitamin D Status and Markers of Bone Mass in 
Non-Weight Bearing Athletes 
No association was observed between serum 25[OH]D concentrations and markers of bone 
mass in non-weight bearing Arabic athletes. This study suggests 25[OH]D concentration is 
irrelevant in predicting bone mass in non-weight bearing athletes. 
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Chapter 7: Systematic serum 25[OH]D screening in athletes is pointless; We have been 
‘Bound’ to the wrong assay all along! 
Chapters 5 & 6 propose that serum 25[OH]D concentration is an inappropriate measure for 
predicting bone mass in an ethnically diverse athletic population, irrespective of exercise 
type (weight/non-weight bearing). Research suggests racial differences in manifestations for 
vitamin D and markers of bone mass do exist. 
Chapter 7 aimed to elucidate if bioavailable vitamin D is a better predictor bone mass than 
total serum 25[OH]D in an athletic cohort of mixed ethnicity. 
Bioavailable vitamin D was closely associated with bone mineral density, whereas no 
association was observed between serum 25[OH]D concentration and BMD at any site. 
 
 
Chapter 8: Severely vitamin D-deficient athletes present smaller hearts than sufficient 
athletes 
Aimed to examine the relationship between 25[OH]D status and cardiac structure and 
function within a large cohort of healthy athletes presenting for pre-competition medical 
assessment at our institution. 
Severely 25[OH]D-deficient athletes present significantly) smaller cardiac structures than 
insufficient (20–30 ng/ml) and sufficient (>30 ng/ml) athletes. 
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9.3 General Discussion 
Although vitamin D is strongly implicated in bone health, these papers contributed to the growing 
body of evidence that suggest serum 25[OH]D concentration is not associated with bone mineral 
density or T-scores in an ethnically diverse athletic population. It is speculated that vitamin D 
binding protein may be responsible for ethnic variations in serum 25[OH]D concentrations in the 
absence of any associated disease, such as osteoporosis. As discussed, observational studies 
demonstrate varying results between markers of bone health and vitamin D status. Serum 25[OH]D 
concentration is a commonly used measure and understood to be an accurate representation of 
vitamin D status, due to the difficult nature of measuring the active metabolite 1,25[OH]2D. To 
date, research on vitamin D status in athletes has focused solely upon serum 25[OH]D and 
consequently, the current advice and guidelines given to athletes and clinicians treating vitamin D 
deficiency should be consider inaccurate. There increasing evidence to support the notion that DBP 
concentrations varying between ethnicities, which in turn impact on the qunatity of bioavailable 
vitamin D (Gozdzik et al., 2011; Powe et al., 2013). Additionally, these data show no clinical 
relationship between bioavailable vitamin D and markers of cardiac structure, whereas a 
correlation between serum 25[OH]D was observed. It may be the case that these ethnic variations 
support the case for measuring DBP and bioavailable vitamin D.  
 
Vitamin D deficiency is a pandemic and the classification for vitamin D status is based on current 
concentration ranges.  The ranges used throughout this thesis are based the inverse relationship 
between serum 25[OH]D concentration and PTH, when 25[OH]D reaches 30-40ng/mL PTH levels 
plateau (Chapuy et al., 1997). Additionally, intestinal calcium transport increases by 45 to 65% 
when 25[OH]D rises from 20 to 32 ng/mL(R. P. Heaney, Dowell, Hale, & Bendich, 2003), 
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suggestive that 25[OH]D of 21 to 29ng/mL can be considered to indicate insufficiency (B. 
Dawson-Hughes et al., 2005). 
It should be acknowledged that the latest evidence from the growing body of vitamin D research 
contributes to the revision of vitamin D status. Recently, Manson et al, highlighted that the vitamin 
D reference values set out by the US Institute of Medicine (IOM) (Ross et al., 2011) could be open 
to misinterpretation (Manson, Brannon, Rosen, & Taylor, 2016). The majority of vitamin D 
research uses serum 25[OH]D concentration ranges <20ng/mL as a cut-off for defining 
insufficiency. These references values are based on dietary reference intakes (DRIs) that comprise 
a series of estimates of a given nutrients needed by different groups of healthy people within a 
population. These may vary from country to country, (e.g. dietary reference values, (DRVs) in the 
UK vs. DRI in USA). The DRI is broken down into two separate values: 
 Estimated Average Requirement (EAR), which is the median of the distribution of human 
requirements, reflects the most likely requirement for the population. 
 Recommended Dietary Allowance (RDA), reflects the estimated requirement for people the 
top at the highest end of the distribution, 97.5% of the population requirements are below the 
RDA.  
The EAR is 400IU/d D3 corresponding to a serum 25[OH]D level of 16ng/mL(40nmol/L), whereas 
the RDA is 600-800IU/D3 corresponding to 20ng/mL(50nmol/L) The RDA is only required by 
2.5% of the population and this misconception may contribute to exaggerated prevalence of 
vitamin D deficiency. The goal of treatment for the clear majority of the population is to present 
above the EAR not the RDA. Additionally, the Tolerable Upper limit (TUL, the level at which 
there may be adverse effects) is >50ng/mL. If our institution used the EAR set by the IOM, 48.5% 
of the athlete population would be considered vitamin D deficient (Table 9.1). 
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Table 9.1 Distribution of vitamin D status of athletes screened at Aspetar based IOM guidelines for EAR, DRI and 
TUL 
25[OH]D concentration N= Percentage (%) 
<16 ng/mL 2619 48.5 
16-20 ng/mL 775 14.4 
20-50 ng/mL 1954 36.2 
>50 ng/mL 52 1.0 
 5400 100.0 
 
Misdiagnosis of true vitamin D status may have adverse financial and healthcare consequences, 
due to the over use of screening and unnecessary use of supplementation. However, these updated 
concentration ranges would not alter the findings from this thesis as serum 25[OH]D concentration 
was not associated with bone mass (BMD or T-score) at any site, and athletes presenting with 
smaller hearts are would still be vitamin D deficient. However, these findings contribute to the 
debate that current concentration ranges are not applicable to all ethnicities.  
9.4 Limitations 
The primary limitation of this thesis is the use of dual energy X-ray absorptiometry (DXA), t-
scores and z-scores in Chapters 5, 6 and 7 to markers of bone health. DXA uses a two-dimensional 
model to measure areal bone mineral density (aBMD, g/cm2), that accounts for about 70% of the 
variance in compressive bone strength. Thus, disregarding volumetric BMD, bone geometry and 
bone microarchitecture. The nature of this modality makes the measurement of true volumetric 
bone mineral density (BMD, g/cm3) of the cortical and trabecular compartments impossible 
(Rantalainen, Nikander, Heinonen, Suominen, & Sievanen, 2010). Additionally, BMD values are 
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based of comparison to the BMD of young, gender matched, healthy individuals to generate a T 
score. BMD of age-matched individuals with normal bone mass generates a Z score, that are 
mostly utilised in cases of severe osteoporosis. The Word Health Organisation (WHO) 
categorisations (−1 and −2.5 indicates osteopenia, −2.5 or below signifies osteoporosis) were 
established in Caucasian, postmenopausal women. Therefore, may be limited in their application 
to a racially diverse, male athletic population. 
Variations in the 3D microarchitecture of bone tissue compromise its structural integrity and 
strength. The measure of bone strength would be markedly improved by using high-resolution, 
peripheral quantitative, computed tomography (HR-pQCT) that provides three-dimensional 
volumetric analysis of bone microarchitecture (Macneil & Boyd, 2008). Allowing the analysis of 
bone mass, BMD, bone geometry, and estimated bone strength Therefore, these chapters are 
examining bone mass an element of, but not a complete measure of bone health. 
A secondary limitation of this work is monoclonal antibody assay (R&D ELISA) and the equation 
adopted to calculate bioavailable D in Chapter 8. Future studies should address these limitations.  
 
9.5 Practical recommendations 
There are several practical recommendations that can be drawn from the findings of this thesis: 
 Systematic screening for vitamin D status in an asymptotic, racially diverse athlete 
population is unnecessary. 
 If testing is warranted, clinicians should use appropriate assays to calculate DBP and 
bioavailable vitamin D status rather than serum 25[OH]D. 
168 
 
 Prophylactic vitamin D supplementation (Oral 1000-2000IU/d D3) is advised. All 
supplements must be batch tested by a recognised quality assurance program, such as 
LGC’s world-class sports anti-doping laboratory. 
 
9.6 Future Studies 
The data presented here disprove the use of serum 25[OH]D concentration as a marker of bone 
mass and cardiac structure in a racially diverse athletic population. Thus, questioning which 
markers of vitamin D status are a true indicator or predictor for normal skeletal and cardiac health. 
Future studies should examine the association between bone health including aBMD, volumetric 
BMD, bone geometry and bone microarchitecture against bioavailable vitamin D concnetrations, 
using monoclonal and polyclonal antibodies. Longitudinal, prospective trials over 10 years with 6 
monthly follow ups are required to examine the association between bioavailable vitamin D and 
markers of bone health in both male and female participants of varying ethnicity. These trials 
should examine both healthy and pathologic athletes with the aim of establishing racially, specific 
concentration ranges for both bioavailable and serum 25[OH]D concentrations. 
A final consideration for this field of research is whether bioavailable vitamin D is associated with 
markers of athletic performance such as, skeletal muscle function. Recent research demonstrates 
that current vitamin D classifications (IOM) are not meaningful for skeletal muscle function, at the 
whole tissue and single fiber scale of analysis.  Defining new classification based on bioavailable 
vitamin D may provide a ‘true’ vitamin D status that is applicable to all ethnicities. However, 
conducting large scale studies to exam bioavailable vitamin D and markers of bone health, cardiac 
function and skeletal muscle function in ethnically diverse populations would be costly and 
complex. 
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9.7 Conclusion 
The key findings from the thesis are; firstly, serum 25[OH]D concentrations are not associated 
with markers of bone health. Secondly, bioavailable vitamin D is a better preceptor of BMD that 
serum 25[OH]D concentration. Therefore, an important message from this paper from is that if 
testing is warranted, clinicians should use the appropriate assays to calculate DBP and bioavailable 
vitamin D concentration rather than total serum 25[OH]D in racially diverse athletic populations. 
Thirdly, severely 25[OH]D deficient athletes present with smaller cardiac structure that sufficient 
athletes. After further adjustment for athletic participation, positive associations between 25[OH]D 
and IVSd, LVIDd, PWTd, LVM, and LVvolD were observed in athletes, that was not maintained 
in the control participants.  
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